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Synthesis of O-Linked Glycopeptides Using Enzymatic Catalysis 
Enzymes have many advantages over conventional synthetic methods. They can be 
used without the need of a protecting group strategy whilst maintaining high stereo- 
and regiochemistry. Over the past few decades, the use of enzymes has become 
commonplace because of their catalytic efficiency and their ability to be used under 
‘green conditions’. The use of glycosyl hydrolases (glycosidases), enzymes that 
catalyse the energetically favourable hydrolysis of glycosidic linkages, is also 
becoming increasingly widespread. In particular, the construction of glycosidic 
linkages using glycosidases has slowly gained prominence, however the tendency for 
the product of the reverse hydrolysis to be a substrate for the natural enzymatic 
hydrolysis reaction has plagued this process with low yields. To remedy this, 
glycosynthases, a class of mutant glycosidases, have been engineered to eliminate 
hydrolytic activity. In the presence of an activated donor substrate and an appropriate 
acceptor, glycosynthases are able to catalyze the formation of the glycosidic linkage 
and not the hydrolysis leading to higher product yields.  
 
The work in this thesis focuses on the synthesis of activated O-glycan donors, and the 
expression, purification, and mutagenesis of glycosidase enzymes of the super-family 
GH101. Subsequent kinetic assays and glycosylation investigations with various 
acceptors using the wild type and mutant enzymes are described. Also, work on the 
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The following abbreviations have been used in this thesis: 
General: 
δ  chemical shift 
νmax  wavenumber 
ºC  degrees Celsius 
µm  micrometer 
µM  micromolar 
Å  Angstrom 
Ac  acetyl 
ADMP  2-azido-1,3-dimethylimidazolium hexafluorophosphate 
ampicillinr ampicillin-resistant 
aq  aqueous 
Ar  aromatic 
at  apparent triplet (in NMR) 
AU  absorbance units 
BAIB  bis(acetoxy)iodobenzene 
BF3.Et2O boron trifluoride diethyl etherate 
Bn  benzyl 




Bz  benzoyl 
c  concentration 
C-(His)6 C-terminal His-tagged 
Calcd.  calculated 
CEC  cation exchange chromatography 
cm  centimeter 
core 1  Galβ1,3GalNAc 
core 2  Galβ1,3(GlcNAcβ1,6)GalNAc 
core 3  GlcNAcβ1,3GalNAc 
COSY  correlation spectroscopy 
CuAAC copper-catalysed azide-alkyne cycloaddition 
d  doublet (in NMR) 
D2O  deuterated water 
Da  Dalton(s) 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DAST  diethylaminosulfur trifluoride 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM  dichloromethane 
dd  doublet of doublets (in NMR) 




DFIH  2-fluoro-1,3-dimethylimidazolium hexafluorophosphate 
DIPEA di-isopropylethylamine 
DMC  2-chloro-1,3-dimethylimidazolinium chloride 
DMF  dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
DNP  2,4-dinitrophenol 
E. coli  Escherichia coli 
e.g.  exempli gratia (for example) 
endo A endo-β-N-acetylglucosaminidase from Arthrobactor protophormiae 
endo M endo-β-N-acetylglucosaminidase from Mucor hiemalis 
engBL  endo-α-N-acetylgalactosaminidase from Bifidobacterium longum 
engCP  endo-α-N-acetylgalactosaminidase from Clostridium perfringens 
engEF  endo-α-N-acetylgalactosaminidase from Enterococcus faecalis 
engSP  endo-α-N-acetylgalactosaminidase from Streptococcus pyogenes 
Enz  enzyme 
ESI  electrospray ionization 
et al.  et alia (and others) 
EtOAc  ethyl acetate 




Fuc  fucose 
g  gram(s) 
Gal  D-galactose 
GalNAc N-acetyl-D-galactosamine 
GlcNAc N-acetyl-D-glucosamine 
Glu  D-glucose 
GNB  galacto-N-biose (Galβ1,3GalNAc) 
h  hour(s) 
HRMS  high resolution mass spectrometry 
hLys  hydroxyllysine 
HPLC  high performance liquid chromatography 
HMBC heteronuclear multiple bond correlation spectroscopy 
HSQC  heteronuclear single quantum coherence spectroscopy 
Hz  Hertz 
IMAC  immobilized metal affinity chromatography 
IPTG  isopropyl β-D-thiogalactopyranoside 
IR  infrared 
J  coupling constant 
kanamycinr kanamycin-resistance 




kDa  kilo-Dalton(s) 
KM  Michaelis constant 
L  litre 
LB  lysogeny broth 
lit.  literature 
LNB  lacto-N-biose (Galβ1-4GlcNAc) 
M  molar 
m  multiplet (in NMR) 
m  meta 
m.p.  melting point 
m/z  mass/charge ratio 
M+  molecular mass ion 
Man  mannose 
mbar  millibar 
Me  methyl 
MeCN  acetonitrile 
MeOH  methanol 
mg  milligram(s) 
MHz  megahertz 




mL  milliliter(s) 
mM  millimolar 
mmol  millimole 
mol  mole 
mol. sieves molecular sieves 
MS  mass spectrometry 
MUC1  mucin 1 
N-(His)6 N-terminal his-tagged 
N.D.   not detected 
NeuAc  N-acetylneuraminic acid 
nm  nanometer 
nmol  nanomole 
NMR  nuclear magnetic resonance 
O/N  overnight 
OD600  optical density of a sample measured at wavelength of 600 nm 
p  para 
PCR  polymerase chain reaction 
Ph  phenyl 
Phth  phthaloyl 




PNGase F peptide-N-glycosidase F 
pNP  para-nitrophenyl 
ppm  parts per million 
Pra  propargyl glycine 
p-TSA  para-toluenesulfonic acid 
py  pyridine 
q  quartet (in NMR) 
quant.  quantitative 
R  generic organic group, unless specified 
Rf  retention factor 
RMSD  root-mean-square deviation 
RNase B ribonuclease B 
RP-HPLC reverse phase high performance liquid chromatography 
rpm  revolutions per minute 
rt  room temperature 
s  singlet (in NMR) 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec  second(s) 
SEC  size exclusion chromatography 




t  tertiary 
t  triplet (in NMR) 
TEA  triethylamine 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
t.l.c.  thin layer chromatography 
TMSOTf trimethylsilyl trifluoromethanesulfonate 
Tris  tris(hydroxymethyl)aminomethane 
UV  ultraviolet 
v/v  volume by volume 
w/v  weight by volume 
WT  wild-type 
 
Amino acids: 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 




H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
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Chapter 1: Introduction 
 
1.1 Significance of Carbohydrates 
Carbohydrates are one of the four key classes of biological macromolecules, alongside 
proteins, DNA, and lipids.1 The functional diversity of carbohydrates stands out 
because of their ability to form highly complex linkages and branched polymers. This 
complexity is made possible by several structural features of carbohydrates such as 
hydroxyl group stereochemistry, ring size, anomeric configuration, linkage position, 
branching position, reducing terminal attachment, and the linear sequence of core and 
linear branches. Such structural diversity means that a unit as small as a hexasaccharide 
is capable of forming 1.05 x 1012 possible carbohydrate structures, whilst a hexapeptide 
is capable of less than 1 x 105 possible structures.2  
 
1.2 Biological Importance of Carbohydrates 
The understanding of the involvement of carbohydrates in a myriad of life-sustaining 
and life-threatening processes has seen carbohydrate chemistry evolve into a broad area 
of research that has captured the interest of the scientific community.3 Initially, 
carbohydrates were thought to be simple molecules involved in the formation of 
structural materials, such as chitin and cellulose, and as a source of energy, such as 
glucose. More recently, carbohydrates have been shown to play vital roles in biological 
processes, leading to the development of the field, Glycobiology. The development of 
a complete understanding of the unique molecular properties of carbohydrates and their 






There are three main categories of protein-linked glycans: N-linked (where the sugar is 
attached to the amide group of Asn), O-linked (where the sugar is attached to the 
hydroxyl group of Ser, Thr, or hydroxyllysine (hLys)), and C-linked (where the sugar 
is attached to the carboxyl group of Trp).  
 
Protein glycosylation is of vital importance, and is essential in many biological 
processes including cell-cell signaling,4 microbial virulence,5 inflammation,6 and 
immune defense.7 Post-translational modification of proteins by glycosylation can play 
a key role in protein folding,8 and can also critically affect important protein properties 
such as conformation and stability,9 susceptibility to proteases,10 and circulatory 
lifetime.11  
 
The study of the above effects, however, is made difficult due to the fact that 
glycoprotein biosynthesis and assembly is not under direct genetic control; this leads to 
glycoproteins being biosynthesized as complex heterogeneous mixtures. These 
glycoprotein mixtures are known as glycoforms, where different oligosaccharide 
structures are linked to the same peptide chain.  
 
Due to their similar physical properties, these mixtures are usually inseparable. 
Interestingly, Rudd et al. successfully separated glycoforms of RNase B and 
demonstrated that different glycoforms conferred different activity to RNase B, and 
that heterogeneous mixtures of glycoforms provide a range of activities that could be 
influenced with fine-tuning of the glycan structure.12 Therefore, to understand the 






1.3  Chemical Synthesis of Oligosaccharides 
The chemical synthesis of complex carbohydrates has been a major focus of many 
research groups. The assembly of individual carbohydrate units is not a straightforward 
process. First, one must appreciate the complexity of the glycosylation reaction, which 
is capable of producing a wide range of products that vary in both stereo- and 
regiochemistry.  
 
In a typical glycosylation reaction, an appropriate electrophilic promoter activates a 
glycosyl donor containing a leaving group at the anomeric centre. The resulting 
glycosyl cation is then reacted with the desired glycosyl acceptor to afford either an α- 
or β-glycoside (Scheme 1). For the synthesis of di- and oligosaccharides, this acceptor 
is a carbohydrate alcohol. 
 
Scheme 1 - General glycosylation reaction. (i) Activation of glycosylation donor with an 
electrophile, E+; (ii) capture of glycosyl cation with acceptor, R’OH to give either an α- or β-
glycoside. 
 
The choice of protecting groups and the sequence of their installation is very important 
for an efficient and successful synthetic route. This, in turn, may dictate the 
stereochemical outcome of the glycosylation reaction where the anomeric linkage can 
be formed in a 1,2-cis or 1,2-trans orientation with regard to the oxygen at C-2 of the 
donor and the new anomeric linkage. For example, an acyl group at C-2 (e.g. acetate, 





neighbouring group participation to form a cyclic oxonium ion (Figure 1). For 
glucosides, the α-face of the sugar is blocked by the neighbouring equatorial C-2 
substituent, disfavouring attack by the acceptor from this direction, giving the β-product 
(Figure 1, top). For mannosides, the epimer of glucose at C-2, neighbouring group 
participation by the C-2 acyl functionality occurs on the top (equatorial) face of the 
anomeric centre, blocking acceptor access to this face and favouring the formation of 
α-mannoside products (Figure 1, bottom). 
 
 
Figure 1- The formation of 1,2-trans glycosides by neighbouring group participation using 
glucosyl (top) and mannosyl donors (bottom). 
 
Research and development over the past thirty years has been focused on discovering 
new anomeric leaving groups and promoter systems which give rise to high yielding, 
stereoselective, and efficient glycosylation reactions.13–18  
 
1.4 O-Glycans 
O-Glycans are one of two major types of protein-linked oligosaccharides, and result 
from the sequential enzymatic transfer of monosaccharide units to the hydroxyl groups 
of the side chains of several amino acids, mainly serine and threonine. O-Glycans are 
widely known for their roles as primary components of the intestinal mucus layer that 





that protects epithelial and intestinal mucosal immune cells from potentially harmful 
luminal microflora and food components. The mucus layer is a dense, carbohydrate-
rich matrix that consists primarily of mucins containing multiple serine and threonine 
residues modified by O-glycans, which account for 80-90% of the total mucin mass.  
 
The roles of O-glycans are also functionally diverse. Generally, O-glycans are involved 
in roles associated with immunity, receptor-mediated signalling, regulation of enzyme 
activity, and protein expression and processing. Moreover, this modification has also 
been found to enhance protein stability, heat resistance, hydrophilic, and protease 
resistance to various proteins.19,20,21 O-Glycans are also found in a wide variety of 
glycoproteins such as fetuin, human gonadotropins, glycophorin, and antifreeze 
glycoproteins.22  
 
O-Linked glycosylation has also been suggested to play vital roles in determining the 
secondary, tertiary, and quaternary structure of a fully folded protein.23 For example, 
the core 1 structures [Galβ1,3GalNAc-α-AA, where AA represents a serine or threonine 
residue] of the T1 fragment of glycophorin interacts with the peptide and limits the 
movement of the chain around a particular conformation which results in the 
stabilization of the conformation of the peptide backbone.24  
 
Another form of O-linked glycosylation involves the attachment of N-
acetylglucosamine (GlcNAc) to serine and threonine residues. Protein O-
GlcNAcylation is regulated by two enzymes: 1) Uridine diphosphate N-
acetylglucosamine:polypeptidyl transferase (OGT),25,26 a glycosyl transferase that 





acceptor proteins and; 2) O-GlcNAcase (OGA)27,28, a glycosyl hydrolase that catalyses 
the cleavage of O-GlcNAc from proteins. The cycling of O-GlcNAc on and off of 
proteins is catalysed by the reciprocal action of these two enzymes. The O-GlcNAc 
modification is known to regulate a diverse range of cellular processing including 
epigenetic regulation of gene expression29, stress response30, and circadian rhythm31. 
Decreases in brain O-GlcNAcylation has also been associated with Alzheimer 
disease.32 More recently, O-GlcNAcylation has been found to be associated with the 
protection of nascent polypeptide chains from premature degradation by decreasing 
translational ubiquitylation.33 
 
Unlike N-glycans, O-glycans are often classified on the basis of the sugar found at the 
reducing end. For mucin O-glycans, this monosaccharide is N-acetylgalactosamine 
(GalNAc) which is typically α-linked to serine or threonine. GalNAc is then extended 








Figure 2 - Core structures of the O-Glycans 
O-Glycans are assembled by the sequential addition of sugar units by several specific, 
membrane-bound glycosyl transferases in a highly controlled fashion.19 The extension 
of the monosaccharide unit gives rise to important biological factors such as the blood 
group determinants (A, B, and H).  
 
To date, there is no known consensus sequence for O-glycans, although there have been 
some noticeable patterns observed between the locations of O-glycosylation. For 
example, only serine and threonine residues that are exposed on the protein surface can 





O-glycosylation have been found in regions with high serine, threonine, and proline 
content.35  
 
The structure of O-glycans present on different cell and protein surfaces has been 
extensively studied.36,37 Traditionally, the first step towards structure elucidation of the 
glycan portion of a glycoprotein involves the glycan release from the polypeptide 
backbone for better analysis (although some non-liberating methods have been 
reported).38 In the case of N-glycans, free reducing sugars can be conveniently and 
quantitatively released from glycoproteins by either the commercially available peptide 
N-glycosidase F (PNGase F) or a variety of endo-α-N-acetylglucosaminidases.39  
 
In contrast, O-glycans are generally liberated by chemical methods due to the lack of 
‘universal’ releasing enzymes. Reductive β-elimination (the Carlson degradation)40, in 
which O-glycans are released from glycoproteins and then reduced to alditols in situ in 
alkaline sodium borohydride solution to prevent “peeling” degradation from occurring, 
is most commonly used (Figure 3). The disadvantage of this method is that the O-glycan 
alditols that are obtained cannot be further labelled with either a chromophore or 







Figure 3 - Reaction mechanism for the release of O-glycans under basic conditions and the 
basis of the degradative ‘peeling’ reaction. 
 
1.5 The biosynthesis of O-glycans 
The biosynthesis of O-glycans is initiated by a family of enzymes, the Golgi-body 
localized polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAcTs), which 
transfer a GalNAc unit from UDP-GalNAc to a Ser or Thr residue of a correctly folded 
protein, so beginning the first step in the biosynthesis of all mucin-type O-glycans.41 
This GalNAc-Ser/Thr unit, also known as the Tn antigen, can serve as an acceptor for 
at least three other Golgi glycosyltransferases: 1) core 1 β1,3-galactosyltransferase 
(core 1 β3GalT or T-synthase), which synthesizes the core 1 structure (also known as 
the T antigen); 2) core 3 β1,3-N-acetylglucosaminyltransferase (core 3 β3GlcNAcT), 
which synthesizes the core 3 structure and; 3) the sialyltransferase ST6GalNAc-I which 





additional transferases involved in the extension of the core 1 and core 3 disaccharides 
to give complex structures. 
 
1.6 O-Glycans in disease states and treatment 
Unnatural changes to the extension of the innermost GalNAc unit have been associated 
with malignancies.42 In 1969, terminal α-linked GalNAc were observed on human 
tumour cells. These cells bound to agglutinins from the snail-lectin HPA that recognizes 
the T antigen (Galβ1,3GalNAc).43 Springer et al. then further reported that the Tn 
antigen was found at high levels in around 90% of breast carcinomas,44 whereas little 
or no expression was observed in normal adult tissues. Further studies have associated 
the Tn antigen expression in cervical cancer,45 lung adenocarcinomas,46 colorectal 
carcinomas,47 breast carcinomas,48 and gastric carcinomas49 with metastatic potential 
and poor prognosis.  
 
These anomalies are associated with erroneous glycosylation in the biosynthetic 
pathways during the transport of proteins through the endoplasmic reticulum and Golgi 
bodies, which is often linked to a set of defective or absent enzymes. For example, a 
deficiency in UDP-GalNAc transferase 3 (polypeptide N-
acetylgalactosaminyltransferase 3, GalNT3; EC 2.4.1.41), renders the organism unable 
to transfer UDP-GalNAc to Thr/Ser of a protein backbone. Patients with familial 
tumoral calcinosis (FTC), an autosomal recessive progressive metabolic disorder 
characterized by large calcium deposits in the skin and subcutaneous tissues, can have 











Changes in O-glycosylation of cell membrane glycoconjugates have been observed in 
neoplastic lesions from a variety of organs including lung, stomach, skin, and 
endometrium.46 Wopereis et al. have published a comprehensive review on the many 
conditions associated with erroneous O-glycosylation.51  
 
The T-antigen (Galβ1,3GalNAc-α-Ser/Thr) and its precursor, the Tn antigen (GalNAc-
α-Ser/Thr), have been found to be over-expressed in more than 85% of human 
carcinomas, but not in healthy human tissues.52–54 Since these truncated O-glycan 
variants are abundant on tumours, peptides containing defined O-glycan structures have 
been proposed as anti-cancer vaccines, which may generate an immune reaction against 
epitopes present on cancer cells.55–57 Thus, identification of abnormal glycosylation 
patterns on cell-surface glycoproteins of malignant cells has motivated research efforts 
towards the development of cancer immunotherapy,42,58,59 an alternative to established 
cancer therapies based on the possibility of activating the human immune system to 
recognize and effectively kill tumour cells.60 The advantages of this approach over 
standard therapies, such as surgical removal of tumours, radiation, and chemotherapy, 
stem from the high selectivity and the delocalization of the immune reaction.61  
 
Antitumoral vaccines are composed of tumour-associated carbohydrate antigens 
attached to peptides which provide stimulating epitopes for T cells.62–64 Pioneering 
experiments were carried out by Springer et al, who used erythrocyte glycoproteins as 
antigens that were isolated from outdated, banked blood and treated with enzymes to 
expose the Tn antigen.65 This worked based on skin hypersensitivity tests, which aimed 
to diagnose various carcinomas years before biopsies and X-ray examinations gave 




been aimed at generating well-defined and pure Tn-antigen preparations. For example, 
Napoletano et al.66, Kaiser et al.67–69, and Boons et al.70,71 have generated glycopeptide 
vaccines carrying clustered Tn antigens that were synthesised by either chemically or 
enzymatically transferring GalNAc to Ser/Thr residues of MUC1 peptide fragments. 
There has also been work published on the synthesis of non-natural mimics of the Tn 
antigen.72 
 
1.7 Glycosyl transferases 
Glycosyl transferases are responsible for the synthesis of glycans during glycoprotein 
biosynthesis. Glycosyltransferases generally act in a stepwise manner and are highly 
specific in their substrate requirements (Scheme 2).73,74 There are two classes of 
glycosyl transferases: Leloir pathway glycosyltransferase have strict specificity for 
their respective nucleotide sugar donor and the acceptor, whereas non-Leloir pathway 
glycosyltransferases use sugar phosphates as the donor substrate.75 
 
 
Scheme 2 – Glycan synthesis using glycosyl transferases. 
 
In practice, glycosyltransferases have been very useful for the synthesis of 
oligosaccharides76 with reactions often furnishing high yields. However, there are 
several difficulties associated with their usage for oligosaccharide construction. For 




donors are required. Moreover, nucleoside diphosphate by-products are often inhibitors 
of the enzymes.77  
 
More recently, a methodology called glycorandomization has slowly gained 
prominence, where non-native glycosyl 1-phosphates could be used as substrates for 
nucleotidyltransferase enzymes which had been modified to have increased 
promiscuity via directed evolution.78 The resultant non-native sugar nucleotides have 
been shown to be effective glycosyl donors for glycosylation of a variety of natural 
products.79–81  
 
1.8 Glycosyl hydrolases (glycosidases) 
Glycosyl hydrolases are enzymes that catalyse the hydrolysis of the glycosidic linkage 
of glycosides, resulting in the formation of a sugar hemiacetal and the corresponding 
free aglycon. The importance of glycosyl hydrolases in biological systems cannot be 
underestimated as they play crucial roles ranging from degrading polysaccharide food 
sources through to manipulating glycoconjugates on the surfaces of proteins and cells. 
Due to the numerous glycosidic linkages found in biological systems, it is not surprising 
that there are correspondingly a vast number of glycosidases. To date, over 260,000 
different glycosyl hydrolases have been identified and grouped into 135 families.82  
 
There are two types of glycosidases: exoglycosidases, which cleave the glycosidic 
linkage to release the terminal residue of an oligosaccharide, and endoglycosidases, 
which cleave internal glycosidic bonds. Exoglycosidases are specific for a particular 
sugar and show varying specificity with regard to the particular linkage between two 




α2,6-linked NeuAc, others are specific in that they only hydrolyse α2,3 linkages. 
Endoglycosidases are highly specific for their respective internal linkage of an 
oligosaccharide, for example, the endo-β-N-acetylglucosaminidases (ENGases) 
specifically cleave the GlcNAcβ1,4GlcNAc linkage of N-linked glycoproteins.  
 
Although their primary role is to catalyse the hydrolysis of the glycosidic linkage, under 
controlled conditions, glycosidases can be used to catalyse the reverse reaction, that is, 
glycosidic bond formation.77 As such, they have been used extensively as biocatalysts 
for oligosaccharide synthesis. 
 
Alternatively, transglycosylases, a class of GH enzymes that can catalyse the intra- or 
intermolecular substitution of the anomeric position of a glycoside, can be used for the 
synthesis of glycoconjugates. In general, transglycosylases utilize the same mechanism 
as various retaining glycosidases whereby the reactive glycosyl-enzyme intermediate 
can be intercepted by water, or by another acceptor (such as a carbohydrate), to give a 
new glycoside. For example, the family GH70 comprises of transglucosylases produced 
by lactic acid bacteria. The enzymes in this family use sucrose as the D-glucopyranosyl 
donor to synthesise α-D-glucans with high molecular masses (>106 Da), releasing D-
fructose as the by-product. In the presence of glucosyl acceptors, glycosylation occurs 
at the expense of polymer formation, and the competition between the two reactions is 
controlled by acceptor recognition by the enzyme. Moreover, polymer extension 







1.9 Mechanism of Glycosidases - Inverting and Retaining Glycosidases 
Glycosidases are further sub-divided in two main classes by their mode of catalysis: 
inverting and retaining glycosidases. 
 
Inverting glycosidases operate via a direct displacement of the glycoside by water 
(Figure 5a). As their name implies, the configuration of the anomeric centre in the 
product is inverted relative to that of the starting glycosyl substrate.  
 
Retaining glycosidases utilize a double-displacement mechanism involving the 
formation of a glycosyl-enzyme intermediate (Figure 5b). This mechanism involves 
initial binding of the substrate to the enzyme followed by general acid-catalysed attack 
of a nucleophilic residue at the anomeric centre to form a glycosyl-enzyme 
intermediate. This intermediate is then hydrolysed by general base-catalysed attack of 
water at the anomeric centre, forming the product with retention of configuration and 
returning the enzyme to its original protonation state. Both the formation and hydrolysis 
of the glycosyl-enzyme intermediate likely proceed through transition states with 






Figure 5 - Mechanism of glycosyl hydrolases. a) Hydrolysis catalysed by inverting 
glycosidases; b) Hydrolysis catalysed by retaining hydrolases; c) Transglycosylation 
catalysed by retaining glycosidases. 
 
The transglycosylation reaction is considered a special type of hydrolysis wherein the 
glycosyl-enzyme intermediate can be reacted with other nucleophiles, such as alcohols 





A major difference between the two classes is the distance between the two carboxylic 
acid residues: for retaining glycosidases, the distance is typically around 5.5 Å, whereas 
for inverting glycosidases it is usually around 10 Å.87 
 
1.10 Uses of Glycosidases 
Glycosidases have the primary function of cleaving glycosidic linkages, however they 
can catalyse the formation of glycosidic bonds if the conditions are correctly chosen. 
The transglycosylation activity of endoglycosidases has been proven useful for 
transferring oligosaccharides to various compounds, making them ideal for the 
synthesis of neoglycoconjugates.88  
 
The two main approaches previously employed to enable the enzyme-catalysed 
formation of the glycosidic bond are thermodynamically controlled and kinetically 
controlled glycosylation.77 The thermodynamic approach involves the reversal of the 
in vivo function of the glycosidase. This can be achieved by using large excesses of 
substrate,77 organic co-solvents, high salt concentrations,89 and/or high temperatures.90 
However, these methods still result in low yields and poor regioselectivity.  
 
Alternatively, kinetic control relies on the formation of a reactive intermediate from an 
activated glycosyl donor that is subsequently reacted with a glycosyl acceptor to form 
a glycosidic bond more rapidly than it can be reacted with water. In such cases, the 
yield is optimised by utilising conditions where the rate of hydrolysis is slower than 
that of transglycosylation. Typically this can be achieved by using high acceptor 




just two of many common activated donors that have been used in glycosidase-
mediated transglycosylation reactions.88,91,92 
 
1.11 Glycosynthases 
To overcome the drawbacks of low yields of glycosidase-mediated transglycosylation 
reactions, glycosynthases, a new class of mutant glycosidases were introduced. The 
first glycosynthases were derived from retaining exo- and endo-β-glucosidases by 
replacing the active site nucleophile with a non-nucleophilic residue such as 
alanine.91,93,94  Introduction of this residue resulted in a correctly folded enzyme, but 
which was catalytically inactive since it lacked the residue required to form the α-
glycosyl-intermediate.  
 
The importance of the mutation can be appreciated if one considers the mechanism of 
the retaining β-glycosidase (Figure 6a). As mentioned in Section 1.9, retaining 
glycosidases operate by a double-displacement mechanism involving the formation of 
a glycosyl-enzyme intermediate. General base-catalysed attack of an appropriate 
acceptor (water or alcohol) forms the product with retention of configuration. Removal 
of the catalytic nucleophile disrupted the natural mechanism of the enzyme (Figure 6b). 
Without the ability to form the glycosyl-enzyme intermediate, the glycosidase could 





Figure 6 - Mechanisms of a) retaining β-glycosidase and; b) β-glycosynthase catalysis. 
 
However, with an intact active site, it could still catalyse the ligation of an activated α-
glycosyl donor to an acceptor bound in the aglycon pocket (Figure 6b). The enzyme, 
without nucleophilic activity, could not form the covalent glycosyl-enzyme 
intermediate, and so hydrolysis of the product did not take place. Withers termed these 
mutated enzymes glycosynthases, “mutant enzymes formed from retaining 
glycosidases that are capable of catalysing glycosyl transfer from glycosyl fluorides to 
acceptor alcohols without hydrolysis of the product”.95 
 
Since the invention of glycosynthases, there have been multiple developments from 
various research groups that have focused on screening a variety of different amino acid 
mutations (e.g. nucleophilic96 and acid/base mutants97) as well as broadening substrate 
specificity to generate desired linkages.97–99 However there is no ‘general strategy’ for 





1.12 Chemical rescue of mutant glycosidases 
The restoration of the activity of inactive mutant enzymes by small exogenous 
molecules is a well-established experimental strategy. In fact, the process has even been 
demonstrated in Nature by myrosinase, a glucosidase expressed in mustard and 
rapeseed.102 Myrosinase lacks a glutamic acid residue at the position which would 
normally act as catalytic acid-base residue (Scheme 3). Instead, the high reactivity of 
the sinigrin substrate means the glycosylation step 1 can be performed without protonic 
assistance. The subsequent de-glycosylation step 2 is then performed by ascorbate (a 
common plant metabolite) acting as a catalytic base (pKa 4.1). 
 
 
Scheme 3 – a) Chemical structure of sinigrin; b) Nature's version of chemical rescue found in 
myrosinase. 
 
This methodology, so-called ‘chemical rescue’, has been used to probe the chemical 
and structural requirements for efficient catalysis by mutant enzymes.76  In the cases of 




residues in the enzyme active site.103,104 As mentioned earlier, mutant glycosidases may 
have little hydrolytic activity on their respective natural substrates. However, in the 
presence of an activated substrate, such as a p-nitrophenyl or dinitrophenyl glycoside, 
and a small charged nucleophile such as azide, formate, or fluoride, the hydrolytic 
product can be formed.75  
 
The mechanism of chemical rescue is illustrated on Scheme 4. Upon binding of the 
substrate by the enzyme, an exogenous nucleophile facilitates anomeric bond cleavage 
in place of the removed catalytic nucleophile. In such a case, the substitution of the 
catalytic nucleophile (commonly glutamate) of an enzyme for a smaller residue, such 
as glycine or alanine, provides a pocket in which the anion can bind. Chemical rescue 
is considered a diagnostic test for the identification of the nucleophilic residue. 
 
 
Scheme 4 - Chemical rescue of mutant glycosidases using exogenous nucleophiles. 
If the in-situ formed glycosyl fluoride is then reacted with an alcohol or a glycosyl 







1.13 Methods of O-linked glycopeptide and glycoprotein synthesis 
Glycoproteins are associated with a wide range of important biological processes. 
However, glycoproteins naturally exist as heterogenous mixtures, in which the same 
protein is linked to a variety of different oligosaccharides. This heterogeneity arises due 
to the fact that glycoprotein synthesis is not under direct genetic control. Each 
glycoform of the protein may have different physical properties. To access pure 
glycoforms of glycoproteins, the glycoscience community has resorted to chemical, 
biochemical, and chemo-enzymatic solutions. 
 
As described earlier, mucin-type proteins are known to serve as important recognition 
elements that mediate a multitude of cell-cell interactions. The importance of O-
glycosylation has inspired much interest in the synthesis of defined glycoproteins for 
structural and functional studies.105 Since certain O-glycan structures are associated 
with tumour progression, there has also been a strong interest in the generation of 
glycopeptide-based tumour vaccines.106  
 
1.13.1. Solid-phase peptide synthesis (SPPS) 
The most common chemical approach to the synthesis of glycopeptides with complex 
O-linked glycans involves the use of a suitably protected O-glycosyl amino acids as 
building blocks in solid-phase peptide synthesis (SPPS) (Scheme 5). In general, a base-
labile amine protecting group, such as fluorenylmethyloxycarbonyl (Fmoc), is 
preferred over acid-labile protecting groups, such as tert-butoxycarbonyl (Boc)-based 
protection for the preparation of glycopeptides since basic conditions are more 






Scheme 5 - General strategy for the synthesis of O-linked glycopeptides by SPPS. 
Methods for the preparation of simple GalNAc-α-Ser/Thr building blocks for the 
assembly of mucin-type glycopeptides have been, for the most part, based on 
methodology introduced by Paulsen et al.107 wherein α-GalNAc derivatives are 
prepared using a glycosyl donor that has a non-participating azido group at C-2 
(Scheme 6). The resulting Fmoc-glycosyl amino acids can be incorporated into peptides 
using standard coupling procedures.108  
 
Scheme 6 - Synthesis of GalNAc building blocks using the methodology introduced by Paulsen 
et al. 
 
1.13.2. Cassette Assembly 
One of the main challenges in the synthesis of O-linked glycosyl amino acids is how to 
achieve high stereoselectivity in the formation of the α-glycosidic linkage between 
GalNAc and Ser/Thr, a problem that is even more pronounced when using 




for the synthesis of complex O-glycosyl amino acids is using a ‘cassette assembly’ 
approach.110 This strategy involves the initial formation of the desired α-Ser/Thr 
linkage prior to elaboration of additional sugars from the core GalNAc moiety (Scheme 
7). Danishefsky and colleagues have used the cassette approach for the preparation of 
a variety of complex building blocks bearing tumour-related antigens.111–113  
 
Scheme 7 - Generic schematic of the 'cassette approach'. 
 
1.13.3. Chemoselective Ligation 
Chemoselective ligation is another technique that has been employed for the synthesis 
of O-linked glycopeptides. This method involves the attachment of preformed 
oligosaccharides to simple glycopeptides, and is an attractive method for the rapid 
assembly of peptides carrying complex O-glycans. Chemoselective ligation reactions 
are mild and selective, and allow for the coupling of unprotected biomolecules (such as 
peptides and carbohydrates) in an aqueous environment.114–116 Rodriguez et al. used 
chemoselective ligation for the synthesis of O-linked glycopeptide mimetics by 
introducing unnatural bonds at the branch points (C-6) of the core GalNAc (Scheme 
8).117 A simple O-linked glycopeptide containing a single GalNAc unit was 




Chemoselective ligation with aminooxy-functionalized sugars gave the unnatural 
glycan containing an oxime linkage. 
 
Scheme 8 - Synthesis of oxime-linked glycopeptide mimetics by chemoselective ligation. 
 
Marcaurelle and Bertozzi have also used chemoselective ligation to generate 
glycopeptides with oligosaccharides attached to C-3 of the core GalNAc unit (Scheme 
9).118 Their synthesis started with building block 1.1 which contained a protected thiol 
at C-3. After glycosyl amino acid 1.2 was incorporated into a peptide by SPPS, the thiol 
was deprotected and then selectively alkylated with a variety of N-bromoacetamido 
glycosides 1.3 to generate thioether-linked glycopeptide mimetics 1.4.  
 
 





1.13.4. Native chemical ligation 
Native chemical ligation (NCL), was first applied to peptide synthesis in the 1990s by 
Kent and co-workers119 and has since found widespread use in the field of protein 
chemistry for the synthesis of large un-glycosylated proteins.120 
The ligation involves the reaction of an N-terminal cysteine of one peptide with the C-
terminal thioester of another by transthioesterification (Scheme 10). Thioester 
formation is followed by a spontaneous S → N acyl shift to afford a native peptide 
bond. The NCL reaction is carried out in aqueous solution and is selective and often 
gives near-quantitative yields of the desired ligation products.  
 
 
Scheme 10 - Mechanism of native chemical ligation. 
 
In 2001, Marcaurelle et al. used NCL to synthesise the O-linked glycoprotein, 




chemoattractant for T cells and natural killer cells.122,123 The protein contains a small, 
mucin-like domain at the C-terminus which is O-glycosylated. The synthesis of Lptn 
was undertaken to investigate the structural and functional significance of the O-
glycosylation. First, two fragments were synthesised (Scheme 11); a 47-residue 
peptide-α-thioester 1.5 and a 46-residue glycopeptide 1.6 containing 8 α-GalNAc 
residues. Ligation of fragments 1.5 and 1.6 by NCL was successful and gave the desired 
glycosylated chemokine 1.7 in milligram quantities. 
 
 
Scheme 11 - Synthesis of glycosylated Lptn 1.7 by NCL. 
NCL has also been used to synthesise a number of important glycoproteins such as 
diptericin124 and Ribonuclease C.125,126 
 
1.13.5. Chemoenzymatic synthesis 
Chemoenzymatic synthesis is a powerful and attractive alternative for the formation of 
glycosidic bonds under mild conditions without the need for protecting groups. The 




preformed glycopeptides containing simple O-linked glycans is an attractive method 
for accessing large glycosyl amino acids.127–131  
 
Koeller et al. have illustrated the elegance of this technique by the synthesis of a PSGL-
1 fragment.132 Herein, the synthesis of glycosyl amino acid 1.8 bearing an α-O-linked 
disaccharide was followed by the incorporation of 1.8 into a peptide using SPPS to give 
the synthetic glycopeptide 1.9 (Scheme 12). The disaccharide was then elaborated using 
a series of glycosyltransferases to give the desired PSGL-1 fragment 1.10.  
 
 
Scheme 12 - Synthesis of PSGL-1 1.10 by Koeller et al.133 Conditions: i) 1. SPPS, 2. SO3.pyr, 
ii) 1. NaOMe, MeOH; 2. UDPGalβ1,4-GalT, 3) CMPNeuAcα2,3-SiaT, 4) GDPFucα1,3-FucT. 
 
Glycosidases have also been successfully employed for glycopeptide synthesis. 




been used for the synthesis of glycoconjugates.134–136 Glycoprotein remodelling, in the 
case of N-glycans, is a process wherein a heterogeneous mixture of glycoforms is 
trimmed down to a single sugar unit using endohexosaminidase enzymes, and is then 




Scheme 13 - Endohexosaminidase-catalysed glycoprotein remodelling. The Fairbanks group 
have developed methods using Endo A from Arthrobactor protomorphiae and Endo M from 
Mucor hiemalis for glycoprotein remodelling. 
 
The use of glycosidases and glycosynthases for the synthesis of homogenous N-glycan 
glycopeptides and glycoproteins has extensively reported by the groups of 
Fairbanks136,137 and Wang,138,139 both groups whom have extensively used 
endohexosaminidases from the family GH18 and GH85. For example, Tomabechi et 
al.140 synthesised glycosylated analogues of the diabetes drug pramlintide by a 
combination of solid-phase synthesis and enzymatic glycosylation (Scheme 14). The 
E173H141 mutant of Endo A142 was used to glycosylate tetrasaccharide oxazoline 1.11 
to peptides 1.12 and 1.13 to give glycopramlintides 1.14 and 1.15 with the core N-




allowed the efficient attachment of the decasaccharide 1.16 to give undecasaccharide 
glycopramlintides 1.17 and 1.18, with complex-type biantennary N-glycans at positions 
3 and 21, respectively. 
 
Scheme 14 - ENGase-catalyzed production of glycopramlintides with N-glycans at N3 and N23 
by Tomabechi et al.140 Conditions: a) Endo A E173H, sodium phosphate buffer, pH 6.5, 23 ˚C, 
82 %; b) Endo M N175Q, sodium phosphate buffer, pH 6.5, 23 ˚C, 58 %; c) Endo A E173H, 
sodium phosphate buffer, pH 6.5, 23 ˚C, 95 %; d) Endo M N175Q, sodium phosphate buffer, 





Lomino et al.139 used Endo M N175A for the synthesis of a complex type glycoform of 
polypeptide C34, a potent HIV inhibitor derived from HIV-1 gp41 (Scheme 15).143–145 
The Glc- 1.19 and GlcNAc-peptide 1.20 acceptors were enzymatically glycosylated, 
using Endo M N175A, with the sialylated complex type N-glycan from SG-oxazoline 
1.21 to give the corresponding glycosylation products 1.22 and 1.23, respectively, with 
yields exceeding 80 % when additional enzyme was added. 
 
Scheme 15 - ENGase-catalysed glycosylation of Glc-C34 and GlcNAc-C34 by Lomino et al.139 
Conditions: SG-oxazoline 1.21, Endo M N175A, phosphate buffer, pH 7.4, 83 % (1.22), 85 % 
(1.23). 
 
Although there are many endo- and exo-glycosidases that trim different O-glycan 
linkages, there is still to our knowledge no endoglycosidase that will cleave the β1,3 
linkage of the reducing end sugar to provide a GalNAc glycosyl ‘handle’ for further 




the α-Ser/Thr linkage.88,146,147 As illustrated in Section 1.6, the multitude of diseases 
associated with erroneous O-glycosylation necessitates the synthesis of vaccines 
containing epitopes which stimulate an immune response. However, the methods used 
for their syntheses often result in multiple synthetic steps which inevitably leads to loss 
of material. Thus, there is an increasing need for syntheses that do not incorporate 
multi-step, protecting group methodologies whilst furnishing high yields and 
stereoselectivities.  
 
Recently, several endoglycosidases that cleave extended O-glycan structures from the 
serine or threonine residues to which they are naturally attached were isolated. These 
enzymes, endo-α-N-acetylgalactosaminidases, belong to family GH101 of the 
glycoside hydrolases (http://www.cazy.org/), and demonstrated properties which 
showed promise for the enzymatic synthesis of homogeneous O-glycan glycopeptides 
and glycoproteins. 
 
Therefore, our interest turned towards developing a methodology to use these enzymes 
for the chemoenzymatic synthesis of O-linked glycopeptides. 
 
1.14 Endoglycosidases of the GH101 family. 
The GH101 glycosyl hydrolase family currently contains proteins from bacterial 
species, most of which are from commensal human bacteria, although some may also 
be human pathogens. Since these enzymes naturally cleave O-glycan oligosaccharide 
structures from peptides and proteins, they can therefore, in theory, be used to catalyse 
the reverse reaction. To date, there are 148 enzymes in family GH101, in which 10 





In 2008, Koutsioulis et al.148 identified putative endo-α-N-acetylgalactosaminidases 
using a BLAST search149 using the protein sequence of engBL from Bifidobacterium 
longum JCM1217. Four potential genes were cloned and expressed: engEF from 
Enterococcus faecalis, engCP from Clostridium perfringens, engAA from 
Arthrobacter aurescens, and engPA from Propionibacterium acnes. The substrate 
specificity of the enzymes were then investigated. Table 1 summarises hydrolytic 
capabilities of the GH101 endo-α-GalNAcases. 
 
 EngCP EngEF EngPA EngSP EngAA 
 Product released (%) 
Galβ1,3GalNAcαpNP (core 1) 100 100 100 100 100 
Galβ1,3(GlcNAcβ1,6)GalNAcαpNP 
(core 2) 
2.5 2 0 0.6 0 
GlcNAcβ1,3GalNAcαpNP (core 3) 6 100 100 3 27 
Galβ1,3GlcNAcαpNP 0 0 0 0 0 
GalNAcαpNP 4.4 2.2 1.8 1.2 30 
Table 1 - Substrate specificity of GH101 endo-α-GalNAcases using pNP substrates. 
 
These enzymes could all release p-nitrophenol from Galβ1,3GalNAc-α-pNP (core 1-
pNP). EngEF and engPA were capable of hydrolysing GlcNAcβ1,3GalNAc-α-pNP 
(core 3-pNP), while engAA could only partially hydrolyse the core 3 disaccharide. 
EngAA was capable of hydrolysing GalNAc-α-pNP while the rest of the enzymes could 




Galβ1,3GlcNAc-α-pNP and low or no activity was detected when 
Galβ1,3(GlcNAcβ1,6)GalNAc-α-pNP (core 2 trisaccharide) was used as a substrate.  
 
The enzymes could also release sugars from asialofetuin and mucin. The kinetic 
parameters of the family GH101 endo-α-GalNAcases using core 1-α-pNP and core 3-
α-pNP were also calculated (Table 2). 
 
  kcat (s
-1) KM (µM) 
core 1-α-pNP 
EngCP 19.9 70.93 
EngEF 51.17 47.85 
EngPA 2.009 3.781 
EngSP 10.51 40.37 
EngAA 25.89 33.87 
EngBF 17.8 21.8 
core 3-α-pNP 
EngEF 9.434 20.03 
EngPA 28.9 11.15 
Table 2 - Kinetic parameters of endo-α-GalNAcases using core 1-α-pNP and core 3-α-pNP as 
substrates. 
 
EngEF exhibited the highest kcat when core 1-α-pNP was used as the substrate, while 
engPA had the lowest activity on that substrate with a kcat approximate 25 times lower 
than that observed for engEF. Interestingly, engPA had a 3-fold higher kcat for the core 
3-α-pNP compared to engEF. None of the enzymes could hydrolyse Galβ1,3GlcNAc-





The transglycosylation activity of the family GH101 endo-α-GalNAcases was also 
investigated. EngCP, engEF, engPA, engSP and engAA were all incubated with core 
1-α-pNP and various alkanols. Analysis of the reaction mixtures by t.l.c. indicated that 
all of the enzymes exhibited similar transglycosylation activity.  
 
Two enzymes from family GH101 were chosen for further studies: engBL, from 
Bifidobacterium longum, had previously been characterised extensively in terms of 
sequence, structure, and kinetics. The enzyme demonstrated potential for further 
development. 
 
EngEF, from Enterococcus faecalis, was capable of hydrolysing both core 1 and core 
3 disaccharides from their substrates thus was chosen for the broader substrate 
specificity of the enzyme.  
 
1.15 Endo-α-N-acetylgalactosaminidase from Bifidobacterium longum (engBL) 
Bifidobacteria are thought to be key commensals that promote a healthy intestinal tract 
because of their many beneficial effects on the host, such as regulation of the state of 
the intestine, reduction of harmful bacteria and toxic compounds, immunomodulation, 
and anti-carcinogenic activity.150–152 Bifidobacteria naturally colonise the lower 
intestinal tract, an environment that has a low abundance of mono- and disaccharides 
because such sugars are preferentially consumed by the host and microbes present in 
the upper intestinal tract. To survive, bifidobacteria produce various kinds of exo- and 
endoglycosidases in surface-bound and/or extracellular forms, which they can utilize 





In 2005, Fujita et al. discovered an enzyme that catalysed the liberation of galactosyl 
β1,3-N-acetyl-D-galactosamine (Galβ1,3GalNAc, core 1 disaccharide) α-linked to 
serine or threonine residues from mucin-type glycoproteins.88 The enzyme was purified 
from the cultural filtrates of Bifidobacterium longum and called endo-α-N-acetyl-
galactosaminidase (EC 3.2.1.97; endo-α-GalNAcase, glycopeptide α-N-
acetylgalactosaminidase, engBF, engBL). EngBL is a protein consisting of 1,966 amino 
acid residues. The central domain (590-1381 amino acid residues) was found to exhibit 
31-53% identity to proposed proteins of several bacteria including Clostridium 
perfringens and Streptococcus pneumoniae. The recombinant protein when expressed 
in E. coli was found to liberate Galβ1,3GalNAc (core 1) from Galβ1,3GalNAc-α-pNP 
(core 1-pNP) and asialofetuin, but did not release GalNAc, 
Galβ1,3(GlcNAcβ1,6)GalNAc (the core 2 trisaccharide), or GlcNAcβ1,3GalNAc (the 
core 3 disaccharide) from their respective p-nitrophenol substrates. An analysis of the 
amino acid residues of the enzyme that were critical for hydrolysis determined them to 
be Asp-682 and Asp-789.  
 
It was also found that engBL was capable of glycosylating a variety of alcohol 
acceptors, and even sugars, with the core 1-pNP disaccharide (Table 3). 
 
Ashida et al. furthered this work by glycosylating free serine and threonine, as well as 
various biologically active peptides with the core 1 disaccharide using engBL and found 







Acceptor Transfer Ratio[1] 
Methanol 53.7 % 
Ethanol 46.8 % 
1-Propanol 32.2 % 
1-Butanol 34.9 % 
1-Pentanol 28.3 % 
1-Hexanol 8.1 % 
1-Heptanol 2.0 % 
1-Octanol Trace 
1-Nonanol ND[2] 
D-Glucose 19.7 % 
D-Galactose 8.3 % 
D-Mannose 2.5 % 
L-Arabinose 18.0 % 
Maltose 14.4 % 
Table 3 - Acceptor specificity of engBL transglycosylation as reported by Fujita et al.88 
Suzuki et al. reported the crystal structure of the native engBL protein at 2.0 Å 
resolution, and also performed docking and mutational analyses to elucidate the critical 
residues for substrate recognition by the GH101 endo-α-N-GalNAc-ases.155 EngBL was 
found to be a monomeric protein (Figure 7). Superimposition of the structures of the 
GH101 enzymes, engBL, and engSP showed that both enzymes are remarkably similar. 
Of the seven domains assigned for the engSP structure, engBL contained domains 2-7, 
but lacked domain 1, which resembles a domain of the GH13 α-amylase family. A 




insertions and deletions located at the periphery of the protein that do not appear to be 
related to substrate binding.  
 
 
Figure 7 – The overall structure of engBL in a ribbon representation (top); and a schematic 
illustration of its domain organisation (bottom). Adapted from Suzuki et al.155 
 
The residues in the active site of engSP that are involved in the catalysis were inferred 
to be Asp764 (nucleophile) and Glu796 (acid/base).156  These residues correspond to 
Asp789 and Glu822 in engBL, which are located at the C-terminal loop of the fourth 
and fifth β-strands in domain 3A, respectively. Mutational studies at these positions 
demonstrated that catalytic activity was abolished.88 
 
Autodocking analyses using Galβ1,3-GalNAc (GNB, galacto-N-biose) and 
Galβ1,3GlcNAc (LNB, lacto-N-biose) showed that the binding interactions for both 
substrates were the same. The anomeric C1 atom of GNB was found to be located in 




pointed in the opposite direction from the nucleophile. The C1 hydroxyl group formed 
a hydrogen bond with the Oε2 atom of Glu822 (2.7 Å). Collectively, these results 
supported the mechanism of a retaining glycosidase.  
 
Using mutagenesis, a third catalytically important residue was also identified, Asp682, 
which formed hydrogen bonds with three hydroxyl groups of the docked GNB (O4 and 
O6 of GalNAc and O6 of Gal), suggesting a substrate binding role for this residue.  
The N-acetyl group of GalNAc fitted into a hydrophobic pocket formed by the side 
chains of His835, Trp836, and Tyr842, with the carbonyl oxygen forming a hydrogen 
bond with the side chain hydroxyl group of Tyr787. The side chain of Gln894 was 
located at subsite -2 and recognizes the C2 hydroxyl group of Gal. 
 
Figure 8 shows the molecular surface of the substrate binding pocket of engBL and the 
partial sequence alignments of GH101 endo-α-GalNAc-ases. 
 
 
Figure 8 - Molecular surface of the substrate-binding pocket of engBL (left); and partial amino 





A protruded surface area formed by the N-terminal region adjacent to Trp748 (white 
dotted line on Figure 2, left) is observed near the C6 hydroxyl group of GalNAc at 
subsite -1. EngCP, engEF, and engPA have a deletion of four or five residues in this 
region allowing the accommodation of the branching β1-6 GlcNAc of the core 2 
structure.148 
 
1.16 Endo-α-N-acetylgalactosaminidase from Enterococcus faecalis (engEF) 
In 2008, Goda et al. published an article detailing the activity of endo-α-N-
acetylgalactosaminidase from Enterococcus faecalis (engEF), an ortholog of engBL.92 
The engEF gene was found to have 3972 base pairs corresponding to 1324 amino acids. 
The enzyme was capable of catalysing the hydrolysis of the core 1-pNP 
(Galβ1,3GalNAc-α-pNP), the core 2-pNP (Galβ1,3(GlcNAcβ1,6)GalNAc-α-pNP), the 
core 3-pNP (GlcNAcβ1,3GalNAc1-α-pNP), Gal-core 2-pNP, and GalNAc-α-pNP 
substrates. In the presence of methanol and ethanol, engEF was found to catalyse the 
transfer of the Galβ1,3GalNAc-α-pNP to generate the corresponding methyl and ethyl 
glycosides (Scheme 16).  
 
 
Scheme 16 - Glycosylation of alkanols by engEF to core 1-pNP. Conditions: i) alkanol (15 % 
v/v), engEF from Entercoccus faecalis, 25 mM NaOAc buffer, pH 6.0, 37 °C. 
 





1) The most preferred carbohydrate structure for the action of engEF was 
Galβ1,3GalNAc (core 1) amongst the substrates tested; 
2) The terminal galactose of core 1 could be replaced by GlcNAc (core 3) but the 
rate of hydrolysis was decreased somewhat by this substitution; 
3) The regiochemistry of the linkage of the terminal sugar in the core disaccharide 
structure was very important, i.e. the enzyme preferred a β1,3-linked sugar, not 
a β1,6-linked sugar; 
4) Substitution of the OH-group at C6 of the internal GalNAc with GlcNAc (core 
2) greatly reduced the activity, but this trisaccharide-pNP was hydrolysed by 
the enzyme and; 
5) GalNAc-pNP and Gal-core 2-pNP were hydrolysed but at a slower rate than 
core 1-pNP or core 3-pNP. 
 
To date, a crystal structure has not been published for engEF, and so the structural 
details that give rise to the broader specificity of this enzyme are not clear. However, 
as mentioned earlier, several residues normally clustered near the C6 hydroxyl of the 
substrate in engBL, were found to be absent in engEF which may allow for 
accommodation of the branching β1-6 GlcNAc unit.148 
 
1.17 Project Objectives 
The main goal of this research project was to develop a chemo-enzymatic method to 
synthesize O-glycan glycopeptides using family GH101 enzymes and their mutants.  
 
This thesis describes the synthesis of activated O-glycan core structures and 




catalysed glycosylations. An additional chapter concerns investigations into the direct 
synthesis of glycosides in water. 
 
Chapter 2 describes the transformation, expression, and purification of two enzymes 
from the family GH101, and their subsequent mutagenesis. 
 
Chapter 3 details the total synthesis of activated O-glycan core structures (GalNAc, 
core 1, and core 3) as the p-nitrophenol and 1-O-acetyl derivatives that were to be used 
for the enzyme catalysed glycosylation reactions in Chapter 4.  
 
Chapter 4 describes the investigations into the activity of the WT and mutant engBL 
and engEF enzymes from Chapter 2. Their kinetic parameters of hydrolysis and 
substrate specificity is quantified and their glycosylation ability is investigated. 
 
Chapter 5 details investigates the use of various nucleophiles in the DMC-activated 
glycosylation of sugars in water. 
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Enzymes have many advantages over conventional synthetic methods and their use is 
becoming more accepted in organic synthesis. Enzymes can be used without the 
requirement of a protecting group strategy whilst they maintain high stereo- and 
regioselectivity. In industrial processes, the use of enzymes is becoming increasingly 
widespread because of their catalytic efficiency, their ability to operate under ‘green’ 
conditions, and the ease of their production in large quantities through fermentation 
procedures.1 
 
Over recent years, both glycosyl transferases and glycosyl hydrolases have been used 
extensively for the construction of glycosidic linkages.2 As discussed in Chapter 1, the 
usage of glycosyl transferases for the construction of oligosaccharides is hampered by 
the lack of available enzymes, as well as the need for complex and expensive nucleotide 
donor substrates. On the other hand, there are glycosyl hydrolase enzymes 
(glycosidases), which naturally cleave the glycosidic linkage. However under 
controlled conditions, they can be used to catalyse the formation of glycosidic 
linkages.3 The biocatalytic utility of glycosidases has been demonstrated on several 
occasions for the synthesis of various oligosaccharides.4 The major issue associated 
with the usage of glycosyl hydrolases is that the product of the synthesis reaction is 
often also a substrate for the natural hydrolytic reaction5,6, a point which led to the 




these improvements, the yields of glycosidase-mediated glycosylations rarely exceeded 
60 % and were not always regioselective. 
 
A significant breakthrough occurred in 1998 when a new class of mutant glycosidases, 
so-called ‘glycosynthases’, was introduced.8 The glycosynthase approach centred on 
the use of specifically mutated retaining glycosidases. In a normal hydrolysis reaction 
catalysed by a retaining glycosidase, the substrate initially binds to the enzyme, and 
this is then followed by the general acid-catalysed attack of nucleophilic residue in the 
enzyme active site at the anomeric centre to form a glycosyl-enzyme intermediate 
(Figure 9a). This covalent intermediate is then hydrolysed by general-base catalysed 
attack of water at the anomeric centre, forming a product with overall retention of 
configuration and returning the enzyme to its original protonation state.  
 





In the original glycosynthase approach,8 the catalytic nucleophile of a retaining 
glycosidase was substituted with a non-nucleophilic residue. The mutagenesis resulted 
in a correctly folded enzyme, but, without the ability to form the glycosyl-enzyme 
intermediate, the enzyme was catalytically inactive. However, in the presence of an 
activated glycosyl donor of the opposite anomeric configuration to the usual hydrolytic 
substrate for the enzyme (which mimics the α-glycosyl-enzyme intermediate), it was 
found that the enzyme could catalyse ligation of the donor to an acceptor substrate 
(Figure 9b). Moreover as the enzyme could not hydrolyse the product, this resulted in 
significantly increased synthetic efficiency. This initial discovery led to many 
subsequent efforts to engineer new glycosynthases to catalyse a variety of synthetic 
reactions .1,9  
 
As described in Chapter 1, several endoglycosidases that cleave extended O-glycan 
structures from the serine or threonine residues to which they are naturally attached 
were recently isolated. These enzymes, endo-α-N-acetylgalactosaminidases, belong to 
super-family GH101 of the glycoside hydrolases,10 and catalyse the hydrolysis of their 
respective substrates by means of a retaining mechanism as proposed by Koshland.11 
Retaining glycosidases use a double-displacement mechanism involving the formation 
of a glycosyl-enzyme intermediate. This intermediate is then hydrolysed by general 
base-catalysed attack of water upon the anomeric centre, forming the hemiacetal 
product with retention of configuration, and returning the enzyme to its original 






Figure 10 - Hydrolysis mechanism of family GH101 endo-α-N-acetylgalactosaminidases. 
 
The enzymes demonstrated properties which showed promise for the enzymatic 
synthesis of homogeneous O-glycan glycopeptides and glycoproteins. Therefore, we 
were interested in glycoengineering glycosynthases from the GH101 hydrolases. 
 
A standard approach for designing a glycosynthase begins with identifying the catalytic 
residues of interest in a target glycosidase. Online sequence alignment tools, such as 
ClustalW,12 contain algorithms for comparing multiple sequences, and are useful for 
identifying residues of a protein involved in catalysis. Once a catalytic residue has been 
identified, the plasmid containing the gene coding for the enzyme can be mutated at the 
appropriate nucleotide position using site directed mutagenesis. 
 
The mutant plasmid is then transformed, and the protein expressed, in a bacterial strain, 
commonly E. coli. The protein is then extracted, purified, and characterised by a variety 
of techniques, including circular dichroism (CD), and sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), to determine whether the protein has 
been correctly expressed and folded.  
 
Two enzymes from the family GH101 were chosen for further studies: engBL, from 




sequence, structure, and kinetics.13–15 The enzyme demonstrated potential for further 
development. EngEF, from Enterococcus faecalis, was capable of hydrolysing both 
Galβ1,3GalNAc (core 1) and GlcNAcβ1,3GalNAc (core 3) disaccharides from their 
substrates and thus was chosen for the broader substrate specificity of the enzyme.16,17 
 
This chapter outlines the expression, purification, and mutagenesis of engBL and 
engEF of family GH101. Three mutations, namely glycine, alanine, and serine, were 
chosen, based on previous work on glycosynthase engineering18,19, to replace the 
catalytic nucleophile of the respective enzyme. 
 
The following sections serve to introduce the aforementioned molecular biology 
techniques to the reader before they are used in later sections of the chapter. 
 
2.1.1 DNA Sequence Alignment using ClustalW 
To date, the CAZY10 database contains the sequences for well over 260,000 different 
glycosyl hydrolases, each which have been grouped into 135 families based on the 
DNA sequence analysis of the respective enzymes. DNA sequence analysis is an 
important bioinformatic technique for arranging multiple genetic data sets and 
identifying regions of similarity that may be a consequence of functional, structural, or 
evolutionary relationships between the sequences. There are several online tools 
capable of performing the alignment of multiple sequences, however for the 
identification of catalytically important amino acid residues in engBL and engEF, 





ClustalW is a general purpose multiple alignment program for DNA and proteins. The 
tool operates by comparing multiple sequences and generating scores that quantify the 
similarity between pairs of sequences. These scores are then used to construct a 
dendrogram (guide phylogenetic tree) which is used as a basis for constructing the 
multiple sequence alignment whereby the most closely related pairs of sequences are 
aligned first.  
 
For enzyme engineering, these tools are very useful for determining residues for 
mutagenesis. As demonstrated in Section 2.4.2., ClustalW was used for the 
identification of important catalytic amino acid residues and subsequent mutagenesis 
of the family GH101 enzyme, engEF. 
 
2.1.2 Site Directed Mutagenesis 
Mutagenesis of proteins is of paramount importance for understanding the relationships 
of protein structure and function. The functional and structural roles of amino acid 
residues in a protein of interest can be studied by comparing the mutant protein, 
carrying changes in amino acid residues, to the WT protein. However, to obtain specific 
mutant proteins, the mutant gene must be isolated or created. 
 
Site-directed mutagenesis (SDM) is an invaluable technique for characterizing the 
dynamic, complex relationships between protein structure and function, for studying 
gene expression elements, and for carrying out vector modification. Three essential 
components are required in an in vitro DNA synthesis reaction: the template DNA, the 
primer, and the four deoxynucleotide triphosphates (dNTPs, Figure 11) in the presence 





Figure 11 - Nucleotide triphosphates used in site-directed mutagenesis. 
Primers are short strands of nucleic acid sequences that serve as a starting point for 
DNA synthesis, which is required since DNA polymerases can only add new 
nucleotides to an existing strand of DNA. Oligonucleotide primers are custom designed 
to incorporate a desired mutation in a double-stranded DNA plasmid. To ensure 
successful DNA mutagenesis, general rules for designing a good primer should be 
followed:  
 
-  A primer for DNA synthesis should be free of strong secondary structures, such 
as hairpins and direct repeats.  
 
- The desired mutation, in general, should be placed in the middle of the primer 
rather than at the 5’ terminus. Mismatches at the 3’-terminus of a primer are 




Mutagenesis Kit (Stratagene) protocol recommends that the desired mutation 
be placed in the middle of the primer sequence with 10-15 nucleotides flanking 
the mutation. 
 
- To hybridize the mutagenic primer correctly and sufficiently to its template, the 
annealing temperature is chosen to be a few degrees below the melting 
temperature (Tm, the temperature at which half of the oligonucleotides are 
annealed to the template) of an oligonucleotide. In general, primers should have 
between 25-45 nucleotides in length with a Tm of 78 ˚C. The Tm can be 
estimated using the equation below, where N is the length of the primer: 
 





- Primers should also have a GC content of at least 40 %. 
 
The design of primers generally follows a general procedure, whereby the DNA 
sequence of interest is identified, for example: 
 
                H      D          L           D         R            L          S           Y          L 
5’ C A T   G A C   C T A   G A T   C G A   C T T   A G C   T A T   C T A 3’ 
3’ G T A   C T C   G A T   C T A   G C T   G A A   T C T   A T A   G A T 5’ 
 
The codon of interest (highlighted in red) is substituted for the one which encodes the 







































CTC CCC CAC CGC 
CTA CCA CAA 
Gln 
CGA 










ATC ACC AAC AGC 














GTC GCC GAC GGC 
GTA GCA GAA 
Glu 
GGA 
GTG GCG GAG GGG 
 
Figure 12 - DNA Codon Table adapted from Garrett and Grisham, Biochemistry, 2nd ed.; 









For example, a substitution of lysine (L) for valine (V):  
 
    H      D          L           D           R          H          S     Y          L 
5’ C A T   G A C   C T A   G A T   C G A   G T T   A G C   T A T   C T A 3’ 
3’ G T A   C T C   G A T   C T A   G C T   C A A   T C T   A T A   G A T 5’ 
 
Short strand primers complimentary to the sequence above are then designed: 
 
5’ A T A   G C T   A A C   T C G   A T C 3’ (complimentary to top strand) 
5’ G A T   C G A   G T T   A G C   T A T 3’ (complimentary to bottom strand) 
 
The Quikchange protocol employs the complementary primer pairs in the above steps 
in the polymerase chain reaction (PCR). The use of complementary primer pairs may 
lead to the formation of 'primer dimers', whereby partial annealing of a primer with a 
second primer in a reaction, due to stretches of complimentary bases, leads to the 
formation of tandem repeats of primers, reducing the yield of a successful 









One drawback of using PCR for DNA mutagenesis is the relatively high rate of 
sequence errors in PCR products, often creating undesired mutations in addition to 
intended ones. Taq polymerase, from Thermus aquaticus, is the most widely used 
thermostable polymerase, however the enzyme lacks the 3’-5’ exonuclease activity that 
“proof-reads” any errors caused by the 5’-3’ DNA polymerase during DNA synthesis. 
The absence of proof-reading capabilities in a polymerase can lead to the accumulation 
of errors through many cycles of amplification. Alternatively, high-fidelity, non-strand-
displacing DNA polymerases, such as Pfu polymerase (from Pyrococcus furiosus), 
which have superior thermostability and proof-reading properties, are used to amplify 
the entire plasmid. Pfu polymerase has been shown to provide up to 15 times the 
sequence fidelity of Taq.24  
 
The product of the reaction is never used as a template, meaning that the amplification 
is linear, as opposed to exponential as observed in standard PCR. 
 
A cycle of the mutagenesis reaction begins with the heating the template DNA until the 
strands are separated (Figure 14). Upon cooling of the reaction mixture, the mutagenic 
primers anneal to their complimentary sequences on the template sequence. The DNA 
polymerase then binds to and extends the primers to generate a full copy of the template 
sequence including the desired mutation. Several repeats of the thermocycling reaction 





Figure 14 - Steps of site-directed mutagenesis, where X and X’ represents the position of the 
desired mutation. 
 
To prevent its transformation into E. coli and increase the likelihood of isolating the 
mutant gene, the template DNA is then enzymatically digested by DpnI, a restriction 
endonuclease, which is specific for methylated DNA (target sequence: 5’Gm6ATC-
3’).25 The mutated plasmid generated in vitro is unmethylated and is therefore 
undigested. The mutant nicked plasmid is then transformed into a bacterial strain, 
commonly E. coli, where it is ligated by ligase enzymes to form a circular plasmid. 
After the growth of the bacteria overnight, the plasmids are isolated using a plasmid 




2.1.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a common technique used to check the purity of protein samples. In the 
presence of the ionic detergent sodium dodecyl sulphate (SDS), proteins are denatured 
and the entire length of the protein is coated with an even distribution of negative charge 
along the protein chain due to the anionic properties of SDS (Figure 15). 
 
 
Figure 15 - Structure of sodium dodecyl sulfate 
The purpose of this charge is multiple-fold. Firstly, since like charges repel, the proteins 
remain linear. Secondly, the even distribution of charges along the polypeptide chain 
results in a fractionation by approximate size during electrophoresis since the mobility 
of the protein depends only on the length and mass-to-charge ratio of the protein. Some 
quaternary structure may remain due to disulfide bonds and therefore a reducing agent 
(such as dithiothreitol (DTT) or β-mercaptoethanol) is added which breaks all disulfide 
bonds in the protein. Samples are normally heated to 70 – 90 ˚C for 10 mins before 
loading onto the gel, which completes the denaturing process. Weight size markers 
containing proteins of known weights are normally added to the gel in a separate lane 
to calibrate the gel and indicate the approximate molecular mass of unknown 
biomolecules by comparing the distance travelled relative to the marker. 
 
An electric field is applied to the gel, causing the negatively charged proteins to migrate 
across the cell away from the negative electrode towards the positive electrode. 
Depending on their size, each biomolecule moves at a different rate through the gel 




larger molecules move more slowly. After allowing the proteins to run through the gel 
for a set amount of time, the gel is then stained, most commonly with Coomassie 
Brilliant Blue, allowing visualisation of the separated proteins. 
 
2.1.4 Immobilised metal affinity chromatography 
Immobilised metal affinity chromatography (IMAC) is a separation and purification 
technique based on the affinity of amino acids, particularly histidine, to metals. Proteins 
with affinity for metal ions are retained on a column that contains immobilised metal 
ions (such as cobalt, nickel, or copper) for the purification of histidine-containing 
peptides or proteins. Because many naturally occurring proteins do not have an affinity 
for metal ions, recombinant DNA technology is often used to introduce a poly-histidine 
tail to the target gene. When loaded onto a column, proteins containing a higher number 
of histidine residues are then able to bind to the column more tightly than those with 
fewer histidine residues.  
 
By far, the most widely-used technique for this application is to use an immobilised 
nickel column, and to insert poly-histidine tags of six or more residues onto the 
recombinant proteins of interest, at either the C- or N-terminus. The bound protein is 
commonly eluted using competitive elution (for example with an imidazole gradient), 
stripping elution (using chelating agents, such as EDTA or EGTA, to strip the metal 
ions from the column), or by pH adjustment.26 
 
2.1.5  Ion exchange chromatography 
Protein purification by ion exchange is possible due to the fact that most proteins bear 




(isoelectric point). At a pH greater than pI, the protein becomes negatively charged. 
Conversely, at a pH lower than pH, the protein becomes positively charged. Ion 
exchange chromatography is based on the electrostatic attraction between buffer-
dissolved charged proteins and oppositely charged binding sites on a solid ion exchange 
adsorbent.  
 
The ion exchange adsorbent usually consists of inert spherical porous beads with 
charged functional groups densely grafted onto the surface. Typically, a protein mixture 
is transferred into a low ionic strength buffer and loaded onto a column which has been 
pre-equilibrated with the same buffer. When the protein mixture is loaded onto the 
column, proteins of the opposite charge to the column are retained whilst all other 
proteins simply pass through the column. The retained proteins are then eluted by 
gradually increasing the ionic strength of the buffer, whereby the proteins are eluted in 
order of increasing net charge. The buffer type, the buffer concentration, the pH, and 
the temperature all have important roles in controlling the separation.  
 
The enzymes in this chapter were purified by cation exchange chromatography. The 







Figure 16 - Schematic of an acidic sulfonated polystyrene cation exchange resin. 
The protein of interest was kept at a pH below its pI, giving the protein an overall 
positive charge. The protein which bound to the column was eluted using an increasing 
gradient of NaCl, as a competitive cationic binder. 
 
2.1.6 Size exclusion chromatography 
Size exclusion chromatography (SEC) separates macromolecules according to their 
hydrodynamic volume, which is defined by the Stokes radius.27 The column consists of 
porous polymer beads designed to have pores of differing sizes. Particles with smaller 
hydrodynamic volumes equilibrate into these pores when a mobile phase is passed 
through the column. In this way, smaller particles have a longer path length than larger 
particles, and therefore molecules of different sizes become separated along the length 
of the column. 
 
SEC is frequently used as a final step in protein purification and to discern between 
high and low molecular weight components in a mixture. It is an important means to 




from a folded protein due to the molecular weight differences between free and 
clustered states. Additional advantages of SEC are that is operationally simple to 
perform and that there is no requirement for specialised equipment.  
 
2.1.7 Circular dichroism (CD) spectroscopy 
UV Circular dichroism spectroscopy is a spectroscopic technique wherein the optical 
rotations of molecules are measured over a range of wavelengths. Due to the chiral 
nature of the constituent amino acids of the peptide backbone, CD is useful for 
estimating the extent of secondary structure present and therefore the conformation of 
proteins. Since the secondary structure of a protein is sensitive to its environment, 
temperature and pH, CD spectroscopy can be used to observe how the secondary 
structure of a protein changes with environmental conditions, or upon interaction with 
other molecules.  
 
Secondary structure can be determined by CD spectroscopy in the “far-UV” region of 
the electromagnetic spectrum (190 - 250 nm), wavelengths which encompasses the 
chromophore of the peptide bond28; a signal arises when the bond is located in a regular, 
folded environment. α-Helices, β-sheets, and random coil structures each give rise to a 
characteristic shape and magnitude in the CD spectrum.  
 
2.2 Objectives 
This chapter outlines the work done on the family GH101 enzymes, engBL14 from 
Bifidobacterium longum and engEF16 from Enterococcus faecalis, respectively. Both 
WT proteins have been well characterised in terms of their kinetics and substrate 




mutagenesis of engBL and engEF, as well as their characterisation using the 
aforementioned techniques, is also reported. 
 
2.3 EngBL from Bifidobacterium longum 
2.3.1 Expression and purification of WT engBL 
The plasmid encoding the protein engBL (340~1694, pET-28b) was provided by Prof. 
Shinya Fushinobu from the University of Tokyo, Japan. The pET-28b vector carried 
the sequence for an N-terminal His tag, and a gene which conferred kanamycin-
resistance to E. coli. 
 
 
Figure 17 - The pET-28d vector. The N-terminal his6-tag sequence is encoded between bases 
140-157 and the kanamycin-resistance gene is encoded between 3995-4807. Adapted from 





The engBL plasmid was transformed into E. coli (TOP10) for plasmid prep, and 
plasmids were isolated using a High Pure Plasmid Isolation Kit (Roche). 
 
The engBL plasmid was then transformed into E. coli (BL21 DE5), grown overnight, 
and diluted into fresh LB media (5 mL into 600 mL), and incubated at 37 ºC. 
Transcription of the engBL genes were under the control of a lac operon, and therefore 
protein expression was induced by the addition of IPTG to a final concentration of 0.5 
mM when cultures were at a mid-logarithmic phase (OD600 of 0.4 to 0.6 AU). The cells 
were grown overnight at 23 ˚C and then harvested by centrifugation. The pellet was 
resuspended in Buffer A (Table 4, Entry 1) and cells were lysed by sonication. The 
lysate was centrifuged at 15,000 rpm, 4 ºC for 35 min to remove the cell debris. The 
supernatant containing the soluble protein was filtered (0.22 µm), and applied to the 
affinity columns for IMAC (See Chapter 6 for detailed experimental procedures). 
 
Adapting previously established protocols16, a HisTrap column (GE Healthcare) pre-
charged with Ni2+ was used to purify engBL. The clarified cell lysate was directly 
loaded onto the column, washed with Buffer A (Table 4, Entry 1), and eluted with an 



















10 mM Tris/HCl, pH 7.5, 150 mM 
NaCl, 
20 mM imidazole 
Buffer 
B 
10 mM Tris/HCl, pH 7.5, 150 mM 
NaCl, 


















10 mM Tris, 150 mM NaCl, pH 7 
Table 4 - Buffers used in the purification of GH101 endo-α-N-acetylgalactosaminidases. 
 
Fractions indicated by the chromatograph to contain protein were pooled and dialysed 
against Buffer A (Table 4, Entry 2) and loaded onto an SEC column. The protein was 
eluted with an increasing gradient of Buffer B (Table 4, Entry 2). Fractions indicated 
by the chromatograph to contain protein were pooled and concentrated to 200 µL, 
directly loaded onto an SEC column, and eluted with Buffer A (Table 4, Entry 3). The 
concentration of pooled protein after SEC was determined to be 3.5 mg/mL by means 





The SDS-PAGE gel showed a large band at ~150 kDa corresponding to the desired 
protein (Figure 18). 
 
Figure 18 - SDS-PAGE analysis of engBL after SEC purification. 
It was necessary then to determine the activity of WT engBL using Galβ1,3GalNAc-α-
pNP (core 1-pNP) as the substrate. The International Union of Biochemistry (IUB) 
defines a standard unit (U) of enzyme activity as the amount of enzyme which catalyses 
the transformation of 1 µmol of the substrate per minute under standard conditions.29  
A standard curve for pNP was plotted for the purposes of monitoring the hydrolysis of 
Galβ1,3GalNAc-α-pNP by UV spectroscopy. 10 µmol of Galβ1,3GalNAc-α-pNP was 
to be used in the subsequent hydrolytic assay16, therefore the absorbance of pNP was 






Figure 19 - Standard curve of varying pNP concentrations. The values of concentration have 
been converted to yield. 
 
Galβ1,3GalNAc-α-pNP (10 µmol) was then incubated with varying dilutions (2-, 5-, 
10-, 100-, 500-, and 1000-fold dilutions) of engBL for 30 mins, after which time, the 
reaction mixture was quenched by the addition of 1 M NaOH, and the sample analysed 
by UV spectroscopy at 405 nm (Scheme 17).   
 
 
Scheme 17 - Determining the activity of WT engBL. Conditions: i) engBL (2 µL of various 
dilutions as described in the text), 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 30 mins. 
 
Whilst the reactions containing 2-, 5-, and 10-fold dilutions of engBL were complete 
after 30 mins, the addition of 100-fold dilution (final concentration of 1.17 x 10-7 mol/L 




























of enzyme) gave an absorbance of 0.037, which was sufficient for the calculation of the 
enzymatic activity of engBL.  
 
Thus, substitution of 0.037 into the equation given by the standard curve in Figure 19 
gives the yield of the reaction after 30 mins: 
 
0.037 = 0.0005x + 0.0028 
x = 68.4 % or 6.84 µmol of pNP released after 30 mins 
 




= 0.228 μmol/min 
 
If 0.07 µg of engBL catalyses the hydrolysis of Galβ1,3GalNAc-α-pNP (core 1-pNP) 
at a rate of 0.228 µmol/min, then the amount of enzyme required to perform the 





= 0.31 μg 
 








The primary sequence of engBF has previously been published,30 and more recently, 
the crystal structure of WT engBF has also been reported.15 Mutational analyses 
revealed the identity of the important residues for substrate binding, with two Trp 
residues (W748 and W750) forming stacking interactions with the β-faces of the sugar 
rings of Galβ1,3GalNAc by substrate-induced fit. The two key catalytic residues were 
determined to be D789 and E822, which act as the catalytic nucleophile and catalytic 
general acid/base, respectively.  
 
We expected that the mutation of the nucleophilic residue should lead to the abolition 
of the hydrolytic activity of engBL.9 Therefore, Asp789 was substituted by site-directed 
mutagenesis to generate glycosynthases. Three common mutations that are normally 
conferred to generate glycosynthases involve converting the nucleophile to glycine, 
alanine, and serine.18,31 These three residues are non-nucleophilic (in the cases of 
glycine and alanine), and smaller in size. The codon of the engBL gene corresponding 
to D789 was identified using ClustalW12. Primers were designed for site-directed 
mutagenesis by replacing the codon corresponding to D789 with the codons 





Mutation Primer Sequence (5’ - 3’) 
D789G 
Fwd GAC TTC ATC TAC CTC GGG GTG TGG GGC AAC CTG 
Rev 
CAG GTT GCC CCA CAC CCC GAG GTA GAT GAA 
GTC 
D789A 
Fwd GAC TTC ATC TAC CTC GCT GTG TGG GGC AAC CTG 
Rev 
CAG GTT GCC CCA CAC AGC GAG GTA GAT GAA 
GTC 
D789S 
Fwd GAC TTC ATC TAC CTC AGC GTG TGG GGC AAC CTG 
Rev 
CAG GTT GCC CCA CAC GCT GAG GTA GAT GAA 
GTC 
Table 5 - Primers for the mutagenesis of engBL. Codons corresponding to D789 are in bold. 
 
The site directed mutagenesis was performed using the Quikchange® II Site-Directed 
Mutagenesis Kit (Agilent) with Phusion® High-Fidelity DNA Polymerase (Thermo 
Scientific), as described in Chapter 6, on the WT plasmid in the presence of the 
respective primers. The parent plasmid was then digested with DpnI, and the 
mutagenesis products were directly transformed into E. coli (DH5α) for plasmid prep 
and grown overnight. The plasmids were sequenced to confirm the desired mutation 
had been incorporated. The mutated products were then transformed and expressed in 
E. coli (BL21 DE5), and purified as described earlier for the WT engBL enzyme.  
 
SDS-PAGE analysis showed the presence of a protein at ~150 kDa corresponding to 






Figure 20 - SDS-PAGE Analysis of engBL mutants after purification. 
 
The CD spectra of WT and variant engBL proteins were compared and were found to 
be similar (Figure 21). These results indicate that displacement of the nucleophile 
Asp789 had no effects on protein folding. 
 
 





The concentrations of pooled protein for engBL D789G, D789A, and D789S after SEC 
were determined to be 9.5, 3.6, and 12.2 mg/mL respectively by means of a Nanodrop 
ND-1000 spectrophotometer. 
 
2.4  EngEF from Enterococcus faecalis 
2.4.1 Expression and purification of WT engEF 
The plasmid for engEF (pET-23b) was obtained from Dr. Makoto Ito of Kyushu 
University, Japan. The pET-23b vector contained both an N-terminal and C-terminal 
his tag. However only the C-terminal his tag is expressed in this construct (Figure 22). 
The vector also had a gene for ampicillin-resistance. 
 
 






The plasmid was transformed into E. coli (TOP10) for plasmid prep, and plasmids were 
isolated using a High Pure Plasmid Isolation Kit (Roche).  
 
Several E. coli cell lines were tested to optimise the expression of engEF, namely BL-
21*, Chaperone 3, and codon plus cell lines. The Chaperone 3 cell line contains genes 
encoding chaperone proteins which, when expressed, assist with the correct folding of 
the target protein, whilst the codon plus cell line includes extra codons that are not 
native to E. coli, but may be required for protein expression. SDS-PAGE analysis 
indicated that the Chaperone 3 cell line expressed a greater amount of protein compared 
to either BL-21* or the codon plus cell lines (gel not shown). Therefore, engEF was 
transformed into E. coli (Chaperone 3), and grown in LB media (1 L). Transcription of 
the engEF gene was under the control of a lac operon, and therefore protein expression 
was induced by the addition of IPTG to a final concentration of 0.5 mM when cultures 
were at a mid-logarithmic phase (OD600 of 0.4 to 0.6 AU), grown overnight at 23 ˚C, 
and harvested by centrifugation. The pellet was resuspended in Buffer A (Table 4, Entry 
1) and the cells lysed by sonication. The lysate was centrifuged at 15,000 rpm, 4 ˚C for 
35 min to remove the cell debris. The supernatant containing the soluble protein was 
filtered (0.22 µm) and applied to the affinity columns. 
 
Adapting protocols established previously,16 a HisTrap column (GE Healthcare) pre-
charged with Ni2+ was used to purify engEF. The clarified cell lysate was directly 
loaded onto the column, washed with elution buffer (Buffer A, Table 4), and eluted 
with an increasing gradient of Buffer B (Table 4, Entry 1). Fractions indicated by the 
chromatograph to contain protein were analysed by SDS-PAGE. The SDS-PAGE gel 





The concentration of pooled protein was determined to be 1.5 mg/mL by means of a 
Nanodrop ND-1000 spectrophotometer.  
 
 
Figure 23 - SDS-PAGE analysis of WT engEF after purification by IMAC. 
As with WT engBL, the activity of engEF was determined. Galβ1,3GalNAc-α-pNP (10 
µmol) was incubated with varying dilutions (2-, 5-, 10-, 100-, 500-, and 1000-fold 
dilutions) of engBL for 30 mins, after which time, the reaction mixture was quenched 
by the addition of 1 M NaOH, and the sample analysed by UV spectroscopy at 405 nm 
(Scheme 18).   
 
 
Scheme 18 - Testing the activity of WT engEF. Conditions: i) engEF (2 µL of various 





Whilst the reactions containing 2-, 5-, and 10-fold dilutions of engEF were complete 
after 30 mins, the addition of 100-fold dilution (final concentration of 1.02 x 10-7 mol/L 
of enzyme) gave an absorbance of 0.019, which was sufficient for the calculation of 
activity.  
 
Thus, substitution of 0.019 into the equation given by the standard curve in Figure 19 
gives the yield of the reaction after 30 mins: 
 
0.019 = 0.0005x + 0.0028 
x = 32.4 % or 3.24 µmol of pNP released after 30 mins 
 




= 0.108 μmol/min 
 
Therefore, if 0.03 µg of engEF catalyses the hydrolysis of Galβ1,3GalNAc-α-pNP (core 
1-pNP) at a rate of 0.108 µmol/min, then the amount of enzyme required to perform the 





= 0.27 μg 
 






2.4.2 Mutagenesis of engEF 
Two putative catalytic aspartic acid residues were identified in engBL to be D628 and 
D789.13 A sequence alignment of engBL and engEF using ClustalW12 indicated that 
the amino acids corresponding to the nucleophilic and catalytic acid/base residues were 
D725 and E754, respectively (Figure 24). 
 
 
Figure 24 - Sequence alignment of engBL and engEF for the identification of the catalytic 
nucleophile (yellow) and catalytic acid/base (turquoise) in engEF. 
 
Replacement of the catalytic nucleophile (D725) with non-nucleophilic residues should 
remove all hydrolytic activity of engEF. The codon of the engEF gene corresponding 
to D725 was identified using ClustalW12. Primers were designed for site-directed 
mutagenesis by replacing the codon corresponding to D725 with the codons 





Mutation Primer Sequence (5’ - 3’) 
D725G 
Fwd GAT TAT ATT TAT GTT GGG GTT TGG GGC AAT CAA GCC 
Rev GGC TTG ATT GCC CCA AAC CCC AAC ATA AAT ATA ATC 
D725A 
Fwd GAT TAT ATT TAT GTT GCT GTT TGG GGC AAT CAA GCC 
Rev GGC TTG ATT GCC CCA AAC AGC AAC ATA AAT ATA ATC 
D725S 
Fwd GAT TAT ATT TAT GTT AGC GTT TGG GGC AAT CAA GCC 
Rev GGC TTG ATT GCC CCA AAC GCT AAC ATA AAT ATA ATC 
Table 6 - Primer design for the mutagenesis of engEF. Codons corresponding to D725 are in 
bold. 
 
Site directed mutagenesis was performed using a Quikchange® II Site-Directed 
Mutagenesis Kit (Agilent) with Phusion® High-Fidelity DNA Polymerase (Thermo 
Scientific), as described in Chapter 6, using the WT plasmid in the presence of the 
respective primers. The parent plasmid was then digested with DpnI, and the 
mutagenesis products were directly transformed into E. coli (DH5α) for plasmid prep, 
and grown overnight. The plasmids were sequenced to confirm the desired mutations 
had been incorporated. The mutated products were transformed and expressed in E. coli 
(BL21 DE5), and then purified as described earlier for the WT engBL enzyme (Section 
2.3.1).  
 
The SDS-PAGE gel showed a large band at ~150 kDa corresponding to the desired 






Figure 25 - SDS-PAGE analysis of engEF mutants. 
 
The CD spectra of WT and variant engEF were compared and were found to be similar 
(Figure 26). These results indicated that displacement of the nucleophile Asp725 had 
no effect on protein folding.  
 
 





The concentration of pooled protein for engEF D725G, D725A, and D725S after SEC 




To date, there has been no published data on the engineering of α-glycosynthases from 
any retaining GH101 endo-α-N-acetylgalactosaminidases. The work described in this 
chapter illustrates an attempt to engineer glycosynthase enzymes from two of the 
members of family GH101: engBL from Bifidobacterium longum and engEF from 
Enterococcus faecalis. 
 
The WT enzymes, engBL and engEF, from Bifidobacterium longum and Enterococcus 
faecalis respectively, were successfully transformed into E. coli (BL21 DE5) 
competent cells. Subsequent protein expression via ITPG induction, followed by 
purification of the WT enzymes were successful. EngBL was isolated at a concentration 
of 3.5 mg/mL, whilst engEF was isolated at a concentration of 1.5 mg/mL.  
 
Site directed mutagenesis was performed on the genes of engBL and engEF where the 
catalytic nucleophilic residue of the respective glycosidases was substituted for 
individual glycine, alanine, and serine mutants. DNA sequencing confirmed the 
substitutions of the appropriate amino acid for the respective proteins.  
 
Plasmid transformation, protein expression and purification of the engBL D789G/A/S 




glycosidases by CD spectroscopy indicated that the proteins were correctly folded. The 
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Chapter 3 – Synthesis of Activated O-Glycan Core Structures 
 
3.1 Introduction 
Oligosaccharides have an undeniable importance in biological systems, especially the 
motifs that decorate glycoproteins, the common glycone portions of a variety of 
antibiotics, and the intricate carbohydrate assemblies that are required for signalling 
processes. In fact, in a large number of cases, the specificity and activity of these 
biological processes rely on the carbohydrate portion of the molecule.1  
 
As described in Chapter 1, the biosynthetic attachment of carbohydrates to proteins is 
an important post-translational process. However, the biosynthesis of glycans is not 
under direct genetic control, so glycoproteins are produced intracellularly as 
inseparable heterogenous mixtures of glycoforms, in which different oligosaccharide 
structures are linked to the same peptide chain. Accessing pure single glycoforms of 
glycoproteins has therefore become an important scientific objective in order to prepare 
therapeutic glycoproteins.  
 
Conventional chemical synthetic approaches are, in most cases, unable to provide large 
amounts of oligosaccharides in a timely fashion due to the complexities involved in 
protecting group manipulations of various glycosyl donors and acceptors. To provide 
useful quantities of these materials, techniques that combine chemical and enzymatic 
methods are increasingly being used.2 
 
An excellent approach to the stereoselective synthesis of glycosidic linkages involves 





established mechanism of retaining glycosidases,6 normal hydrolysis occurs when the 
glycosyl intermediate of a donor sugar reacts with water (Figure 27). If the glycosyl 
enzyme intermediate is intercepted with a sugar, then the result will be a glycosyl 
transfer to afford a new glycosidic linkage with net retention of stereochemistry. 
 
 
Figure 27 - Mechanism of transglycosylation with a retaining α-glycosidase. 
Although there have been many reports of the use of retaining α-glycosidases as 
biological tools for enzymatic syntheses,7 reports of α-glycosynthases developed from 
retaining α-glycosidases are scarce.  Correspondingly, little synthetic work on the β-
glycosyl donors that would be the required donors for these synthases has been 
reported. In fact, most glycosynthase enzymes to date have been engineered from 
retaining β-glycosidases.8,9 The research in this thesis aims to investigate the use of α-
retaining glycosidases for the synthesis of O-linked glycans. The rationale behind 
enzymatic donor design is discussed in Section 3.3. 
 
3.1.1. Glycosyl donors for glycosidases and glycosynthases 
3.1.1.1. Glycosyl fluorides 
Over the last decade, glycosyl fluorides have been used numerous times as reliable 
donors for enzymatic glycosylations.10 The interest in these compounds has led to the 





fluorine, comparable to that of a hydroxyl group, means that there is minimal steric 
difference upon introduction of this atom to a molecule.15  
 
α-Glycosyl fluorides are the only glycosyl halides stable enough to be dissolved in an 
aqueous buffer without appreciable rates of spontaneous hydrolysis.  In fact, in an 
aqueous solution, most α-glycosyl fluorides are stable for periods of weeks or longer, 
especially if kept below 0 ºC and buffered to minimize auto-decomposition arising from 
acid-catalysed solvolysis.10 In contrast, β-glycosyl fluorides are less stable, but are still 
useful substrates provided that the rates of enzymatic reactions are sufficiently high. 
Measurements made of the spontaneous rates of hydrolysis of α- and β-D-
glucopyranosyl fluoride in 1 M NaClO4 at 50 ºC showed that the β-fluoride hydrolyses 
around 40-fold faster than the α-fluoride.16  
However, 2-acetamido-2-deoxy glycosyl fluorides with a 1,2-trans configuration 
hydrolyse rapidly in water (7.1 x 10-3 sec-1 at 25 ˚C) or methanol due to neighbouring 
group participation17, which makes the synthesis of such donors very difficult. 
 
Since their first reported use, glycosyl fluorides have been proven particularly useful as 
substrates for glycosidases. Their employment as substrates has been associated with 
high substrate turnover rates, which make them very useful as substrates for 
determining the stereochemical outcome of enzyme-catalysed glycoside hydrolysis 
since the hydrolysis reaction is much faster than mutarotation.18,19 
 
Before the development of glycosynthases, glycosyl fluorides had been used as 
substrates for enzymatic oligosaccharide synthesis via the Hehre re-synthesis 





substrate possessing the ‘wrong’ anomeric configuration (i.e. the opposite 
configuration to that of the natural substrate). The hydrolysis reaction is believed to 
proceed by way of an initial transglycosylation from one glycosyl fluoride molecule to 
another to form a glycosidic linkage with inversion of anomeric stereochemistry 
(Figure 28). The transglycosylation product, which has the ‘correct’ anomeric 
stereochemistry for the enzyme, is then rapidly hydrolysed, affording the product with 
inverted stereochemistry. The net result is retention of stereochemistry from the initial 




Figure 28: Hehre resynthesis-hydrolysis mechanism for the hydrolysis of the 'wrong' anomeric 
fluoride using inverting β-glycosidases. 
 
Glycosyl fluorides have been successfully used in multiple glycosidase-related studies 
including as probes for enzyme mechanism,25,26 for enzyme inhibition,27,28 and for 
investigations of kinetic isotope effects.29,30 Their uses as donors for glycosidases,22,31–
38 donors for glycosyl transferases,39 and donors for glycosynthase reactions40 has also 
been well established. As stated before, β-glycosyl fluorides containing a 2-acetamido 
functionality with a 1,2-trans configuration are readily hydrolysed in aqueous solution. 
Investigations into the synthesis of β-glycosyl fluorides are described in Chapter 4, and 





acetamido sugars (see Section 5.3.1). However, they were later discounted as viable 
substrates for the enzymatic studies of this thesis due to their lability. 
 
3.1.1.2. Dinitrophenol glycosides 
Originally introduced by Capon and Thomson,41 2,4-dinitrophenyl (2,4-DNP) 
glycosides are one of the most useful classes of chromogenic substrates used to assay 
glycosidase activity.42 The utility of DNP glycosides arises due to the low pKa of the 
2,4-DNP leaving group (~4.0).43–45 Ballardie et al. have determined the rate constant 
for the spontaneous hydrolysis of 2,4-dinitrophenyl β-D-glucopyranoside to be 1 x 105 
sec-1 at 25 ºC, 10-20 times faster than that of the corresponding glucoside.17 Due to the 
low pKa of 2,4-dinitrophenol, performance of continuous assays at relatively low pH 
values is possible, which is important in some cases, for example for the kinetic 
analyses of lysosomal glycosidases whose optimal pH is typically around pH 4-5.  
 
Direct glycosylation of dinitrophenol to sugars using conventional glycosylation 
protocols has proven to be difficult, especially in the cases of sugars containing an N-
acetamido functionality at the 2-position.42 van Boom et al. reported an alternative 
approach wherein a partially protected sugar hemiacetal was reacted with 1-fluoro-2,4-
dinitrobenzene in the presence of a hindered base, typically 1,4-
diazabicyclo[2.2.2]octane (DABCO).46 In this nucleophilic aromatic substitution 
reaction, the kinetic β-glycoside was often obtained in good yields. Facile isomerisation 
to the α-glycoside can be achieved, if desired, by treatment with a stronger base, such 
as potassium carbonate, in solvents such as DMF or DMSO (Scheme 19).46 The 







Scheme 19 - Synthesis of 2,4-dinitrophenyl 2-acetamido-2-deoxy-α-D-glucopyranoside. i) 1-
fluoro-2,4-dinitrobenzene, K2CO3, DMF, rt; (ii) AcCl, methanol, 0 ºC. 
 
Although there have been several methods published on the syntheses of DNP 
glycosides,17,49–51 these glycosylations have rarely focussed on hexoses with a 2-
acetamido functionality. In fact, Chen and Withers51 found that the extreme lability of 
2,4-dinitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside due to neighbouring 
group participation of the amide made their synthetic attempts fruitless.  
 
Attempts at the synthesis of DNP glycosides are also discussed in Chapter 5. However 
due to the aforementioned shortfall of using 2,4-dinitrophenyl β-N-acetylhexosamines 
as donors for glycosidases, they were not used for the work in this thesis. 
 
3.1.1.3. Glycosyl azides 
In 2005, Fiavolá et al. found that the β-N-acetylhexosaminidase from Talaromyces 
flavus CCF2686 could catalyse the self-condensation of N-acetyl-β-D-glucopyranosyl 
azide (β-D-GlcNAc-N3) to give the disaccharides β-D-GlcNAc-1,4-β-D-GlcNAc-N3 
and β-D-GlcNAc-1,6-β-D-GlcNAc-N3, demonstrating that glycosyl azides could also 







Scheme 20 - Self-condensation of β-D-GlcNAc-N3 catalysed by β-N-acetylhexosaminidase 
from T. flavis CCF 2686. 
 
Subsequently, in 2008, Cobucci-Ponzano et al. produced mutants of an α-L-fucosidase 
from the hyperthermophilic archaeon Sulfolobus solfataricus (Ssαfuc, GH29).53,54 The 
mutants, SsD242G/A/S, were completely inactive as expected. Whilst the initial 
chemical rescue experiment of the mutants with sodium formate, 4-nitrophenyl and 2-
chloro-4-nitrophenyl α-L-fucopyranoside (2C4MP-Fuc) showed clear reactivation, no 
fucosylated oligosaccharides were produced (Scheme 21). 
 
 
Scheme 21 – Mechanism of chemical rescue of GH29 SsD242G/A/S using sodium formate. 
Interestingly, treatment of 2C4MP-Fuc with the Ssαfuc mutants in the presence of 
sodium azide lead to the formation of β-L-fucopyranosyl azide (β-Fuc-N3) and the 
disaccharide α-L-fucopyranosyl-1,3-β-L-fucopyranosyl azide (α-L-Fuc-1,3-β-L-Fuc-







Scheme 22 - Ssαfuc mutants catalysing the self-condensation of a fucosyl azide donor to 
generate disaccharides. 
 
The mechanism proposed suggested that the β-L-Fuc-N3 product became a donor and, 
as a result of its accumulation, also an acceptor (Scheme 23). 
 
 
Scheme 23 - Proposed mechanism for the self-condensation of β-L-fucopyranosyl azide 
catalysed by the Ssαfuc mutants. 
 
This result was a surprise since glycosyl azides were considered to be able compounds 
that were not hydrolysed by glycosidases.55 However direct use of β-L-Fuc-N3 as the 
donor with the SsD242S mutant lead to fucosylation to produce the aforementioned 
disaccharide in 40 % yield. In light of these results, it was then hypothesized that β-L-
Fuc-N3 could be a donor for efficient α-fucosynthases (that is, α-fucosynthases that had 
a high substrate turnover rate with respect to the glycosyl azide).  
 
The same methodology was later applied to an α-L-fucosidase from Thermotoga 





azide using 4-nitrophenyl and 2-chloro-4-nitrophenyl α-L-fucopyranoside substrates.58 
Analysis of the reaction mixture revealed that the mutant, in the presence of sodium 
azide and 2C4NP-Fuc, did not produce disaccharides, but rather only β-L-Fuc-N3 
(Scheme 24).  
 
 
Scheme 24 - Chemical rescue of TmD224G using sodium azide. 
 
However, in the presence of β-L-Fuc-N3 and 4NP-β-D-Xyl as the donor and acceptor 
respectively, the mutant synthesized disaccharides as a mixture of the α1,4 and α1,3 
regioisomers, with a fucosylation yields of up to 91 % (Scheme 25).  
 
 
Scheme 25 - Glycosylation of p-nitrophenyl β-D-xyloside to β-L-Fuc-N3 by TmD224G. 
To demonstrate that the usage of β-glycosyl azides was not limited to α-fucosynthases, 
Cobucci-Ponzano et al. tested β-galactosyl azide (β-Gal-N3) as a possible donor for 
some α-galactosynthases.59 The α-galactosidase from Thermotoga maritima (TmGalA, 





reaction mechanism in which D327 and D387 are the catalytic nucleophile and catalytic 
acid/base, respectively.60 Mutants of TmGalA were prepared and the activity of the 
enzymes was assessed. Whilst the activity of the TmGalA D327A and D327S mutants 
could not be rescued, the D327G mutant was chemically rescued with sodium azide 
using 4-nitrophenyl α-D-galactopyranoside (4NP-Gal) by 30-fold compared to the 
D327G incubated with 4NP-Gal alone. Using the TmGalA D327G mutant, the authors 
demonstrated galactosylation of a variety of glycosyl acceptors using β-D-Gal-N3 as the 
donor, with efficiencies of up to 51 % (Scheme 26). 
 
 
Scheme 26 - Mechanism of the D327G mutant α-galactosynthases using galactosyl azides as 
donors. R = Glc-α-pNP, Xyl-α-pNP, Xyl-β-pNP, Man-α-pNP. 
 
It is therefore possible that β-glycosyl azides might act as viable donors for α-
glycosynthases generated from a GH101 N-acetyl-α-D-galactosaminidase. Glycosyl 
azides may serve as better donors than the more commonly used glycosyl fluorides for 
several reasons. As stated before β-glycosyl fluorides have much shorter half-lives with 
respect to aqueous hydrolysis than α-glycosyl fluorides due to the anomeric effect.61  
Therefore β-glycosyl fluorides are probably too unstable to survive the long reaction 
times typically required by α-glycosynthases. A substrate with a better balance between 






3.1.1.4. p-Nitrophenyl glycosides 
p-Nitrophenyl glycosides are excellent substrates for glycosidases both for analysing 
their kinetic activity, as well as their utility as substrates for glycosylation reactions. 
Their utility stems from the leaving group ability of p-nitrophenol (pKa 7.16), and the 
strong UV chromophore which allows reactions to be easily monitored by HPLC or 
UV-vis spectroscopy. In a typical reaction, nitrophenyl glycosides are incubated with 
an enzyme at the desired pH and substrate concentrations for a specified period of time. 
The reaction is then quenched and the p-nitrophenolate ion is spectrophotometrically 
measured at an alkaline pH, usually 10-11. Alternatively, a continuously monitored 
spectrophotometric assay62 can be performed, which is preferable to the former static, 
fixed time assay due to errors associated with inaccuracies with initial sample mixing 
times and final sample quenching times. A continuous assay allows for the entire kinetic 
course of the reaction to be obtained with one small sample. 
 
A kinetic assay of glycosidases is typically followed by measuring the increase in 
absorbance at 318 nm, although for high concentrations slightly longer wavelengths 
can be used, which reduces the background absorbance and sensitivity (Δε) of the 
assay.62 Also, the cleavage of p-nitrophenol from a sugar can be monitored due to the 
differences in the absorptions of p-nitrophenol and p-nitrophenyl glycosides.62 
 
In investigations performed with engBL and engEF, the p-nitrophenyl glycosides were 
used substrates for hydrolytic studies, and as the donors for glycosylation of a set of 
alkanols.63,64 In 2011, Hollinger et al. published a paper on the synthesis of the p-nitro 
and p-aminophenyl glycosides of the mucin O-glycan core structures.65 This paper 





galactose as the starting material. Work reported in this chapter extends this route to 
additionally generate glycosyl acetates of these core structures for use in the 
glycosidase-catalysed glycosylation reactions reported in Chapter 4. 
 
3.1.1.5. Glycosyl acetates 
The development of new donors that, in conjunction with glycosidases, results in high 
glycosylation activity, is essential to increase the yield and efficiency of these 
processes. Ideally, the donor used should be relatively stable to normal storage 
conditions, and readily activated when used as a substrate in enzymatic reactions. Of 
the currently available glycosyl donors, fluoro-, p-nitrophenyl, and dinitrophenyl 
glycosides have been used most extensively. The use of glycosyl acetates as donors has 
been much less common. The first report on their use was by Zinin et al. who, in 2002, 
demonstrated that a β-galactosidase from Penicillium sp. was capable of using 1-O-
acetyl-β-D-galactopyranoside as a novel donor for glycosylation (Scheme 27). They 
found that, not only was this β-galactosidase able to catalyse the hydrolysis of 1-O-
acetyl-β-D-galactopyranoside, but it could also catalyse self-condensation of the donor 
to give the disaccharide β-D-galactopyranosyl-1,6-1-O-acetyl-β-D-galactopyranoside 
in 70 % yield after 10 mins. 
 
 







This observation is not surprising given the low pKa of acetic acid (4.76), meaning that 
acetate is a better leaving group than p-nitrophenolate. Indeed, it was demonstrated that 
the catalytic activity of the β-galactosidase from Penicillium sp. for the hydrolysis of 
1-O-acetyl-β-D-galactopyranoside was 100-fold greater than that for p-nitrophenyl β-
D-galactopyranoside, and 21000-fold greater than that for the equivalent methyl 
glycoside. Typically, syntheses of the 1-O-acetyl donor requires a multi-step synthetic 
sequence where the acetyl group is installed at the anomeric centre via a glycosyl 
imidate by means of a carboxylate66 or using AcOH.67–69 
 
However since the report by Zinin et al69, there has been no further work published on 
the usage of glycosyl acetates as donor substrates for glycosidases. This lack of usage 
may be due to the difficult in synthesizing the required donors as the single anomers 
required for enzyme reactions, and the low yields in which they can be produced.68 
Therefore, there is a need for a facile route to access deprotected glycosyl acetates. 
Chapter 5 details a method that allows direct access to glycosyl acetates in water 
directly from unprotected sugars in high yields, some of which are formed exclusively 
as single anomers. 
 
3.2. The synthesis of activated O-glycan core structures 
There are currently 10 core O-glycan structures known, each of which differs in their 
extensions from the N-acetyl-D-galactosamine unit at the reducing end (Figure 2).  
 
The two enzymes acquired for use in this thesis were engBL from Bifidobacterium 
longum63,70,71 and engEF from Enterococcus faecalis.64,72 EngBL has a hydrolytic 





disaccharide), whilst engEF has a broader substrate specificity, catalysing the 
hydrolysis of GalNAc, Galβ1,3GalNAc, and GlcNAcβ1,3GalNAc (the core 3 
disaccharide).  
 
As explained in Chapter 1, the two main approaches previously employed to enable the 
enzyme-catalysed formation of the glycosidic bond are thermodynamic controlled 
reverse hydrolysis and kinetically controlled glycosylation, whereby the latter method 
is preferred due to higher yielding reactions. One attributing component to the high 
yields is the use of activated glycosyl donors.  
 
The GH101 endo-α-N-acetylgalactosaminidases catalyse the hydrolysis of the GalNAc-
α-Ser/Thr linkage via the formation of a β-glycosyl-enzyme intermediate. Therefore, a 
kinetically controlled glycosylation using the GH101 WT enzymes requires the 
synthesis of activated α-glycosyl donors. Since the GH101 enzymes have substrate 
specificity for GalNAc, Galβ1,3GalNAc (core 1), and GlcNAcβ1,3GalNAc (core 3), 
the synthesis of activated α-glycosyl donor derivatives is necessary for their use as 
substrates in the enzyme-catalysed glycosylation reaction. 
 
The research of this thesis also includes the design of GH101 mutant glycosidases, 
where the nucleophilic residue of the respective protein had been substituted with a 
non-nucleophilic residue. Without the ability to form the β-glycosyl-enzyme 
intermediate, we would expect the mutant glycosidase to be inactive. However, in the 
presence of an activated β-glycosyl donor, which acts to mimic the β-glycosyl-enzyme 
intermediate, the enzyme should be able to catalyse the ligation of the donor to an 





synthesised as substrates for the GH101 glycosynthase enzymes. Suitable activated β-
glycosyl donors for an α-glycosidase-derived glycosynthase include β-glycosyl 
fluorides73, β-glycosyl azides52,58, β-p-nitrophenyl glycosides74, and β-glycosyl 
acetates. 
 
3.2.1. Attempted synthesis of glycosyl fluorides of GalNAc 
The synthesis of 2-acetamido-2-deoxy-β-D-glucosaminyl fluoride 3.1 has only been 
previously reported once in the literature (Scheme 28).17 
 
Scheme 28 - Synthesis of β-glycosyl fluorides from 2-acetamido sugars. Conditions: i) Ac2O, 
pyridine, rt, 24 h; ii) hydrazine acetate, DMF, rt, 17 h, 72 %; iii) 1,1,1-trichloroacetonitrile, 
DCM, DBU, 0 °C, 3 h, 93 %; iv) HF (70 % solution in pyridine), DCM, 0 °C, 5 mins, 37 %; v) 
1 M NaOMe in MeOH, 1 min; vi) Methylamine or n-propylamine, THF. 
 
Following the published route17, GlcNAc 3.2 was acetylated with pyridine and acetic 
anhydride to give the peracetate 3.3. Selective anomeric cleavage using hydrazine 





trichloroacetonitrile and DBU. Treatment of imidate 3.5 with HF/pyridine gave the β-
glycosyl fluoride 3.6 in 37 % yield. However, Zemplén de-acetylation to yield 
deprotected fluoride 3.1 using the reported procedure did not occur as described. 
Instead, it was found that the reaction mixture consisted predominantly of the glycosyl 
oxazoline 3.7, indicating that the β-glycosyl fluoride was unstable toward the de-
esterification conditions used. The use of either methylamine or n-propylamine for ester 
cleavage also produced the acetylated glycosyl oxazoline 3.8 as the major product. 
 
After discussion with Prof. Stephen Withers, it was concluded that β-glycosyl fluorides 
derived from 2-acetamido sugars were probably too unstable to be used as substrates 
for glycosidase-catalysed synthesis, and therefore route development towards 
deprotected glycosyl fluorides was abandoned. 
 
3.2.2. Synthesis of 2-acetamido-2-deoxy-β-D-galactopyranosyl azide 3.9 
Full details of the development of the synthetic method for the one-pot synthesis of 
glycosyl azides will be further discussed in Chapter 5. Under optimised conditions, 2-
acetamido-2-deoxy-D-galactose 3.10 was reacted with ADMP 3.11 in the presence of 
triethylamine in D2O/MeCN (4:1) (Scheme 29). After 3 h, 
1H NMR analysis revealed 
that both oxazoline 3.12 and azide 3.13 were present in the reaction mixture in equal 
amounts. The oxazoline by-product is formed due to the competing nucleophilic 
properties of the 2-acetamido functionality which may react with the β-imidazolinium 
intermediate that is formed by reaction of the β-anomeric hydroxyl group with DMC 
(see Chapter 5, Figure 46). A simple adjustment of the pH to 2 by dropwise addition of 
HCl led to the production of the desired azide 3.9 in 77 % yield and the complete 






Scheme 29 - (i) a) ADMP, triethylamine, D2O/MeCN (4:1), 0 °C, 3 h, then HCl to pH 2, 77 % 
of 3.13. 
 
Investigations into use of azide 3.13 as a donor for glycosynthase-catalysed 
glycosylation are reported in Chapter 4. These studies suggested that the glycosynthase 
mutants of engBL and engEF did not utilize glycosyl azides as substrates. In light of 
these disappointing results, the syntheses of Galβ1,3GalNAc-β-N3 (core 1-β-N3) and 
the GlcNAcβ1,3GalNAc-β-N3 (core 3-β-N3) glycosyl donors were not undertaken. 
 
3.2.3. The synthesis of p-nitrophenyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-
deoxy-α-D-galactopyranoside 3.13 (core 1 α-pNP) and p-nitrophenyl 2-acetamido-
2-deoxy-β-D-glucopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-galactopyranoside 
3.14 (core 3 α-pNP) disaccharides 
Scheme 30 illustrates the route used to access the common acceptor 3.22 used for the 







Scheme 30 - Synthetic route towards core 1-pNP. Conditions (i) Ac2O, NaOAc, 120 °C, 1 h, 
37 %; (ii) 33 % HBr in AcOH, DCM, 3 h, 100 %; (iii) Zn dust, 2,6-lutidine, EtOAc, 60 °C, 2 
h, 79 %; (iv) BAIB, NaN3, (PhSe)2, DCM, 17 h, 40 %; (v) NIS, THF:H2O (1:1), 5 h, 99 %; (vi) 
Cl3CCN, DBU, DCM, 0 °C, 3 h, 98 %; (vii) pNP-OH, TMSOTf, DCM, 4Å MS, 3.5 h, 76 %; 
(viii) 1) NaOMe, MeOH; 2) 4-methoxybenzaldehyde dimethyl acetal, p-TSA, DMF, MeCN, 
24 h, 37 %. 
 
Firstly, D-galactose 3.14 was acetylated with sodium acetate and acetic anhydride to 
give exclusively the β-pentaacetate 3.15, which was then converted to the α-bromide 
3.16 using hydrogen bromide in AcOH in quantitative yield. Reductive elimination 
using zinc dust then afforded the triacetyl galactal 3.17 in 79 % yield. 
Azidophenylselenation was performed with sodium azide and diphenyldiselenide in the 
presence of bis(acetoxy)iodobenzene (BAIB).75 As expected, a mixture of 
stereoisomers was observed, all of which had similar polarities by TLC and were 







Scheme 31 - Stereoisomers formed during the azidophenylselenation of galactal. Conditions: 
NaN3, BAIB, (PhSe)2, DCM. 
 
However the desired product could easily be crystallised from the crude mixture to give 
selenoglycoside 3.18 in 40 % yield. An attempt was made to directly convert 
selenoglycoside 3.18 to the p-nitrophenyl glycoside 3.19 using NIS and p-nitrophenol, 
unfortunately this was unsuccessful, only yielding the hydrolysed starting material 
(Scheme 32).  
 
 
Scheme 32 - Attempted glycosylation of p-nitrophenol to selenoglycoside 3.18. Conditions: 
p-nitrophenol, NIS, DCM. 
 
An alternative route was devised wherein the selenoglycoside was hydrolysed by 
treatment with NIS and water to give the hemiacetal 3.20, which was converted to the 
imidate 3.21 using Schmidt’s method.76 Activation of the imidate with TMSOTf in the 
presence of p-nitrophenol as the acceptor afforded the desired p-nitrophenyl glycoside 
3.19, as the α-anomer exclusively. Zemplén deacetylation of triacetate 3.19 followed 
by treatment with anisaldehyde dimethyl acetal and p-toluene sulfonic acid gave the p-
methoxybenzylidene 3.22, which was used as the common acceptor unit for the 






The non-reducing sugar of the core 1 disaccharide is galactose which is linked to the 
N-acetyl-D-galactosamine via a β1,3 linkage. A galactose donor suitable for 
glycosylation of acceptor 3.22 was synthesised by treating galactose 3.14 with benzoyl 
chloride in pyridine to obtain the perbenzoylated galactoside 3.23 (Scheme 33). It is 
well established that glycosyl donors with an ester functionality at the 2-position give 
exclusively the 1,2-trans glycoside. Normally, acetyl protecting groups are used at the 
2-position to facilitate neighbouring group participation during glycosylation. However 
in this case, the corresponding peracetylated donor was found to favour orthoester 
formation during the glycosylation reaction.65 Using benzoyl esters mitigated this issue 
(Figure 29).  
 
Figure 29 - Neighbouring Group Participation a C-2 acetyl ester compared with a benzoyl 
ester. Nucleophilic attack to form the orthoester product is prevented by the decreased 
electrophilicity of the acetoxonium carbon due to resonance stabilisation by the benzyl group. 
 
Benzoyl glycoside 3.23 was then regioselectively deprotected with hydrazine acetate 








Scheme 33 - Synthesis of galactosyl donor 3.25. Conditions: i) D-galactose, benzoyl chloride, 
pyridine, 0 ºC → rt, 18 h, 79 %; ii) hydrazine acetate, DMF, rt, 5.5 h, 95 %; iii) 1,1,1-
trichloroacetonitrile, DBU, DCM, 0 ºC, 5 h, 81 %. 
 
Acceptor 3.22 was then coupled with the trichloroacetimidate donor 3.25 under Lewis 
acid catalysis to give the desired disaccharide 3.26 in 45 % yield (Scheme 34).  
Hydrolysis of the 4,6-benzylidene with 80 % acetic acid then gave the diol 3.27. The 
azide was converted to the required acetamide in one step using thioacetic acid. 
Subsequent Zemplén deacetylation of the crude product from this reaction then gave 







Scheme 34 - Synthesis of core 1-pNP. Conditions: i) 3.25, TMSOTf, DCM, 4Å MS, -30 ºC, 4 
h, 45 %; ii) 80 % aq. AcOH, DCM, rt, 19 h, 85 %; (iii) 1) AcSH, pyridine, rt, 36 h; 2) NaOMe, 
MeOH, rt, O/N, 9 %. 
 
The synthesis of the core 3 disaccharide was also achieved using the common core 
monosaccharide acceptor 3.22. However, an N-acetyl-D-glucosamine donor also 
needed to be synthesised. Hollinger et al. had previously reported glycosylation of 
acceptor 3.22, using a GlcNAc thioglycoside. However, we decided to use a 
trichloroacetimidate donor so as to avoid the use of malodorous thiols.  
 
The required donor was easily synthesised in three steps as shown in Scheme 33. 
Firstly, the amine of glucosamine hydrochloride 3.29 was protected with a phthalimide 
functionality using phthalic anhydride, which was immediately followed by 
esterification of the remaining hydroxyl groups by treatment with acetic anhydride to 
give fully protected glucosaminide 3.30 (Scheme 35). Glycosyl acetate 3.30 was 
regioselectively deprotected using hydrazine acetate in DMF to yield the free 







Scheme 35 - Synthesis of glycosyl donor 3.32. Conditions: i) 1) Phthalic anhydride, NaOH, 
methanol, water, acetone, NaHCO3, 25 h, rt; 2) Acetic anhydride, pyridine, rt, O/N, 75 %; ii) 
hydrazine acetate, DMF, rt, 23 h, 69 %; iii) 1,1,1-trichloroacetonitrile, DBU, DCM, 0 ºC, 6 h, 
93 %. 
 
Imidate 3.32 (2.3 equiv) was activated with TMSOTf at -30 oC in the presence of 
acceptor 3.22 (Scheme 36). After 7 h, TLC indicated that the acceptor had been 
completely consumed and that a new product had formed with a polarity very similar 
to the donor, which would have made isolation of disaccharide 3.33 very difficult. The 
addition of water to the reaction mixture then hydrolysed any remaining imidate 3.32 
and give disaccharide 3.33 in 68 % yield. The p-methoxybenzylidene was then 
hydrolysed using 80 % aqueous AcOH to give the diol 3.34. The phthalimide protecting 
group was subsequently converted to an acetamide 3.35 in three steps using sodium 
methoxide, then hydrazine acetate, followed by subsequent acetylation using acetic 
anhydride. The azido functionality of 3.35 was then converted in one step to an 
acetamide using thioacetic acid, and this was followed by Zemplén deacetylation of the 







Scheme 36 - Synthetic route towards core 3-pNP. Reactions and conditions: (i) 3.32, TMSOTf, 
DCM, 4 Å MS, -30 °C, 7 h, 72 %; (ii) 80 % AcOH, DCM, 44 h, 68 %; (iii) 1) NaOMe, MeOH, 
O/N; 2) Hydrazine acetate, EtOH, 70 °C, 18 h; 3) Ac2O, pyridine, DMAP, O/N, 80 %; (iv) 1) 
AcSH, pyridine; 2) NaOMe, MeOH, 11 %. 
 
3.2.4. The synthesis of 1-O-acetyl core structures 
To access glycosyl acetate donors, it was necessary to generate the glycosyl hemiacetals 
from the core disaccharide structures. The hydrolysis of the Galβ1,3GalNAc-α-pNP 
(core 1-pNP) and the GlcNAcβ1,3GalNAc-α-pNP (core 3-pNP) glycosides were easily 
performed using the well reported hydrolytic capabilities of engEF from Enterococcus 
faecalis.64  
 
To this end, core 1-pNP 3.13 was dissolved in the appropriate buffer and treated with 
engEF (Scheme 37). Hydrolysis was monitored by RP-HPLC, and was found to be 







Scheme 37 - Hydrolysis of core 1-pNP. Conditions: i) engEF from Enterococcus faecalis, 25 
mM NaOAc, pH 6.0, 37 ºC, 1 h, 99 %. 
 
In a similar manner, the core 3-pNP glycoside was also hydrolysed using engEF to give 
the disaccharide hemiacetal 3.38 in 45 % yield (Scheme 38). 
 
 
Scheme 38 - Hydrolysis of core 3-pNP. Conditions: i) engEF from Enterococcus faecalis, 25 
mM NaOAc, pH 6.0, 37 ºC, 1 h, 45 %. 
 
Two of the core O-glycan structures were then converted to their 1-O-acetates for use 
in later enzymatic investigations (Table 7). Firstly, N-acetyl-D-galactosamine 3.9 was 
converted to the 1-O-acetate 3.36 using 2-chloro-1,3-dimethylimidazolidinium chloride 











Entry Sugar Product Yield (α/β) 
1 
  
86 % (1:1.1) 
2 
  
87 % (1.3:1) 
Table 7: Conversion of O-glycan-associated structures to their 1-O-acetates. Conditions: (i) 
sugar, TEA, AcSH, H2O, 0 ºC, then DMC, 1 h. 
 
The formation of a mixture of anomers can be rationalized by the consideration of the 
putative mechanism of the reaction (Figure 30). Firstly, thioacetate, generated by the 
deprotonation of thioacetic acid by triethylamine, reacts with DMC to generate a 
reactive thioester intermediate. This thioester is then attacked by the anomeric hydroxyl 
group of N-acetyl-D-galactosamine 3.9. Since 3.9 exists as a mixture of anomers in 




Figure 30 - Mechanism of glycosyl acetate formation using DMC and thioacetic acid. 
  
However, in order to be used as substrates for enzyme catalysed glycosylations, it was 





evidenced by TLC because of very small differences in their Rf values, meaning an 
alternative to normal phase chromatography was necessary. It was found that both 




Figure 31 - HPLC trace of the separation of GalNAc-1-O-acetate 3.36 anomers by RP-HPLC. 
Detector: CAD. 
 
The core 1 disaccharide was also converted to the corresponding 1-O-acetate using the 
same method, which again produced the acetates as a mixture of anomers (Table 7, 
Entry 2). These were again easily separated by RP-HPLC (Figure 32) to give the desired 
product as the pure single anomers in 87 % overall yield. 
The revelation that the GH101 mutant ENGases, which are discussed in Chapter 4, were 
in fact inactive towards the core 1 disaccharide glycosyl acetates meant that a decision 







Figure 32 - HPLC trace for the separation and isolation of core 1-OAc anomers. Detector: CAD. 
 
3.3. Conclusions 
Herein, activated substrates for the GH101 N-acetyl-α-D-galactosaminidases were 
synthesised. GalNAc-α-OAc, Gal1,3GalNAc-α-pNP (core 1-pNP), and 
GlcNAcβ1,3GalNAcαpNP (core 3-pNP) were synthesised as substrates for the WT 
engBL and engEF enzymes whilst GalNAc-β-OAc, GalNAc-β-N3, and 
Galβ1,3GalNAc-β-OAc were synthesised for the mutant engBL and engEF enzymes. 
An attempt was made to synthesise activated β-glycosyl fluoride derivatives of the core 
structures using a published method however this was unsuccessful due to the 
instability of the β-fluoride towards de-esterification conditions. Also, due to 
disappointing results of their usage as enzymatic substrates (Chapter 5), the β-glycosyl 






The compounds synthesised in this Chapter will be used as substrates for assaying the 
kinetic activity of these enzymes as well as being used for enzyme-catalysed 
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4.1.1. Carbohydrate processing enzymes 
The use of enzymes to synthesise glycosidic linkages is an area of research that has 
received considerable attention in recent years. The ability to stereoselectively, and 
sometimes also regioselectively, catalyse reactions in water without the need of a 
protection strategy are just a few of the advantages associated with this method of 
catalysis. Over recent years, both glycosyltransferases and glycosidases have been used 
extensively for the construction of glycosidic bonds.1–3 
 
Glycosyltransferases are often used for the assembly of oligosaccharides and 
glycopeptides, and additionally have also been applied to the synthesis of a small 
number of glycoproteins.4,5 In general, glycosyltransferases act in a stepwise manner 
and are highly specific in their substrate requirements.6,7 However, the requirement for 
complex sugar nucleotide donors and the lack of commercially available enzymes 
makes the use of glycosyltransferases unattractive. Moreover, the generation of 
nucleoside diphosphates as side products, which can inhibit the enzyme, is also 
problematic.8 
 
Glycosyl hydrolases, on the other hand, are plentiful in nature and readily hydrolyse 
glycosidic bonds of numerous oligosaccharides. To date, well over 260,000 different 
glycosyl hydrolases have been identified, and, based on sequence analysis, grouped into 




The hydrolysis of the glycosidic bond by glycosidases can give two possible 
stereochemical outcomes; either retention or inversion of configuration. A detailed 
analysis of the active site mechanism of retaining and inverting glycosidases is detailed 
in Chapter 1. 
 
4.1.2. Mechanism of family GH101 endo-α-N-acetylgalactosaminidases 
In 2005, Fujita et al. discovered an enzyme that catalysed the liberation of 
Galβ1,3GalNAc (core 1) from mucin-type glycoproteins.9 The enzyme was purified 
from Bifidobacterium longum and was the first enzyme to be allocated into family 
GH101. 
 
Since that time, several other enzymes have been discovered and classed as family 
GH101. The GH101 enzymes catalyse the hydrolysis of their respective substrates by 
means of a retaining mechanism. As described in Chapter 1, retaining glycosidases use 
a double-displacement mechanism involving the formation of a glycosyl-enzyme 
intermediate. This intermediate is then hydrolysed by general base-catalysed attack of 
water upon the anomeric centre, forming the hemiacetal product with retention of 
configuration, and returning the enzyme to its original protonation state (Figure 33).  
 
 






In 1998, a number of research groups investigated the mutagenesis of catalytic active 
site residues in glycosidases and their applications in oligosaccharide synthesis.1,10 
These studies on β-glycosidases had revealed that site-directed mutagenesis of the 
catalytic nucleophile to a non-nucleophilic amino acid (such as alanine) removed 
hydrolytic activity. The importance of the mutation can be appreciated if one considers 
the mechanism of the retaining β-glycosidase (Figure 34). As mentioned in Chapter 1, 
retaining glycosidases operate by a double-displacement mechanism involving the 
formation of a glycosyl-enzyme intermediate (Figure 34a, Step 1).  
 
 
Figure 34 - Mechanisms of a) retaining β-glycosidase and; b) β-glycosynthase catalysis 
 
General base-catalysed attack of an appropriate acceptor (such as water, Figure 34a, 
Step 2) then forms the product with retention of configuration. Removal of the catalytic 
nucleophile disrupted the natural mechanism of the enzyme (Figure 34b). Without the 




the hydrolysis of its natural substrates. However, with an intact active site, it could still 
catalyse the ligation of an activated α-glycosyl donor (Figure 34b, Step 1) (i.e of 
opposite anomeric configuration to the natural hydrolytic substrate) to an acceptor 
bound in the aglycon pocket. The enzyme, without nucleophilic activity, could not form 
the covalent glycosyl-enzyme intermediate, and so hydrolysis of the product did not 
take place (Figure 34b, Step 2).  
 
The groups of Planas10 and Withers1 investigated the use α-glycosyl fluorides as 
substrates that mimicked the glycosyl-enzyme intermediate. They observed that the 
glycosylation occurred with inversion of configuration to give a β-product, which was 
not subsequently hydrolysed by the enzyme. The rationale behind this observation was 
that the remaining acid/base residue catalysed the glycosylation step but the loss of the 
catalytic nucleophile eliminated the hydrolytic activity of the enzyme. 
 
The use of such mutant enzymes, termed glycosynthases, is now well established in 
oligosaccharide synthesis, and the field undergoes continuous expansion with new 
classes of glycosidase mutants being developed. 
 
4.1.4. Chemical rescue of mutant glycosidases 
The theory on the use of chemical rescue for mutant glycosidases is described in 
Chapter 1 (Section 1.12). Briefly, glycosidases which have undergone a substitution of 
the catalytic nucleophile for a non-nucleophilic residue (such as glycine or alanine) 
have no (or in some cases, residual) activity towards their respective natural substrates. 
However, when the mutant glycosidase is presented with an activated glycosyl 




exogenous nucleophile, such as azide, formate, or fluoride, the hydrolytic activity can 
be restored (Scheme 39).  
 
 
Scheme 39 - Chemical rescue of mutant glycosidases using exogenous nucleophiles. 
4.1.5. Michaelis-Menten kinetics 
Michaelis-Menten kinetics is one of the best representations of enzyme kinetics,11 and 
serves to explain how an enzyme can cause kinetic rate enhancements of a reaction, 
and also shows how reaction rates depend on the concentration of enzyme and substrate. 
The Michaelis-Menten model for enzyme kinetics presumes a simple two-step reaction. 
The first step involves the binding of the substrate to the enzyme, which is then 
followed by catalysis (conversion of the substrate to product), and then finally the 
subsequent release of the product from the enzyme active site (Figure 35). 
 
 
Figure 35 - General reaction scheme of an enzyme catalysed reaction. k1 represents the rate 
constant for the binding of the substrate (S) to the enzyme (E) to form the enzyme-substrate 
complex (ES); k-1 represents the rate of dissociation of the (ES) complex to free (E) and (S); 
k2 is the rate determining step and represents the catalysis reaction producing the reaction 





Based on several assumptions, explained below, the Michaelis-Menten model takes the 
form of an equation which describes the rate of enzymatic reactions by relating reaction 










Here, Vmax represents the maximum rate achieved when the active site of all the 
enzymes in the system are occupied. The ratio of constants (k-1 + k2)/k1 is itself a 







In cases where k2 is much smaller than k-1 (i.e. where ES complex dissociation to E + S 
is faster than product formation), KM is an inverse measure of the substrate’s affinity 
for the enzyme (i.e. a small KM indicates high affinity, meaning that the rate will 
approach Vmax faster, and vice-versa). When k2 is larger than k-1, KM values for the 
enzyme are meaningless because the Michaelis constant, no longer a measure of 
substrate affinity, is lower than the dissociation constant Ks = k-1/k1.
12 In such cases, it 
is important to establish whether the glycosylation (k1) or deglycosylation (k2) step is 
rate limiting. Sinnott and Souchard reported a Bronsted analysis of leaving group ability 
of the donor substrate and the subsequent effect on the rate of reaction.13 They found 




groups were used as substrates. Conversely, k1 was rate limiting in cases where donors 
with poor leaving groups (i.e. leaving groups with a high pKa) were used. 
 
There are several underlying approximations involved in the derivation of the 
Michaelis-Menten equation: 
1) The binding step (k1) is fast, allowing the reaction to quickly reach equilibrium 
ratios of [E], [S], and [ES]. The catalytic step (k2) is also slower, thus rate 
limiting. 
2) At early time points, where initial velocity (V0) is measured, [P] is 
approximately equal to zero; since if we observe V0 for the reaction immediately 
after E and S are mixed in the absence of P, the rate of any back reaction,  is 
negligible because its rate will be proportional to [P], and [P] is essentially 0. 
3) ES immediately comes to a steady state, so [ES] is constant (throughout the 
measurement of initial velocity) – this is the steady-state approximation and is 
an important part of the Michaelis-Menten model. 
4) Since [S] is significantly greater than [E] at the start of the reaction, the fraction 
of S that binds to E is negligible, and so [S] effectively remains constant at early 
time points. 
5) There are only two forms of the enzyme, either free (E) or bound to the substrate 
(ES). Therefore, the total [E] is the sum of the free and substrate-bound 
concentrations.  
 
An enzyme kinetics assay involves performing a series of experiments at varying 
substrate concentrations and monitoring the absorbance of a UV-active chromophore, 




to initial rate (ν0) values by application of the Beer-Lambert law, which relates the 
attenuation of light to the properties of the material through which the light is travelling, 
and is given by the equation: 
 
A = ε c l 
 
where the absorbance (A) is directly proportional to the concentration (c), path length 
(l), and the extinction coefficient (ε) of the chemical species being observed. 
 
By plotting the initial rates against [S], and using non-linear regression of the 
Michaelis-Menten equation (often by means of software, such as GraFit or Prism), the 
values for the parameters Vmax and KM can be obtained (Figure 36). Other parameters 
such as kcat and kcat/KM can be calculated from the data.  
 
 
Figure 36 – A Michaelis-Menten plot. 
 
kcat is the turnover number of an enzyme, and is a measure of its maximal catalytic 




enzyme molecule per unit time when the enzyme is saturated with substrate, and can 
be calculated from a standard enzyme kinetics assay once Vmax has been obtained, 
providing the total concentration of enzyme, [ET], is known. At saturating [S], ν = Vmax 







Another parameter, kcat/KM, is the pseudo second-order rate constant for the reaction of 
E and S to form product, and a measure of the efficiency of Michaelis-Menten-type 















When [S] << KM, the concentration of free enzyme, [E], is approximately equal to 










Because KM is inversely proportional to the affinity of the enzyme for its substrate, and 
kcat is directly proportional to the kinetic efficiency of the enzyme, kcat/KM provides an 
index of the catalytic efficiency of an enzyme operating at substrate concentrations 
substantially below saturation amounts. 
 
Due to the hyperbolic shape of ν versus [S] plots (Figure 36), Vmax can only be estimated 
from an extrapolation of the asymptotic approach of ν to some limiting value as [S] 
increases indefinitely. Linear plots can be derived from the Michaelis-Menten 
equations.  
 
One such plot is known as the Lineweaver-Burk double-reciprocal plot. Taking the 















This equation conforms to y = mx +c, where y = 1/ν; m, the slope is KM/Vmax; x = 1/[S]; 
and c = 1/Vmax. A plot of 1/ν versus 1/[S] gives a straight line whose x-intercept is 






Figure 37 - The Lineweaver-Burk double-reciprocal plot, depicting extrapolations that allow 
the determination of the x-and y-intercepts and slope. 
 
The expression and purification of engBL from Bifidobacterium longum and engEF 
from Enterococcus faecalis, as well as their mutagenesis, is detailed in Chapter 2. The 
kinetic parameters of the WT enzymes have been well characterised. However mutants 
of engBL and engEF enzyme have not. Therefore, it was necessary to perform enzyme 
kinetics assays to determine the kinetic parameters of the mutants and to demonstrate 
the extent to which mutagenesis had affected the activity of the respective WT enzymes. 
The Michaelis-Menten kinetics of the WT and mutant glycosidases investigated in this 
thesis were obtained and are described later in the relevant sections. 
 
4.2. Objectives 
Fujita et al.9 and Ito et al.14 demonstrated that both engBL and engEF, could catalyse 
the hydrolysis of the disaccharide Galβ1,3GalNAc (core 1) from mucin-type 
glycoproteins. EngBL could also catalyse the glycosylation of Galβ1,3GalNAc to 
various peptides containing serine or threonine residues.15 Moreover, both enzymes 
could catalyse the hydrolysis Galβ1,3GalNAc-α-pNP (core 1-pNP), however, only 




pNP), demonstrating that this enzyme possesses a broader substrate specificity.14 These 
observations stimulated our interest and led us to investigate whether it was possible to 
use engBL and engEF to chemoenzymatically access O-glycan glycopeptides by using 
the glycosylation potential of the family GH101 endo-α-N-acetylgalactosaminidases. 
Furthermore, we were interested in performing mutageneses of the family GH101 
enzymes to generate glycosynthase enzymes with improved glycosylation abilities. To 
date, the mutageneses of these two enzymes to generate glycosynthases has not been 
reported.  
 
The expression and purification of engBL15 and engEF14, as well as their mutagenesis, 
is described in Chapter 2. Chapter 3 details the synthesis of various activated O-glycan 
donors as substrates for engBL and engEF. This chapter outlines the kinetic analyses 
that were performed on the WT and mutant GH101 glycosidases. The substrate 
specificity of the WT and mutant variants of engBL and engEF using glycosyl acetates 
(see Chapter 5) was investigated to determine whether these could be better donors for 
the glycosylation reaction compared to more common p-nitrophenyl glycoside 
substrates.  
 
Investigation of the kinetic parameters of the WT and mutant engBL and engEF 
enzymes, using Michaelis-Menten steady-state approximations, is also detailed. 
Chemical rescue experiments were also performed using various nucleophiles to 
determine whether the activity of the mutants could be recovered.  Finally, the 
glycosylation of serine by a variety of O-glycan donors using engBL, engEF, and their 





4.3. EngBL from Bifidobacterium longum 
4.3.1. The hydrolytic activity and Michaelis-Menten kinetics of WT engBL 
Michaelis-Menten steady-state approximations were utilised to determine the kinetic 
parameters of engBL16 for the hydrolysis of Galβ1,3GalNAc-α-pNP (core 1-pNP) 
(Figure 38). A continuous assay was used whereby the release of p-nitrophenol was 
directly monitored by UV spectroscopy at 235 nm (ε235nm 1176 L mol
-1 cm-1). The 




Figure 38 – a) Michaelis-Menten curve for WT engBL with Galβ1,3GalNAc-α-pNP  (core 1-






The values for kcat and KM of Galβ1,3GalNAc-α-pNP for WT engBL were calculated 
to be 9.62 s-1 and 13 µM, respectively, varying slightly from the values of  kcat = 17.8 
s-1 and KM = 21.8 µM.
16 The differences in values attained in the previous studies are 
likely a result of variation in methodology and conditions used in the analysis. 
 
The kinetics of the hydrolysis of the activated disaccharide, Galβ1,3GalNAc-α-OAc 
(core 1-α-OAc) were also investigated. Zinin et al. had found that glycosyl acetates 
were a better donor for β-galactosidase from Penicillium sp.17 where the catalytic 
activity (kcat) of the enzyme for the glycosyl acetate substrate was three orders of 
magnitude greater than that for the p-nitrophenyl glycoside. 
 
Using methods published by Parsons et al.18, Michaelis-Menten analysis of WT engBL 
revealed that for the hydrolysis of Galβ1,3GalNAc-α-OAc (core 1-α-OAc) the kcat and 
apparent KM were 26.7 s





Figure 39 – a) Michaelis-Menten curve for WT engBL with Galβ1,3GalNAc-α-OAc (core 1-
OAc). Data points are shown as black circles and a line of best fit in red.  
b) A Lineweaver-Burk Plot. 
 
The use of core 1-α-OAc led to higher catalytic activity of the enzyme due to higher 
lability of the anomeric acetate as compared to the p-nitrophenyl glycoside. In terms of 
the kinetic scheme presented here, the data observed indicates that core 1-α-OAc is a 
better substrate for engBL (kcat/KM 1161 mM
-1 s-1) than core 1-α-pNP (kcat/KM 740 mM
-
1 s-1), with the enzyme displaying almost two times the activity of that of the p-
nitrophenyl glycoside. The KM values for the pNP disaccharide (21.8 µM) and core 1-
α-OAc (23 µM) were almost identical, indicating that the affinity of engBL for both 





An investigation was made to determine whether WT engBL could hydrolyse the 
monosaccharide, GalNAc-OAc. The original research published by Fujita et al. 
indicated that engBL was not capable of hydrolysing the monosaccharide, GalNAc-α-
pNP.9  
 
To this end, both anomers of GalNAc-OAc were individually incubated with engBL 
(226 mU) for 16 h, and then directly freeze-dried and analysed by 1H NMR. The 
International Union of Biochemistry (IUB) defines a standard unit (U) of enzyme 
activity as the amount of enzyme which catalyses the transformation of 1 µmol of the 
substrate per minute under standard conditions.19 The amount of engBL required for 
one unit of activity was calculated in Chapter 2 to be 0.31 µg. 
 
Non-enzymatically catalysed hydrolysis of GalNAc-OAc was also measured by 
incubating the respective anomers in buffer without the addition of enzyme. 
 
 
Enzyme GalNAc-α-OAc 4.1 GalNAc-β-OAc 4.2 
No enzyme 22 % 45 % 
engBL 48 % 56 %  
Table 8 - Hydrolysis of monosaccharide donors 4.1 and 4.2 by engBL. Conditions: i) engBL 
from Bifidobacterium longum (226 mU), 25 mM NaOAc, pH 6.0, 37 ºC. After 16 h, yields were 





After 16 h, 1H NMR analysis of the control (no enzyme) indicated that 45 % of the β-
anomer 4.2 was hydrolysed compared to 22 % of that of the α-anomer 4.1. The 
differences in the amount of hydrolysed starting material suggests that the mechanism 
of hydrolysis involves cleavage of the anomeric bond (Figure 40a, 1), and not the C-O 
bond of the ester by an ester hydrolysis mechanism with water (Figure 40a, 2). If the 
ester linkage was cleaved, a substantial difference in the amount of hydrolysis of the 
two different anomers should not be observed. 
 
 
Figure 40 – Mechanism of spontaneous hydrolysis of GalNAc-β-OAc 4.2 in water. a) 
cleavage of the anomeric linkage 1 or ester linkage 2; b) mechanism of hydrolysis via 
anchimeric assistance by the 2-acetamido group. 
 
The rate of hydrolysis of the β-anomer 4.2 of GalNAc-OAc is likely accelerated by the 
presence of the acetamido functionality at C-2 which is suitably positioned to provide 
anchimeric assistance in the departure of the β-anomeric group (Figure 40b). 
 
Next, both anomers of GalNAc-OAc were separately incubated with engBL. After 16 
h, the α-anomer 4.1 was found to have hydrolysed by 48 %, whereas the β-anomer 4.2 
was hydrolysed by 56 % (Table 8). Preliminary analysis of the reaction mixture 




hydrolysis of the β-anomer, albeit very slowly. The ability of glycosidases to binding 
and performing catalysis on substrates of the ‘wrong’ configuration (i.e. opposite 
configuration to that of the natural substrate) is well documented for mutant 
glycosidases.20 Therefore, it is possible that WT glycosidases can also bind the ‘wrong’ 
anomer of GalNAc-OAc (i.e. the β-anomer). However in this case, the amount of 
hydrolysis of GalNAc-β-OAc 4.2 was low. The low hydrolytic rate could arguably be 
due to steric hindrance by the nucleophilic residue (D789) which may interfere with the 
ability of GalNAc-β-OAc to fit into the binding pocket.  
 
The observation that engBL bound and hydrolysed GalNAc-α-OAc 4.1 was also 
interesting since the initial investigations of engBL substrate specificity indicated that 
GalNAc-α-pNP was not a substrate for the enzyme.9 The ability of engBL to catalyse 
the hydrolysis of GalNAc-α-OAc 4.1 is likely due to the increased lability of the 
anomeric acetate (pKa ~ 4.76). Glycosyl acetates have previously been found to be 
better substrates for glycosylation reactions as compared to their p-nitrophenyl 
counterparts17, and, for example, have increase the catalytic activity of the enzyme by 
up to 100-fold. 
 
4.3.2. Chemical rescue and Michaelis-Menten kinetics of engBL mutants 
A substitution of the catalytic nucleophile (D789) of engBL for residues glycine, 
alanine, and serine respectively was expected to affect the hydrolytic activity of the 
enzyme. To determine the magnitude of the effect of the D789 point mutations, the 
kinetic parameters for the mutant engBL enzymes were determined for the hydrolysis 




approximations, and a continuous assay to monitor the release of p-nitrophenol by UV 
spectroscopy at 235 nm (ε235nm 1176 L mol
-1 cm-1) (Figure 41). 
 
As expected, the mutagenesis of engBL led to a significant decrease in the catalytic 
activity in the enzyme (Table 9). The turnover number (kcat) of the D789G/A/S mutants, 
which represents the number of times each enzyme site converts substrate to product 
per unit time, all decreased by over 200-fold compared to that of WT engBL when 
incubated with Galβ1,3GalNAc-α-pNP (core 1-pNP). The highest substrate turnover 
was observed for the D789S mutant (Table 9, Entry 4) with a kcat value of 0.69 s
-1, 
which is approximately 15 times lower than the WT enzyme. However, KM increased 
100-fold to 1.3 mM compared to that of the WT enzyme indicating that the substitution 
may have had a negative effect on the ability of the enzyme to bind the substrate. The 
activity of the D789G (Table 9, Entry 2) and D789A (Table 9, Entry 3) mutants were 
also significantly reduced, with measured kcat values of 0.54 s
-1 and 0.019 s-1, 
respectively. The rate decreases observed here for the engBL D789 mutants collectively 
suggested that the mutagenesis has affected an important residue in the active site that 
is involved in catalysis. It is well reported that mutageneses which target the 







Figure 41 – (Top) Michaelis-Menten curves for a) engBL D789G; b) engBL D789A and; c) engBL D789S. Data points are shown as white circles and the 
















1 WT - 0.0131 9.62 738 - 
2 D789G - 0.170 0.543 3.20 0.434 % 
3 D789A - 0.272 0.0195 0.0714 0.00967 % 
4 D789S - 1.34 0.689 0.514 0.0696 % 
5 D789G 100 mM NaN3 0.0498 0.647 13.0 1.76 % 
6 D789A 100 mM NaN3 0.322 0.0347 0.108 0.0146 % 
7 D789S 100 mM NaN3 0.0321 0.244 7.61 1.03 % 
8 D789G 200 mM NaBr 0.0616 0.385 6.25 0.847 % 
9 D789A 200 mM NaBr 0.0481 0.00919 0.191 0.0259 % 
10 D789S 200 mM NaBr 0.113 0.199 1.77 0.240 % 
11 D789G 1 M NaHCOO 0.0486 0.435 8.96 1.21 % 
12 D789A 1 M NaHCOO 0.0242 0.0123 0.508 0.0688 % 
13 D789S 1 M NaHCOO 0.0307 0.102 3.32 0.450 % 
Table 9 - Kinetics and chemical rescue of engBL D789G/A/S using various nucleophiles. 
Conditions: engBL D789G/A/S, nucleophile, 25 mM NaOAc buffer, pH 6.0, 37 °C. Chemical 
reactivation experiments of the inactive nucleophilic variants were also performed using NaN3, 
NaBr, and NaHCOO as external nucleophiles. a activity recovered relative to WT engBL. 
 
Chemical rescue experiments were performed to determine whether the activity of the 
mutants could be recovered in the presence of an exogenous nucleophile. As mentioned 
in Chapter 1, due to the absence of the catalytic nucleophile, the mutants should lose 




engBL mutants would be inactive against the pNP disaccharide. However, in the 
presence of a small exogenous nucleophile such as azide, the activity of the enzyme 
should be restored.23  
 
A variety of concentrations of the respective exogenous nucleophile were investigated 
to determine which, if any, concentrations would restore activity to the mutant 
enzymes. These analyses indicated 100 mM, 200 mM, and 1 M were appropriate for 
NaN3, NaBr, and NaHCOO, respectively. 
  
As shown in Table 9, chemical rescue of the mutants by the added various nucleophiles 
was not very effective. The best rescue was observed with the D789G mutant (Table 9, 
Entry 5), which recovered 1.8 % of its original catalytic efficiency (calculated by taking 
100 % the kcat/KM of the WT enzyme (Entry 1)), when 100 mM NaN3 was used as a 
nucleophile. The D789S (Entry 7) and D789A (Entry 6) mutants recovered low 
percentage activities, namely 1 % and 0.02 % respectively, of the WT enzyme.  
 
Incubation of the mutants with alternative nucleophiles did not lead to greater 
recoveries of catalytic activity. The best activity was recovered when 200 mM of NaBr 
was used to rescue the D789G mutant (0.9 %, Entry 8), followed by D789A (Entry 9) 
and D789S (Entry 10) mutants (0.026 and 0.24 %, recovered activity respectively). The 
greater recovery observed for the D789G mutant could be due to the size of the cavity 
created upon removal of the carboxylate, allowing room for the large bromide ion to 






Figure 42 - Chemical rescue with bromide. a) Steric hindrance by the catalytic nucleophile 
means that the bromide nucleophile cannot access the binding site for chemical rescue; b) 
Substitution of the catalytic nucleophile for a smaller residue forms a large pocket which fits 
the exogenous bromide. 
 
Finally, chemical rescue with sodium formate was investigated. It is known that 
exogenous formate can act as a mimic of the carboxylic acid of the enzyme and so may 
assist in the catalysis (Scheme 40).24 In this case, the activated α-glycosyl donor should 
result in the in situ generation of β-glycosyl-intermediate which can be used by the 
glycosynthase. 
 
Similar decreases in rate constants have also been observed in reported chemical rescue 
experiments. For example, Hommalai et al. found that mutagenesis of rice β-
glucosidase (BGlu1) affected the activity of the enzyme.22 Chemical rescue 
experiments of the E414A and E414S mutants led to only modest increases in activity 
(up to 0.229 % and 0.0145 % for the E414A and E414S mutants, respectively. 
Hommalai et al. suggested that the bulkier hydroxymethyl of serine and the methyl 
group of alanine might hinder the attack of the nucleophile on the substrate. Cobucci-
Ponzano et al. have also seen similar decreases in their chemical rescue experiments of 
mutants of the α-L-fucosidase from Sulfolobus solfataricus (SSα-Fuc) using formate 






Scheme 40 - Chemical rescue of mutant glycosidase using sodium formate. 
 
Chemical rescue of the mutant glycosidases with sodium formate was also poor. Again, 
engBL D789G showed the greatest recovery (1.2 %, Entry 11), followed by the D789S 
(Entry 13), and D789A (Entry 12) mutants.  
 
As with WT engBL, investigations into the hydrolytic activity of the engBL mutants 










No enzyme - 22 % 48 % 0 % 
engBL 
D789G 22 % 67 % 0 % 
D789A 23 % 69 % 0 % 
D789S 23 % 68 % 0 % 
Table 10 - Hydrolysis of monosaccharide donors (100 nmol) by engBL mutants. Conditions: 
engBL D789G/A/S, 25 mM NaOAc buffer, pH 6.0, 16 h, 37 °C. After 16 h, yields were 
calculated by 1H NMR by comparing the integrals of H-1 and COCH3 of the starting material 





The spontaneous hydrolysis of GalNAc-α-OAc 4.1 was measured by incubating the 
glycoside in the reaction conditions without enzyme. After 16 h, it was found that 22 
% of the starting material had hydrolysed to produce the hemiacetal. 
 
Due to the absence of a catalytic nucleophile, it was expected that the engBL mutants 
would not be able to catalyse the hydrolysis of α-anomer 4.1 of GalNAc-OAc. After 16 
h of incubation of GalNAc-α-OAc 4.1 with the respective mutants, analysis of the 
reaction mixture indeed indicated that only background hydrolysis was occurring, 
suggesting again that a catalytically important residue had been removed.  
 
Hydrolysis of the β-anomer 4.2 of GalNAc-OAc did occur albeit very slowly, with a 
maximum yield of 69 % when the substrate was incubated with the D789A mutant. 
This result (i.e. that the mutant enzyme was capable of hydrolysis of the β-acetate) is 
consistent with the understanding that mutant glycosidases are able to bind activated 
substrates of the opposite stereochemical configuration to that of the natural substrate 
and catalyse glycosylation reactions.1,10 
 
Cobucci-Ponzano et al. have observed that glycosyl azides can also be donors for 
glycosynthases.21 Therefore, we wanted to determine whether GalNAc-β-N3 4.3 was a 
viable donor for our engBL mutant enzymes. To this end, GalNAc-β-N3 4.3 was also 
incubated with the engBL mutants. Disappointingly, 1H NMR analysis showed that no 
hydrolysis of the starting material suggesting that glycosyl azides were not donors for 





4.3.3. Glycosylation reactions catalysed by engBL 
4.3.3.1. Glycosylation of MeOH using WT engBL 
The glycosylation activity of WT engBL was investigated. Firstly, the reported 
glycosylation of MeOH by Galβ1,3GalNAc-α-pNP 4.4 (core 1-pNP) was performed to 
determine whether the enzyme could perform the same reaction.  
 
Core 1-pNP was incubated with engBL (226 mU) with 15 % v/v MeOH for 16 h, at 
which point, the reaction was quenched by addition of 1 M aqueous NaOH (Scheme 
41). Analysis by mass spectrometry and RP-HPLC confirmed the formation of the 
expected methyl glycoside 4.5 in 49 % yield indicating that the expressed enzyme was 
active as described.9 
 
 
Scheme 41 - Glycosylation of MeOH by engBL. Conditions: engBL from Bifidobacterium 
longum (226 mU), 15 % MeOH, 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 16 h, 49 %. 
 
As described in Section 4.3.2., we observed that WT engBL could catalyse the 
hydrolysis of the monosaccharide, GalNAc-α-OAc 4.1. Based on this result, we 
expected the enzyme should also catalyse glycosylation of MeOH by GalNAc-α-OAc 
4.1.  
 
Therefore, GalNAc-α-OAc 4.1 was incubated with 15 % MeOH (v/v) and WT engBL 




MeOH with GalNAc-α-OAc 4.1, showing 15 % yield of the desired methyl glycoside 
4.6 and hydrolysis of the remaining substrate. 
 
 
Scheme 42 - Glycosylation of MeOH to GalNAc-α-OAc 4.1 by engBL. Conditions: engBL 
from Bifidobacterium longum (226 mU), 15 % MeOH, 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 
16 h, 15 %. 
 
Analysis of the control reaction, where no enzyme was added, showed that there was 
no methyl glycoside was formed, indicating that the enzyme was indeed responsible for 
catalysing formation of the methyl glycoside 4.6. 
 
It was found that WT engBL could also catalyse the glycosylation of MeOH by 
Galβ1,3GalNAc-α-OAc 4.7 (core 1-α-OAc) (Scheme 43). After 16 h, the desired 
methyl glycoside 4.5 was obtained in 38 % yield. Disappointingly, the yield obtained 
using the glycosyl acetate donor was lower than that which was reported for the 
corresponding p-nitrophenyl glycoside (49 %). Due to the lack of substrate, we could 
not optimise this yield any further. 
 
Scheme 43 - Glycosylation of MeOH to core 1-α-OAc 4.7 by WT engBL. Conditions: engBL 
from Bifidobacterium longum (226 mU), 15 % MeOH (v/v), 25 mM NaOAc buffer, pH 6.0, 37 






4.3.3.2. Glycosylation of MeOH by mutants of engBL 
An attempt was made to glycosylate MeOH with activated β-glycosyl donors using the 
engBL mutant enzymes. The first set of reactions was performed using GalNAc-β-OAc 
4.2 as the donor. As observed in Section 4.3.1, WT engBL was capable of catalysing 
the hydrolysis of the monosaccharide, GalNAc-α-OAc 4.1. In theory, the mutant engBL 
enzymes may be able to bind substrates of the opposite configuration, in this case, 
GalNAc-β-OAc 4.2, and catalyse the transfer of GalNAc to an appropriate acceptor to 
give the product with inverted stereochemistry (Figure 43). 
 
 
Figure 43 - Mechanism for the transfer of an acceptor by a GH101 glycosynthase. 
 
GalNAc-β-OAc 4.2 was incubated with 15 % MeOH (v/v), and the mutant enzymes 







Scheme 44 - Attempted glycosylation of MeOH to GalNAc-β-OAc 4.2 using engBL 
D789G/A/S. Conditions: engBL D789G/A/S (20 µL of a 14.3/9.4/8.6 mg/mL solution), 15 % 
MeOH, 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 16 h. 
 
To our disappointment, the formation of the methyl glycoside 4.6 was not observed for 
any of the mutant enzymes, by either RP-HPLC (product retention time confirmed by 
synthesis of the methyl glycoside by the chemical means) or t.l.c. analysis. Although 
this observation suggests that the mutants are unable to catalyse the transfer of MeOH 
to GalNAc, it was difficult at that point to conclude that the enzyme was completely 
inactive towards activated β-glycosyl donors since the monosaccharide is not the 
preferred substrate for the GH101 endo-α-N-acetylgalactosaminidases. A more 
appropriate substrate to glycosylate MeOH was the therefore Galβ1,3GalNAc (core 1) 
disaccharide.9  To this end, Galβ1,3GalNAc-β-OAc 4.8 and MeOH were incubated with 
the engBL D789G/A/S mutants for 16 h (Scheme 45).  
 
 
Scheme 45 - Attempted glycosylation of MeOH by core 1-β-OAc 4.8 using engBL 
D789G/A/S mutants. Conditions: engBL D789G/A/S (20 µL of a 14.3/9.4/8.6 mg/mL 
solution), 15 % MeOH, 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 16 h. 
 
After 16 h, RP-HPLC analysis of the reaction mixture indicated that the core 1-β-OAc 




analysis of the reaction mixture at hourly intervals did not indicate any formation of the 
desired methyl glycoside. 
 
To determine whether it was a substrate for the enzyme, core 1-β-OAc 4.8 was 
incubated in the presence and absence of engBL D789G for 16 h. Direct analysis of the 
respective reaction mixtures by RP-HPLC indicated that yields of the non-enzymatic-
catalysed and enzymatic-catalysed reactions were essentially the same (87 % without 
enzyme, 84 % with enzyme). 
 
In light of this disappointing result further investigations were abandoned. 
 
4.3.3.3. Glycosylation of Ser-OH by mutant engBL 
The aim of this project was to develop chemoenzymatic methodology for the synthesis 
of O-linked glycoconjugates. Therefore, as a prior step to peptides, it was appropriate 
to determine whether the engBL mutants could transfer single serine and threonine units 
to activated core O-glycan structures. Ashida et al. found that yields of glycosylation 
using serine as the acceptor were greater than when threonine was used.15 Therefore, 
GalNAc-β-OAc 4.2 was incubated with 10 equivalents of Ser-OH and engBL 
D789G/A/S mutants to investigate whether the enzyme could catalyse the glycosylation 
of the unprotected amino acids (Scheme 46). A control reaction was performed where 






Scheme 46 - Attempted glycosylation of Ser-OH to GalNAc-β-OAc 4.2 using engBL 
D789G/A/S mutants. Conditions: engBL D789G/A/S (20 µL of a 14.3/9.4/8.6 mg/mL 
solution), Ser-OH (10 equiv), 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 16 h. 
 
The reaction was monitored by t.l.c. and after 16 h, the starting material was found to 
be completely hydrolysed with no evidence of desired product formation. The absence 
of product was also confirmed with RP-HPLC and mass spectrometry. 
To confirm the lack of any glycosynthase activity was not due to substrate preference, 
Galβ1,3GalNAc-β-OAc 4.8 (core 1-β-OAc) was also incubated with 10 equivalents of 
Ser-OH and the mutant enzymes.  
 
Scheme 47 - Attempted glycosylation of Ser-OH to Galβ1,3GalNAc-β-OAc 4.8 using engBL 
D789G/A/S mutants. Conditions: engBL D789G/A/S (20 µL of a 14.3/9.4/8.6 mg/mL 
solution), Ser-OH (10 equiv), 25 mM NaOAc buffer, pH 6.0, 37 ˚C, 16 h. 
 
After 16 h, RP-HPLC and t.l.c. analysis showed complete hydrolysis of core 1-β-OAc 
4.8 indicating that the engBL mutants are incapable of catalysing the transfer of serine 
to the core 1-β-OAc 4.8 donor. Mass spectrometry did not indicate the presence of the 






This section details investigations into the properties of engBL and its mutant variants. 
Michaelis-Menten kinetics obtained for WT engBL determined kcat and KM for 
Galβ1,3GalNAc-α-pNP (core 1-pNP) were determined to be 9.62 s-1 and 13 µM, 
respectively. The kinetic parameters for the hydrolysis of disaccharide, 
Galβ1,3GalNAc-α-OAc (core 1-pNP), were found to be 26.7 s-1 and 23 µM for kcat and 
KM, respectively. These values were in line with the observation that glycosyl acetates 
are better donors for glycosidases than pNP glycosides.17  
 
WT engBL could hydrolyse GalNAc-α-OAc, which was unexpected since the original 
investigations9 had found that GalNAc-α-pNP was not a substrate for this enzyme. The 
glycosylation of methanol by both GalNAc-α-OAc and Galβ1,3GalNAc-α-OAc using 
WT engBL, in unprecedented reactions, were successful indicating that glycosyl 
acetates are viable substrates for the GH101 endo-α-N-galactosaminidases. 
 
The activity and kinetic parameters of the three engBL mutants were also investigated. 
Chemical rescue experiments with azide, formate, and bromide resulted in low recovery 
of activity (< 2 %) in all cases when compared to the activity of WT engBL, suggesting 
that the enzyme active site had been perturbed by the mutagenesis. Disappointingly, the 
engBL mutants could not catalyse the glycosylation of either MeOH or Ser-OH by 
either GalNAc-β-OAc or Galβ1,3GalNAc-β-OAc. The underlying reasons for these 
observations are not clear at this point in time. Future computational and 
crystallographic studies may shed light on the impact of the point mutation on the active 





4.4. EngEF from Enterococcus faecalis 
4.4.1. Michaelis-Menten kinetics of WT engEF 
Michaelis-Menten steady-state approximations were utilised to determine the kinetic 
parameters of WT engEF for the hydrolysis of Galβ1,3GalNAc-α-pNP (core 1-pNP). 
The hydrolysis of core 1-pNP by engEF was monitored by UV spectroscopy using a 
continuous assay at various concentrations of core 1-pNP. The release of p-nitrophenol 
was directly monitored at 235 nm (ε235nm 1176 L mol
-1 cm-1). The values for KM and 
kcat for WT engEF were previously reported to be 59.6 µM and 49.9 s
-1, respectively.14 
For the engEF expressed for this work, the values for KM and kcat were found to be 53.5 
µM and 76.4 s-1, respectively, confirming that the protein expressed for this research to 






Figure 44 - a) Michaelis-Menten curve for WT engEF with Galβ1,3GalNAc-α-pNP (core 1-
pNP). Data points are shown as black circles and a line of best fit in red.  
b) A Lineweaver-Burk plot. 
 
The kinetic parameters of hydrolysis were also determined using Galβ1,3GalNAc-α-
OAc (core 1-α-OAc) as the substrate. Using methods published by Parsons et al.18, the 
values for KM and kcat were calculated to be 42 µM and 104 s
-1, respectively (Figure 
45). As previously seen with WT engBL, the use of core 1-α-OAc led to higher catalytic 
activity of the enzyme due to higher lability of the anomeric acetate as compared to the 
p-nitrophenyl glycoside. This observation demonstrates that core 1-α-OAc is a better 
substrate for engEF (kcat/KM 2476 mM
-1 s-1) than core 1-α-pNP (kcat/KM 1428 mM
-1 s-1), 
with the enzyme displaying almost two times the activity of that of the p-nitrophenyl 
glycoside. The similar KM values suggests that the affinity of engEF for both the core 






Figure 45 - a) Michaelis-Menten curve for WT engEF with Galβ1,3GalNAc-α-OAc (core 1-
OAc). Data points are shown as white circles and a line of best fit in red.  
b) A Lineweaver-Burk plot. 
 
The monosaccharide, GalNAc-OAc, was also tested as a substrate for hydrolysis by 
WT engEF. Both the α-anomer 4.1 and β-anomers 4.2 of GalNAc-OAc (100 nmol) 
were separately incubated with engEF (110 mU) for 16 h at 37 ºC, at which point the 
reaction mixture was lyophilised and analysed by 1H NMR. Interestingly, WT engEF 
catalysed the hydrolysis of the α-anomer of GalNAc-OAc 4.1 with a greater efficiency 






Enzyme GalNAc-α-OAc 4.1 GalNAc-β-OAc 4.2 
No enzyme 22 % 45 % 
engEF 88 % 56 % 
Table 11 - Hydrolysis of GalNAc-OAc 4.1 and 4.2 (100 nmol) by WT engEF. Conditions: 
engEF from Enterococcus faecalis (110 mU), 25 mM NaOAc buffer, pH 6.0, 37 ˚C. After 16 
h, yields were calculated by 1H NMR by comparing the integrals of H-1 and COCH3 of the 
respective sugars of the starting material and hydrolysed sugars. 
 
Koutsioulis et al. reported that engEF could catalyse the hydrolysis of GalNAc-α-pNP; 
however the amount of p-nitrophenol released after 16 h was only 2.2 %, though the 
amount of enzyme used was not stated.25 Goda et al. also reported the same reaction 
with engEF, and observed approximately 60 % hydrolysis of Galβ1,3GalNAc-α-pNP 
(core 1-pNP) when the substrate was incubated with 300 mU of enzyme for 16 h. 
 
Incubation of GalNAc-β-OAc 4.2 with WT engEF (110 mU) did not result in a 
significant amount of hydrolysis, and only 11 % of the substrate was converted to the 
hemiacetal after 16 hrs.  
 
4.4.2. The hydrolytic activity and Michaelis-Menten kinetics of mutant engEF 
The mutant enzymes engEF D725G/A/S were incubated with Galβ1,3GalNAc-α-pNP 
4.4 (core 1-pNP) to determine whether the mutations of the nucleophilic residue had 
affected the activity of the enzymes (Table 12). Chemical rescue experiments were also 














1 WT - 0.064 49 763 - 
2 D789G - N.D. N.D. N.D. N.D. 
 D789A - N.D. N.D. N.D. N.D. 
3 D789S - N.D. N.D. N.D. N.D. 
4 D789G 100 mM NaN3 N.D. N.D. N.D. N.D. 
5 D789A 100 mM NaN3 N.D. N.D. N.D. N.D. 
6 D789S 100 mM NaN3 N.D. N.D. N.D. N.D. 
7 D789G 200 mM NaBr N.D. N.D. N.D. N.D. 
8 D789A 200 mM NaBr N.D. N.D. N.D. N.D. 
9 D789S 200 mM NaBr N.D. N.D. N.D. N.D. 
10 D789G 1 M NaHCOO N.D. N.D. N.D. N.D. 
11 D789A 1 M NaHCOO N.D. N.D. N.D. N.D. 
13 D789S 1 M NaHCOO N.D. N.D. N.D. N.D. 
Table 12 - Kinetic parameters for the hydrolysis of core 1-pNP by engEF mutants. N.D. Not 
Detected. aCompared with the activity of WT engEF. 
 
In contrast to the engBL mutants, the engEF mutants were all completely inactive when 
incubated with Galβ1,3GalNAc-α-pNP 4.4 (core 1-pNP) as monitored by UV 
spectroscopy. Moreover, the mutants could not be chemically rescued by azide, 
formate, or bromide (Table 12). As the engEF mutants were confirmed to be folded 
using circular dichroism spectroscopy (see Chapter 2), it was unclear which aspect of 





The hydrolytic activity of the engEF mutants on both anomers of GalNAc-OAc (4.1 










No enzyme - 22 % 48 % 0 % 
engEF 
D725G 23 % 50 % 0 % 
D725A 22 % 53 % 0 % 
D725S 23 % 53 % 0 % 
Table 13 - Hydrolysis of GalNAc substrates using mutant engEF. Conditions: engEF 
D725G/A/S, 25 mM NaOAc buffer, pH 6.0, 37 ˚C. Hydrolysis after 16 h was measured by 
integral analysis of H-1 and COCH3 of the respective anomers of GalNAc-OAc and GalNAc.  
 
The non-enzymatic-catalysed rate of hydrolysis of the GalNAc-OAc substrates after 16 
h was found to be 22 % and 48 % for the α-anomer 4.1 and β-anomer 4.2, respectively.  
The engEF mutants were also incubated with GalNAc-β-OAc 4.2. After 16 h, there was 
no appreciable amount of extra hydrolysis (i.e. only ~5 % difference from base 
hydrolysis) was observed for any of the mutant enzymes.  
 
The hydrolysis of GalNAc-α-OAc 4.1 by the mutant engEF enzymes was also 
investigated. After 16 h, approximately 23 % of GalNAc-α-OAc 4.1 was hydrolysed in 
all cases, i.e. the same amount as the control, suggesting that the mutant ENGases did 




catalytic nucleophile has been removed, and so the enzyme is no longer capable of 
forming the glycosyl-enzyme intermediate required for hydrolysis.1  
 
The engEF mutants were also incubated with GalNAc-β-N3 4.3. However, after 16 h, 
there was no hydrolysis of the substrate indicating that glycosyl azides are not viable 
substrates for engEF. 
 
4.4.3. Reactions catalysed by engEF 
4.4.3.1. Glycosylation of MeOH using WT engEF 
Goda et al. reported that WT engEF could catalyse the glycosylation of both MeOH 
and EtOH using Galβ1,3GalNAc-α-pNP 4.4 (core 1-pNP) as the donor.14 We wanted 
to determine whether the engEF enzyme that we had expressed and purified in Chapter 
2 could perform the same reaction. To this end, core 1-pNP 4.4 was incubated with 
engEF with 15 % MeOH (v/v) as described by Goda et al (Scheme 48). 
 
Scheme 48 - Glycosylation of MeOH using Galβ1,3GalNAc-α-pNP 4.4 (core 1-pNP) as the 
donor. Conditions: i) engEF from Enterococcus faecalis (110 mU), 15 % v/v MeOH, 25 mM 
NaOAc buffer, pH 6.0, 37 ˚C, 16 h, 56 %. 
 
 
RP-HPLC and mass spectrometric analysis confirmed the formation of the desired 
methyl glycoside 4.5 in 56 % yield, indicating that the enzyme expressed in this 





Our attention then turned to the glycosylation of MeOH with GalNAc-α-OAc 4.1. As 
stated in Section 4.4.1, WT engEF was capable of hydrolysing the monosaccharide, and 
therefore we expected that the enzyme may be able to catalyse the glycosylation of 
MeOH. To this end, GalNAc-α-OAc 4.1 and WT engEF were incubated with 15 % 
MeOH (v/v) as the acceptor for 16 h (Scheme 49).  
 
 
Scheme 49 - Glycosylation of MeOH to GalNAc-α-OAc 4.1 using WT engEF. Conditions: 
engEF from Enterococcus faecalis (111 mU), 15 % MeOH (v/v), 25 mM NaOAc buffer, pH 
6.0, 37 ˚C, 16 h, 40 %. 
 
Analysis of the reaction mixture after this time indicated that the enzyme had 
transferred MeOH to the donor with a 40 % yield to the methyl glycoside 4.6, as 
observed by 1H NMR. T.l.c. also indicated the formation of a major product of lower 
polarity as compared to the starting material 4.1. The control reaction mixture (no 
enzyme) did not contain any methyl glycoside 4.6. The higher yield observed for 
engEF-catalysed glycosylation of MeOH to GalNAc-α-OAc 4.1 compared to that with 
engBL could be due to the broader substrate specificity of the former enzyme.25 
 
Finally, we wanted to determine whether WT engEF could also catalyse the 
glycosylation of MeOH by Galβ1,3GalNAc-α-OAc 4.7 (core 1-α-OAc) (Scheme 50). 






Scheme 50 - Glycosylation of MeOH to Galβ1,3GalNAc-α-OAc 4.7 (core 1-α-OAc) using WT 
engEF (111 mU). Conditions: engEF from Enterococcus faecalis, 15 % MeOH (v/v), 25 mM 
NaOAc, pH 6.0, 37 ˚C, 16 h, 37 %. 
 
After 16 h, the reaction was quenched by addition of 1 M NaOH. RP-HPLC analysis 
of the reaction mixture indicated the formation of the desired methyl glycoside 4.5 in 
37 % yield. Disappointingly, the yield obtained from the glycosylation was lower than 
obtained from the glycosylation of MeOH by the monosaccharide, GalNAc-α-OAc 4.1. 
Due to lack of substrate, this reaction could not be optimised further. 
 
4.4.3.2. Glycosylation of MeOH using engEF mutants  
As with the mutant engBL enzymes, the glycosylation potential of the engEF 
D725G/A/S mutants was assessed. Firstly, we wanted to determine whether the mutant 
enzymes could glycosylate MeOH with the monosaccharide, GalNAc-β-OAc 4.2. We 
had observed earlier that WT engEF was capable of hydrolysing GalNAc-α-OAc 4.1 
and, moreover, catalysed the glycosylation of MeOH. However without the 
nucleophilic residue, the mutant engEF enzymes cannot form the glycosyl-enzyme 
intermediate. The idea was therefore that in the presence of an activated substrate 
containing an anomeric linkage opposite to that of the natural substrate, we may expect 
the mutant to be capable of catalysing the glycosylation of MeOH to give the 
corresponding methyl glycoside 4.6 with an inverted configuration. 
 
Therefore, GalNAc-β-OAc 4.2 was incubated with 15 % MeOH for 16 h with the 
respective engEF D725G/A/S mutants (Scheme 51). The reaction was also monitored 






Scheme 51 - Attempted glycosylation of MeOH to GalNAc-β-OAc 4.2 using engEF 
D725G/A/S mutants. Conditions: engEF D725G/A/S, 15 % MeOH (v/v), 25 mM NaOAc 
buffer, pH 6.0, 37 ˚C, 16 h. 
 
To our disappointment, RP-HPLC did not indicate any formation of the desired methyl 
glycoside 4.6 for any of the mutant reactions. T.l.c. analyses only showed the slow 
hydrolysis of the starting material over time. Mass spectrometry did detect the 
formation of the desired product 4.6, however, since RP-HPLC and t.l.c. analyses did 
not show product formation, it is likely that the methyl glycoside observed was a result 
of direct substitution at the anomeric centre by MeOH, since product was also observed 
by mass spectrometry in the control reaction, where no enzyme was added. 
 
Although these observations suggest that the mutants were unable to catalyse the 
transfer of MeOH to GalNAc-β-OAc 4.2, it was still uncertain whether the enzymes 
were completely inactive towards activated β-glycosyl donors since it is the 
disaccharide, Galβ1,3GalNAc, and not the monosaccharide, that is the preferred 
substrate for the GH101 endo-α-N-acetylgalactosaminidases. 
 
To this end, Galβ1,3GalNAc-β-OAc 4.8 (core 1-β-OAc) and 15 % MeOH were 
incubated with the respective engEF mutants for 16 h, at which point the reaction was 






Scheme 52 - Attempted glycosylation of MeOH to Galβ1,3GalNAc-β-OAc 4.8 using engEF 
D725G/A/S mutants. Conditions: engEF D725G/A/S, 15 % MeOH (v/v), 25 mM NaOAc 
buffer, pH 6.0, 37 ˚C, 16 h. 
 
The reaction mixtures were also monitored by t.l.c. at hour intervals. However, once 
again no product formation was observed; in all cases RP-HPLC and mass 
spectrometric analyses did not indicate the presence of any of the desired methyl 
glycoside. 
 
Further investigations were abandoned in light of these disappointing results. 
 
4.4.3.3. Glycosylation of Ser-OH using engEF mutants  
Goda et al14 and Koutsioulis et al25 performed extensive studies on the kinetic activity 
and substrate specificity of engEF from Enterococcus faecalis. However, to date, there 
are no reports detailing the use of engEF for the synthesis of O-linked glycosyl amino 
acids, glycopeptides, or glycoproteins. EngEF was selected for the work in this research 
due to the broad substrate specificity of the enzyme.  We wanted to glycoengineer 
engEF to generate glycosynthases capable of glycosylating Ser/Thr residues of 
glycopeptides and glycoproteins, with not only the core 1-disaccharide, but also the 
core 3-disaccharide. However, as a preliminary step, it was appropriate to determine 
whether the engEF mutants could transfer activated core O-glycan structure onto single 





Therefore, in a similar vein to the mutant engBL enzymes, engEF D725G/A/S were 
incubated with GalNAc-β-OAc 4.2 and 10 equivalents of Ser-OH to investigate 




Scheme 53 - Attempted glycosylation of Ser-OH to GalNAc-β-OAc 4.2 using engEF 
D725G/A/S mutants. Conditions: engEF D725G/A/S, Ser-OH (10 equiv), 25 mM NaOAc 
buffer, pH 6.0, 37 ˚C, 16 h. 
 
The reactions were monitored by t.l.c. and after 16 h, the starting material was found to 
be completely hydrolysed with no evidence of desired product formation. The absence 
of the glycosyl amino acid was confirmed by RP-HPLC and mass spectrometry. To 
confirm the lack of glycosynthase activity was not due to substrate preference, the 
preferred disaccharide substrate, Galβ1,3GalNAc-β-OAc 4.8, was also incubated with 
10 equivalents of Ser-OH and the mutant enzymes (Scheme 54). 
 
Scheme 54 - Attempted glycosylation of Ser-OH to Galβ1,3GalNAc-β-OAc 4.8 (core 1-β-
OAc) using engEF D725G/A/S mutants. Conditions: engEF D725G/A/S, Ser-OH (10 equiv), 





T.l.c. analysis of the reaction mixture at hourly intervals again did not indicate the 
formation of the desired glycosyl amino acid 4.10. After 16 h, the reaction was 
quenched and analysed by RP-HPLC and mass spectrometry, both of which did not 
indicate any product formation. These results suggested that the engEF mutants were 
incapable of catalysing the transfer of core 1-β-OAc 4.8 to serine. 
 
4.4.4. Conclusions 
Studies by Goda et al14 had reported that engEF from Enterococcus faecalis was 
capable of releasing p-nitrophenol from, not only Galβ1,3GalNAc-α-pNP (core 1-
pNP), but also core 3-pNP demonstrating broad substrate specificity. Therefore, we 
were interested in using engEF for the synthesis of O-linked glycopeptides and 
glycoproteins. Chapter 2 details the expression, purification, and mutagenesis of 
engEF. 
 
This chapter detailed investigations into the properties of engEF and its mutant variants. 
Michaelis-Menten kinetics were obtained for WT engEF. The KM and kcat values for 
engEF were calculated to be 53.5 µM and 76.4 s-1, respectively for Galβ1,3GalNAc-α-
pNP (core 1-pNP), and 42 µM and 104 s-1, respectively for Galβ1,3GalNAc-α-OAc 
(core 1-α-OAc), indicating that glycosyl acetates are better donors for engEF compared 
to the p-nitrophenyl glycosides. WT engEF could also hydrolyse the monosaccharide, 
GalNAc-α-OAc. 
 
The mutant enzymes, engEF D725G/A/S, were all completely inactive towards 




rescued by azide, bromide, or formate. These results suggested that the mutagenesis 
had affected an important residue in the active site of engEF.  
 
WT engEF could catalyse the glycosylation of MeOH by core 1-pNP, core 1-OAc, and 
GalNAc-α-OAc, in yields of 56, 37, and 40 %, respectively. 
 
None of the mutant enzymes could catalyse the glycosylation of MeOH or Ser-OH with 
GalNAc-β-OAc or core 1-OAc. The underlying reason for this disappointing result is 
not apparent. Future computational and crystallographic studies may shed light on the 
impact of the point mutant on the active site of the enzymes. 
 
4.5. Overall conclusions and future work 
Whilst the WT engBL and engEF enzymes were found to be active, their mutant 
variants were found to be catalytically inactive with the donors assayed. 
Disappointingly, the engBL and engEF mutant enzymes could not catalyse the 
glycosylation of MeOH or Ser-OH to their respective activated β-glycosyl donors. It is 
unclear as to which, as well as how many, aspects of the protein active site may have 
been affected, chemically and structurally, by the point mutations which led to these 
results. 
Future work involving computational and crystallographic studies are required to 
determine the structural changes upon the substitution of the catalytic nucleophile for 
non-nucleophilic residues. 
 
We also observed that glycosyl acetates were viable substrates for the GH101 endo-α-




not contain a chromophore, necessitating the use of alternative time-consuming 
methodologies for assaying enzyme kinetics. Methodologies to access glycosyl esters 
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Chapter 5 – One-Pot Synthesis of Glycosides in Water 
 
5.1. Introduction 
Protecting groups are typically used in organic syntheses to ‘mask’ competing reactive 
centres around a molecule. However, this approach suffers from the need for additional 
synthetic steps, loss of material, and generates a huge amount of waste – not only 
chemical waste, but also in costs and time. Thus, there is an increasing need for 
syntheses that do not incorporate protecting group methodologies whilst furnishing 
high yields and stereoselectivities.  
 
There are multiple examples of protecting-group-free modifications to the anomeric 
sugars, most of which Hanessian and Lou have covered in an excellent review article.1 
In 2009, Shoda and co-workers reported the use of the reagent 2-chloro-1,3-
dimethylimidazolinium chloride (DMC) for the direct synthesis of glycosyl oxazolines 
from reducing sugars in water.2 This reaction drew the attention of the glycoscience 
community, as glycoside formation in water is generally difficult due to competitive 
hydrolysis in such reactions. 
 
The proposed mechanism2 of oxazoline ring formation involves preferential attack of 
the hemiacetal hydroxyl group to DMC to yield reactive intermediate 1 (Figure 46) 
with a β-configuration. Intramolecular attack of the 2-acetamido group, as well as 
abstraction of the oxazolinium ion proton by a suitable base such as triethylamine, 
affords the oxazoline. The α-imidazolinium intermediate 2 can also form if the α-




regenerate the free sugar since intramolecular ring formation of the α-adduct is not 
possible by an SN2 substitution pathway. 
 
 
Figure 46 - Plausible mechanism for sugar oxazoline formation using DMC 
Subsequently to this initial report, DMC and its derivatives have been applied to the 
synthesis of glycosyl azides,3 pyridyl thioglycosides,4 peptides linked to carbohydrates 
through a sulphur atom,5 and sugar nucleoside diphosphates,6 by intercepting the α-
imidazolinium intermediate 25 with different nucleophiles. This chapter outlines further 
developments of the DMC procedure wherein reducing sugars are activated in water in 
the presence of various nucleophiles to generate glycosides. 
 
5.2. Attempted Synthesis of Various Glycosides in Water 
5.2.1. Nitrophenyl glycosides 
The synthesis of phenyl glycosides is well reported in the literature. However, accessing 
these compounds typically involves several protecting group manipulations, then 






Nitrophenyl glycosides are of importance as they are substrates for glycosidases. p-
Nitrophenyl (pNP) and dinitrophenyl (DNP) glycosides have proven to be pivotal for 
monitoring and determining the kinetics of glycosidases by way of their inherent UV 
activity.9,10 The synthesis of activated phenyl glycosides is also pertinent to other 
studies reported in this research. This section details investigations into the possible 
synthesis of nitrophenol glycosides in water using the aforementioned DMC 
methodology. 
 
Table 14 details the conditions used in attempts to synthesise p-nitrophenyl glycosides 
of N-acetylglucosamine in water using DMC as an activator. 
 
Firstly, a screen of different bases was performed3,11 employing TEA, DIPEA, 2,6-
lutidine, and K2CO3 (Entries 1-4). However, p-nitrophenol was insoluble under these 
conditions. A mixed solvent consisting of D2O/MeCN (4:1) was then investigated to 
solubilize p-nitrophenol (Entries 5-10).  Additionally p-nitrophenol was also converted 
to a phenolate prior to the addition of DMC (Entry 9), and the number of equivalents 
of p-nitrophenol that was added was also increased (Entry 10). However these reactions 










Solvent Base (equiv) 
Result 
1 3 D2O TEA (8) Oxazoline only 
2 3 D2O DIPEA (8) Oxazoline only 
3 3 D2O 2,6-lutidine (8) No reaction 
4 3 D2O K2CO3 (8) No reaction 
5 3 D2O/MeCN (4:1) TEA (8) Oxazoline only 
6 3 D2O/MeCN (4:1) DIPEA (8) Oxazoline only 
7 3 D2O/MeCN (4:1) 2,6-lutidine (8) 
Oxazoline and 
Starting material 
8 3 D2O/MeCN (4:1) K2CO3 (8) No reaction 
9 3 D2O/MeCN (4:1) NaOH (8) No reaction 
10 8 D2O/MeCN (4:1) TEA (8) 
Oxazoline and 
starting material 
Table 14: Conditions screened for the attempted synthesis of pNP glycosides  
 
Withers et al. have also utilised di-nitrophenyl glycosides as donors for 
glycosynthases.12 These are better donors than p-nitrophenyl glycosides due to their 
better leaving group properties corresponding to their lower pKa values. The pKa of 
DNP is 4.11 compared with p-nitrophenol, which has a pKa of 7.16. Table 15 lists the 










Solvent Base (equiv) Conversion[a] 
1 10 D2O TEA (10) - 
2 10 D2O DIPEA (10) 12% 
3 10 D2O 2,6-lutidine (10) - 
4 10 D2O K2CO3 (10) Oxazoline only 
5 10 D2O/MeCN (4:1) TEA (10) 
Oxazoline + starting 
material 
6 10 D2O/MeCN (4:1) DIPEA (10) 
Oxazoline + starting 
material 
7 10 D2O/MeCN (4:1) 2,6-lutidine (10) 
Oxazoline + starting 
material 
8 10 D2O/MeCN (4:1) K2CO3 (10) 
Oxazoline + starting 
material 
9 1 D2O TEA (10) 12% 
10 2 D2O TEA (10) 7% 
11 5 D2O TEA (10) 3% 
12 20 D2O TEA (10) 2% 
Table 15: Conditions screened for DNP glycoside synthesis 
[1] Determined by 1H NMR by comparing integrals of the anomeric proton of the products and 
that of the unprotected sugar in D2O. 
 
As previously, a screen of organic bases typically used in DMC-associated reactions 




partially soluble under these conditions. No reaction occurred when TEA and 2,6-
lutidine (Entries 1 & 3) were used as bases. However, using DIPEA (Entry 2) furnished 
the desired β-DNP glycoside in 12 % conversion (as observed by 1H NMR). However 
the reaction did not proceed further. The use of K2CO3 as the base (Entry 4) completely 
converted GlcNAc to the undesired oxazoline. A D2O/MeCN (4:1) solvent mixture was 
then used which completely solubilised the DNP. However the reactions were 
unsuccessful (Entries 5-8), producing only mixtures of oxazoline and recovered starting 
material. Increasing the DNP concentration (Entries 9-12) did result in the production 
of some of the desired product, but only in low conversion. Further investigations into 
this transformation were abandoned. 
 
5.2.2. β-o-Carboxyphenyl glycosides 
In 1995, Wang and Withers tested these glycosides as donors substrates for 
glycosynthases.13 This type of glycoside could undergo substrate-assisted catalysis 









The carboxyl group of β-o-carboxyphenyl glycosyl donors can act as a mimic of the 
general acid residue in the wild type enzyme, but which has been removed from the 
glycosynthase enzyme active site by mutagenesis. The acceptor nucleophilically reacts 
with the anomeric centre in the active site of the enzyme, which then causes the leaving 
phenolate to intramolecularly abstract a proton from the carboxylic acid to give the 
desired glycosylation product that is then released from the active site.  
 
Table 16 details the set of conditions that were investigated using methyl salicylate as 








Base (+ additional 
reagents) 
Product?[1] 
1 D2O Triethylamine Yes (<1) 
2 D2O 2,6-Lutidine No 
3 D2O K2CO3 No 
4 D2O - No 
5 D2O/acetone (1:1) Triethylamine No 
6 D2O/MeCN (2:1) Triethylamine No 
7 D2O/DMF (1:4) Triethylamine No 
8 DMF Triethylamine No 
9 DMSO Triethylamine No 
10 D2O Triethylamine (+ LiBr)
[2] No 
11 D2O Triethylamine (+ KI)
[2] No 
12 D2O/MeCN (4:1) Triethylamine (+ LiBr)
[2] Yes (N.D) 
13 D2O/MeCN (4:1) Triethylamine (+KI)
[2] Yes (5) 
14 D2O/MeCN (1:1) Triethylamine (+ LiBr)
[2] No 
15 D2O/MeCN (1:1) Triethylamine (+KI)
[2] No 
Table 16: Glycosylation of methyl salicylate using DMC in water. N.D. Not Detected. 
[1] Determined by 1H NMR by comparing integrals of the anomeric proton of the products and 
that of the unprotected sugar in D2O. Numbers in parentheses refer to the conversion yield of 
the product. 






Initial attempts were made to directly glycosylate N-acetyl-D-glucosamine with methyl 
salicylate. Firstly, the reaction was performed in water, either with various added bases 
(Table 16, Entries 1-3) and without base (Entry 4), but in all these cases, either little or 
no desired product was observed. Instead, competing oxazoline formation and 
hydrolysis and reactions predominated. Aqueous solvent mixtures (Entries 5-7) and 
polar aprotic solvents (Entries 8-9) were also screened to try and reduce or eliminate 
the hydrolytic reactions. However these reactions was sluggish and no desired product 
observed. The following attempts used LiBr and KI to encourage in situ oxazoline ring 
opening (Entries 10-15), with only two of the six reactions (Entries 12-13) having low 
(< 5%) conversions. 
 
 
Entry Solvent Base Acid Outcome 
1 D2O/MeCN 
(4:1) 




triethylamine 1 M aq. HCl Complete 
hydrolysis 
3 D2O triethylamine p-TSA Partial hydrolysis 
4 D2O triethylamine CSA Partial hydrolysis 





Treatment of the crude reaction mixture directly with various acids in order to try and 
induce acid catalysed opening of the oxazoline by methylsalicylate was also attempted, 
with no success (Table 17). 
 
In light of the results observed for the attempted pNP and DNP glycoside formation 
using DMC in water, it was concluded that methyl salicylate was simply too poor a 
nucleophile in water to warrant any further investigation at this point in time.  
 
5.2.3. Glycosyl fluorides 
Glycosyl fluorides are known to be excellent donors in glycosylation reactions 
catalysed by glycosynthases.14,15 An advantage of using a glycosyl fluoride as a donor 
for a glycosynthase is the small size of fluorine, which is comparable to a hydroxyl 
group, meaning that steric demands are minimized when using such donors. 
 
There have been extensive efforts towards the synthesis of β-glycosyl fluorides. 
Notably, Helferich’s original halogen exchange reaction on glycosyl bromides with 
silver fluoride is a reliable method that affords β-glycosyl fluorides, and is still used 
today.16 Since then, the development of alternative methods to access β-glycosyl 
fluorides have been investigated, including the use of 2-fluoropyridinium salts, 
HF/pyridine complex, hexafluoropropene-amine complex, and the treatment of sugars 
with a free anomeric hydroxyl functionality with DAST.17–21 A broad review has been 
published which details the widely used methods for the synthesis of glycosyl 
fluorides.22 The primary issue that has to be overcome is the instability of β-glycosyl 
fluorides relative to α-glycosyl fluorides. It is known that β-glycosyl fluorides 




anomeric effect. This becomes a significant issue since glycosylation conditions are 
performed in an aqueous environment.23 Zechel et al. overcame this problem by 
generating glycosyl fluorides in situ by the enzyme catalysed reaction of DNP 
glycosides with nucleophilic fluoride.24 
However at the time of writing this thesis, there are still no known methods for forming 
glycosyl fluorides in water. 
 
Initially, an attempt was made to synthesise a derivative of DMC that was also capable 
of donating fluoride. The advantage of using such a derivative is the generation of 
fluoride in situ. Therefore, it was chosen to convert DMC to 2-fluoro-1,3-
dimethylimidazolium hexafluorophosphate 5.3 (DFIH, Scheme 55). 
 
 
Scheme 55 - Synthesis of DFIH 5.3. Conditions: i) NaPF6, MeCN, 30 mins, 99 %; ii) KF, 
MeCN, reflux, 4 h, 60 %. 
 
First, DMC 5.1 was converted to the hexafluorophosphate salt 5.2 by treating with 
NaPF6. This was then followed by displacement of chloride for fluoride by treating 5.2 
with KF in MeCN and heating at reflux which gave DFIH 5.1 in 60 % yield. 
 
N-Acetyl-D-glucosamine 5.4 was then subjected to reaction with DFIH under a variety 



























3 DMSO TEA (3) 
Minor oxazoline formation. 




3 water DIPEA (9) 
Trace amount of product but 
major oxazoline formation. 
Table 18: Attempted fluorination reactions of GlcNAc with DFIH 5.3 
 
It is clear that the competing oxazoline formation 5.6 was the predominant reaction and 
it was quite possible that any β-fluoride formed in fact underwent immediate reaction 
by participation of the 2-acetamido group to give the oxazoline.  
 
5.2.4. Conclusions 
It was thought that the low nucleophilicity of fluoride, due to hydrogen bonding 
interactions with water, prevented glycosyl fluoride formation. It is known that 




the rate of hydrolysis of the imidazolium intermediate that is formed during the 
reaction.25 Additionally, oxazoline ring formation was found to outcompete the desired 
β-fluoride formation. Due to these difficulties, further investigations into the aqueous 
synthesis of glycosyl fluorides was not undertaken at this point in time. 
 
5.3. Synthesis of Glycosyl Triazoles in Water 
5.3.1. The Cu-catalysed Azide-alkyne Huisgen Cycloaddition (CuAAC) 
The azide-alkyne Huisgen cycloaddition of organic azides and alkynes has garnered 
considerable attention over the past decade, especially due to the introduction of Cu(I) 
catalysis, which lead to a major advancement in both the regioselectivity and rate of the 
reaction.26–28 In his review in 2001, Barry Sharpless defined click chemistry to be a 
group of reactions that “…must be modular, wide in scope, give very high yields, 
generate only inoffensive by-products that can be removed by non-chromatographic 
methods, and be stereospecific (but not necessarily enantioselective). The required 
process characteristics include simpler reaction conditions (ideally, the process should 
be insensitive to oxygen and water), readily available starting materials and reagents, 
the use of no solvent or a solvent that is benign (such as water) or easily removed, and 
simple product isolation. Purification, if required, must be by non-chromatographic 
methods, such as crystallization or distillation, and the product must be stable under 
physiological conditions”.29  
 
More commonly known as the Cu(I)-catalysed azide-alkyne Huisgen cycloaddition 
(CuAAC), the versatility of this reaction has been demonstrated by its insensitivity, 
robustness, and generality, as well as by a multitude of applications in the chemical and 




water-tolerant conditions, and generate products in high yields with minimal 
requirements for product purification. Indeed, triazole chemistry has been used to 
modify and potentiate antitumor, antibacterial, antifungal, and antiviral compounds.31–
34 Thus, in the past decade, a multitude of catalytic conversions of acetylenes and azides 
in a wide range of syntheses and chemical ligations has been observed,35–38 as well as 
for the synthesis of peptidomimetics and bioconjugations,39–41 and has been touted a 
“green” aqueous reaction.42 The triazole ring has been demonstrated to be effectively 
chemically inert to a variety of reaction conditions, such as oxidation, reduction, and 
hydrolysis. Furthermore its synthesis can be performed in aqueous or organic 
environments.41,43  
 
The mechanism of the CuAAC reaction has been extensively investigated and 
debated.44,45 The major energetic difference between the CuAAC and its non-catalysed 
counterpart is the activation energy barrier. Quantum mechanical calculations of the 
non-catalysed reaction show that the transition state is largely non-polarized.46 Most of 
the energy is associated with the distortion energy of the azide constituting 18.1 of the 
29.9 kcal/mol ΔG† for the reaction with acetylene. A stepwise process reduces the 
transition state energy by 11 kcal/mol thus achieving rate enhancement.47 The Cu+ 
coordinates first with the acetylene π–electrons, lowering the pKa of the acetylene 
proton by up to 9.8 pKa units, allowing de-protonation to occur in an aqueous solvent 
without the addition of a base (Scheme 56). This coordination step is followed by an 
exothermic formation of a copper acetylide 2. The Cu+-acetylide complex then 
coordinates to the azide 3, which is followed by rearrangement of the complex first into 
a metallocycle 4, and then further into the copper-metallated triazole 5. The Cu-triazole 






Scheme 56 - Proposed catalytic cycle for the CuAAC reaction. 
There have been minor revisions to this mechanism, 44,45 however the contribution of 
the reduction of the transition state energy to the catalysis remains unchallenged. 
Although the reaction can be performed with almost any source of solvated Cu(I),44 
Cu(I) can be oxidized to Cu(II), rendering the catalyst useless. There are multiple 
methods to generate the active catalyst for the CuAAC reaction. One of the most 
common is to reduce Cu(II) salts, such as CuSO4
.5H2O, in situ to form Cu(I) salts. 
Sodium ascorbate is typically used as the reducing agent,44 but other reducing agents, 
including hydrazine48 and tris(2-carboxyethyl)phosphine (TCEP)49 have also been used 
with success. 
Alternatively, it is possible to directly add Cu(I) salts such as CuBr, CuI, CuOTf.C6H6, 





These methods do not require a reducing agent, but suffer from the need to be 
performed in a deoxygenated environment, and in an organic (or mixed) solvent system, 
meaning that protecting groups will probably be needed. Also, side product formation 
has been observed.50,51 It can be concluded that the usage of Cu(I) salts is not as reliable 
as the Cu(II) procedure.  
 
In 2005, pentamethyl cyclopentadienyl ruthenium (II) complexes (Cp*Ru), such as 
Cp*RuCl(PPh3)2, were discovered as novel catalysts for click chemistry. This process, 
named the Ruthenium-catalysed Azide-Alkyne Cycloaddition (RuAAC), affords only 
1,5-substituted 1,2,3-triazoles (Figure 48).52 
 
 
Figure 48 - Ruthenium-catalysed Azide-Alkyne Cycloaddition 
Furthermore, this procedure can be used to click both terminal and internal alkynes 
alike. 53 
 
5.3.2. Biological Applications of 1,2,3-triazoles 
Cu(I)-catalysed triazole formation has been utilized extensively for the modification of 
natural products and pharmaceuticals. This methodology may allow the attachment of 
property modifying chemical entities to a drug in order to enhance its effects (e.g. by 
increasing its solubility and/or bioavailability).54,55 The bio-isosteric similarities 
between triazoles and the amide bond56 have also stimulated investigations into 




peptidomimetics. There are several reviews available which highlight the advantages 
of using click chemistry for pharmaceutical applications.57 
Carbohydrates are an important class of signalling molecules in nature, and have also 
been subjected to CuAAC chemistry. In fact, a prevalent method for linking sugars to 
other organic molecules has been to introduce an azide in the 1-, 2-, or 6-positions of 
the sugar and then to react this with a variety of organic alkynes.58–60 Triazoles have 
also been used to link a carbohydrate functionality to different carbohydrates and amino 
acids.61,62 There have also been several investigations into the application of triazoles 
as inhibitors of glycosidases.63 The biological interest in triazoles stems from the fact 
that they are fairly easy to install and are extremely stable under standard 
conditions.64,65 Their ability to tolerate oxygen, water, common conditions used for 
organic synthesis, biological molecules, a large range of solvent and pH’s, and the 
reaction conditions of living systems (reducing environment, hydrolysis, etc.), makes 
them ideal candidates as isosteres of the amide bond in biological compounds.44,49,64 
 
5.3.3. Synthesis of glycosyl azides 
The traditional method for glycosyl azide formation involves at least three or four 
protecting group manipulations to furnish the desired deprotected glycosyl azide. A 
synthetic route typically involves converting the desired sugar, for example N-acetyl-
D-glucosamine, into a protected glycosyl halide 5.7, followed by a nucleophilic 
displacement by an azide nucleophile to give the glycosyl azide 5.8 (Scheme 57). 
Finally, the ester protecting groups are removed using Zemplén deacetylation to give 






Scheme 57 - Synthesis of de-protected glycosyl azides. Conditions: i) AcCl; ii) NaN3, sat. aq. 
NaHCO3, tBuNH4.HSO4, DCM; iii) Na, MeOH. 
 
5.3.4. Synthesis of glycosyl azides using ADMP 
The original Shoda method potentially generates up to two equivalents of HCl per 
equivalent of DMC used; one equivalent produced from deprotonation of the anomeric 
hydroxyl group, and one from water in the case of a hydrolysis reaction. This 
necessitates the use of excessive amounts of triethylamine. We proposed that if we 
replaced the chloride on the dimethylimidazolidinium ring with azide, it would allow 
for the activation of reducing sugars, as well as furnishing an azide source without the 
use of sodium azide. 2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 5.10 
(ADMP) has been used on several occasions in the literature as an efficient diazo-
transfer reagent.66,67 Impact sensitivity tests and friction sensitivity tests have 
demonstrated that ADMP is not explosive,67 making it in fact safer to handle than 
sodium azide. Additionally unlike its DMC counterpart, which suffers from 
hygroscopicity,67,68 ADMP is isolated as a stable crystalline solid and so it is easily 
handled. ADMP was synthesized following the procedure reported by Kitamura et al. 
(Scheme 58).66 Firstly, DMC 5.1 was converted to the hexafluorophosphate salt 5.2, 






Scheme 58 - Synthesis of ADMP 5.10. Conditions: i) NaPF6, MeCN, rt, 30 mins, 99 %; ii) 
NaN3, MeCN, 0 °C, 3 h, quant. 
 
The ability of ADMP to convert sugars into glycosyl azides was tested. N-Acetyl-D-
glucosamine 5.4 was chosen as the first substrate. Five equivalents of triethylamine was 
used based on the need to deprotonate the anomeric hydroxyl group as well as 
accounting for any hydrolysis of ADMP. Thus, N-acetyl-D-glucosamine was reacted 
with ADMP 5.10 (Scheme 59). A solvent mixture of D2O/MeCN (4:1) was used to 
improve the solubility of ADMP. 
 
 
Scheme 59 - Reaction of GlcNAc 5.4 with ADMP 5.10. 
 
By 1H NMR analysis, it was clear that competing oxazoline formation 5.6 was 
occurring concurrently to β-azide 5.9 formation. It was also found that oxazoline 5.6 
was not converted to azide 5.9 under the reaction conditions (Scheme 60). This 
observation suggests that the oxazoline is not an intermediate on the pathway from the 
reducing sugar to the glycosyl azide, and that nucleophilic azide must either intercept 






Scheme 60 - Evidence that the glycosyl oxazoline is not an intermediate on the pathway from 
the reducing sugar to the glycosyl azide. 
 
Yoshida et al. encountered a similar problem in their attempted synthesis of 
pyridylthioglycosides.4 Under similar conditions, GlcNAc was treated with 2-
mercaptopyridine and DMC in the presence of triethylamine to afford the 
corresponding 2-pyridyl 1-thio-N-acetyl-D-glucosaminide 5.11 (Scheme 61), however 
1H NMR analysis of the reaction mixture revealed that a considerable amount of 
oxazoline 5.6 was formed as a by-product. 
 
 
Scheme 61 - Pyridylthio-glycosidation of GlcNAc using DMC 
By treating the oxazoline with 1 M HCl, they found that the resulting oxazolinium ion 
could be easily attacked by 2-mercaptopyridine to afford the desired β-glycoside 5.11 
in high yield. In a similar vein, we found by 1H NMR that when the crude reaction 
mixture obtained by treatment of GlcNAc with ADMP was treated dropwise with 1 M 
aqueous HCl until the solution was acidic, and then immediately neutralized using sat. 
NaHCO3 solution, the anomeric oxazoline proton completely disappeared (5.9 ppm), 






Figure 49 - 1H NMR spectra of before (bottom) and after (top) acid workup of reaction of N-
acetylglucosamine with ADMP. 
 
5.3.5. Synthesis of glycosyl triazoles in a one-pot reaction 
The next step of the investigation was to develop a one-pot click reaction. Propargyl 
alcohol was chosen to the alkyne coupling partner in order to optimize the reaction 
conditions. After the formation of the glycosyl azide was complete, propargyl alcohol, 
copper sulphate, and sodium ascorbate were added, and the mixture was heated to 50 
°C, which led to the formation of the glycosyl triazole in excellent yields and 
stereoselectivities. This procedure was applied to a number of sugars ranging from 
mono- to trisaccharides (Table 19). 
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Sugar Product Yield α/β 
GlcNAc 
5.4 




75 % β only 
Glucose 
5.15 
 73 % β only 
Mannose 
5.17 
 73 % α only 
Isomaltose 
5.19  




88 % β only 
Table 19: One-pot synthesis of glycosyl triazoles directly from corresponding reducing sugars in 
water. Conditions: sugar, Et3N (5 equiv), ADMP (3 equiv) in D2O/MeCN (4:1, 270 mM) at 0 ˚C. 
After 3 h, alkyne (2 equiv), CuSO4.5H2O (1.5 mol%) and L-ascorbic acid (0.2 equiv) were added 











The generality of the one-pot process with respect to the alkyne towards the reaction 
conditions was then assayed.  Table 20 shows the range of alkynes tested. Entries 1-3 
demonstrate that the process is extendable toward a wide variety of substituted alkynes 
such as in the case of a tertiary alcohol (Entry 1), carboxylic acid (Entry 2), and toward 
more interesting and biologically relevant applications (Entry 4). These reactions 
furnished the product in high yield and with complete stereoselectivity. As expected, 
internal alkynes are unable to undergo the cycloaddition (Entry 5) due to the inability 
to form the Cu-acetylide complex (absence of alkyne proton) rendering this reaction 





Entry Sugar Alkyne Product Yield 
1 
glucose 


















5.15   
No 
reaction 
Table 20: Scope of Alkyne Substrate. Conditions: sugar, Et3N (5 equiv), ADMP (3 equiv) in 
D2O/MeCN (4:1, 270 mM) at 0 ˚C. After 3 h, alkyne (2 equiv), CuSO4.5H2O (1.5 mol %) and 
L-ascorbic acid (0.2 equiv) were added and the mixture heated to 50 ˚C for 14 h. 
 
The direct linking of carbohydrates to generate triazole-linked oligosaccharides as 
glycomimetics has been of interest over the past few decades.69,70 These methods have 









application of a one-pot method, without the need for protecting group manipulations, 
would therefore provide a rapid and efficient technique to assemble mimics of 
oligosaccharide structures in which the carbohydrate units were linked by triazoles. 
Therefore, several sugars incorporating an alkyne functionality were synthesized. 
An alkyne functionality was easily installed at the 6-position of galactose simply by 
treating diacetone galactose 5.28 with propargyl bromide in the presence of K2CO3 to 
give propargylated glycoside 5.29 (Scheme 62).71 The acetonides were then removed 
under acidic conditions to give alkyne 5.30. 
 
 
Scheme 62 - Synthesis of alkyne 5.30. Conditions: (i) Propargyl bromide, KOH, MeCN, rt, 16 
h, 76 %; (ii) Dowex® 50WX8 (H+), water, 80 °C, overnight, 88 %. 
 
Alkynes were installed linked to the anomeric centres of glucose and lactose using 
reported procedures by kinetic peracetylation to give glucoside 5.31 and lactoside 5.25. 
These were glycosylated with propargyl in the presence of BF3
.Et2O to give propargyl 
glucoside 5.32 and propargyl lactoside 5.36. Zemplén deacetylation of 5.32 and 5.36 






Scheme 63 - Synthesis of alkyne 5.33 and 5.37. Conditions: (i) Ac2O, NaOAc, 120 °C, 78 % 
(5.31), 68% (5.45); (ii) propargyl alcohol, BF3.OEt2, DCM, rt, 24 h, 79 % (5.32), 44 % (5.36); 
(iii) Na metal, MeOH, rt, 1 h, 96 % (5.33), quant. (5.37). 
 
These were then subjected to the one-pot click reaction conditions (Table 21). Glucose 
was successfully clicked to propargyl ether to give a bis-linked triazole 5.38 in 84 % 
yield. Glucose 5.15 and galactose alkyne 5.30 were also conjugated to give a 1,6-
disaccharide mimic 5.39 in 80 % yield. Glucose was linked to the gluco alkyne 5.33 
and the lactol alkyne 5.37 in a head-to-head fashion to give glycosyl triazoles 5.40 and 
5.41 in 84 % and 75 % yields, respectively. Pentasaccharide mimic 5.42 was 
synthesised by conjugating isomaltotriose 5.21 and lactosyl alkyne 5.37 under click 











































Table 21: Direct linking of deprotected carbohydrates to access mimics of oligosaccharides. 
Reaction conditions: a) sugar, ADMP, Et3N, D2O, MeCN, 0 ˚C, 3 h, then add alkyne, 
CuSO4.5H2O, L-ascorbic acid, and heat to 50 ˚C for 14 h. 
 
Click chemistry has been applied previously to access both glycopeptides56,72 and 
glycoproteins.73 However, these reported procedures require multiple protecting group 
manipulations. Therefore, to further exemplify this method, an attempt to directly 













repeat domain of the cancer-associated mucin MUC174,75 have shown potential as 
components of synthetic anticancer vaccines.76,77 
Two synthetic MUC1 peptides that incorporated propargyl glycine (Pra) were supplied 
to us as alkyne bearing peptides for glycoconjugation (Scheme 64).  
 
 
Scheme 64 - Two MUC1 peptides, a 10-mer 5.43 and 20-mer 5.44, incorporating Pra. 
 
Fragment 5.43, which corresponds to residues 11-20 in which T16 has been replaced 
by Pra, and the full-length tandem repeat domain 5.44, in which both T4 and T16 have 
been replaced by Pra, were assembled by solid-phase peptide synthesis by the group of 
Brimble as previously described78 and supplied to us.  
GalNAc 5.13 was again converted to the azide using ADMP and then reacted with 
peptides 5.43 and 5.44, respectively, in the presence of CuSO4
.5H2O, to yield the 





Scheme 65 - Conjugation of GalNAc with 10-mer 5.43 and 20-mer 5.44; Reaction conditions: 
(i) sugar, ADMP, Et3N, D2O, MeCN, 0 ˚C, 3 h, then add alkyne, CuSO4.5H2O, L-ascorbic acid, 
and heat to 50 ˚C for 14 h. 
 
More complex sugars were also ligated to peptide 5.43. The core N-glycan 
tetrasaccharide 5.4779 was attached to peptide 5.43 to give glycopeptide 5.48 in 42 % 
yield (Scheme 66) 
 
Scheme 66 - Reaction of tetrasaccharide 5.47 with 10-mer 5.43. Reaction conditions: i) sugar, 
ADMP, Et3N, D2O, MeCN, 0 ˚C, 3 h, then add alkyne, CuSO4.5H2O, L-ascorbic acid, and heat 
to 50 ˚C for 14 h. 
 
As a final example of the utility of this method a complex biantennary N-glycan 5.49 
decasaccharide80,81 was converted to the glycosyl azide using ADMP, and then reacted 
with peptide 5.43 in the presence of CuSO4.5H2O to furnish glycopeptide 5.55 in 42 % 






Scheme 67 - Ligation of decasaccharide 5.49 to 10-mer 5.43. Reaction conditions: i) sugar, 
ADMP, Et3N, D2O, MeCN, 0 ˚C, 3 h, then add alkyne, CuSO4.5H2O, L-ascorbic acid, and heat 
to 50 ˚C for 14 h. 
 
5.3.6. Conclusion 
The Cu(I)-catalysed Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes 
has emerged as the most popular click reaction. It has found numerous applications 
across a wide variety of disciplines and is of particular interest to the pharmaceutical 
community for its tolerance of biological conditions, most functional groups, and for 
the high aqueous solubility of 1,2,3-triazoles. Here, a one-pot method has been 
developed that allows the direct conjugation of sugars to alkynes under aqueous 
conditions. This reaction does not seem to have any limitations in terms of carbohydrate 
and alkyne coupling partner. Its simplicity has the potential to find numerable 
applications in the field of carbohydrate chemistry. 
 
5.4. One-Pot Synthesis of Glycosyl Thiols in water 
5.4.1. Introduction 
Glycosyl thiols have been used previously as useful building blocks for the synthesis 
of glycoconjugates that may be considered to be analogues of glycopeptides and 
glycoproteins.82–85 Given their potential uses, there is a drive to discover less protracted 





5.4.2. Synthesis of Glycosyl Thioacetates in Water using DMC 
A series of sulfur nucleophiles were screened for their ability to react with GlcNAc 
when activated with DMC (Table 22). 
 
Entry S-Nuc R Observations[1] 
1 Na2S H No reaction 
2 NaSH H No reaction 
3 SC(NH2)2 C(NH2)2 No reaction 
4 KSAc Ac No reaction 
5 AcSH Ac New product formed 
Table 22: Sulfur nucleophiles. 
Initially, it was thought that introducing a thiol directly by using sodium sulfide would 
be the easiest option (Entry 1); unfortunately this yielded no desired product. In 
reported procedures, it was found that bases with high pKa’s retarded the progress of 
the respective desired reactions.68 For example, when GlcNAc was reacted with 2-
chloro-1,3-dimethyl-1H-benzimidazol-3-ium chloride (CDMBI) using sodium 
hydroxide (pKa ~13), sodium carbonate (pKa ~ 10.3), and potassium carbonate (pKa ~ 
10.3) as bases, the yields did not exceed 65 %, with yields decreasing to 24 % in the 






Scheme 68 - Oxazoline formation using CDMBI 
Therefore, the lack of product formation can be attributed to the high pKa of sulfides 
(pKa > 14). Sodium hydrogen sulfide was also investigated (Entry 2), but no reaction 
progress could be observed by TLC and 1H NMR. At this point, investigations into 
direct routes to the glycosyl thiol were abandoned. 
 
Alternative sulfur nucleophiles were investigated, where the thioglycoside that would 
be generated could then be de-protected to furnish the desired glycosyl thiol. Thiourea86 
(Entry 3) and potassium thioacetate87 (Entry 4) have been used previously to introduce 
thiols at the anomeric centre. However they proved to be unsuccessful for this reaction.  
 
Finally, thioacetic acid was used as the source of sulfur (Entry 5). GlcNAc, 
triethylamine, and thioacetic acid were first dissolved in D2O and cooled to 0 °C. DMC 
was then added portionwise to the reaction mixture. After 30 mins, TLC analysis 
indicated the formation of a major product and 1H NMR analysis indicated the expected 
downfield shift of the anomeric proton from 4.6 ppm and 5.1 ppm to 5.5 ppm and 6.1 
ppm for H-1β and H-1α, respectively. However, mass spectrometric analysis of the 
isolated material indicated that the mass of the product was 286.0904, which 
corresponded to that mass of anomeric O-acetate. Moreover, the product was then 




A mechanistic rationale for the unexpected generation of the glycosyl acetate is shown 
in Scheme 69. 
 
Scheme 69 - Mechanism of glycosyl acetate formation using DMC. 
 
It appeared that the thiolate reacted with DMC directly to generate an activated thioester 
intermediate 5.51. Following this, the anomeric hydroxyl group of GlcNAc reacted 
directly with the thioester to generate the glycosyl acetate 5.52 and the thiourea 5.53 as 
the by-product.  Further developments of this unexpected reaction will be discussed in 
Section 5.6. 
 
It was then thought that changing the order of addition may help bypass the problem of 
forming the glycosyl acetate. The above reaction was therefore repeated but the order 
of adding the thioacetic acid was changed - in this second case, GlcNAc and 




Scheme 70 - Synthesis of thioglycoside 5.54. Reaction conditions: (i) TEA, H2O, 0 °C, then 





As anticipated, the glycosyl oxazoline 5.6 was formed as the major product. The crude 
reaction mixture was then treated directly with thioacetic acid. As was the case for the 
oxazoline opening in the synthesis of glycosyl azides, the oxazoline was opened by SN2 
attack of an external nucleophile, in this case thiolate. The desired anomeric thioacetate 
5,54 was formed exclusively as the β-anomer.  
 
Further work on the generation of glycosyl thiols based on these initial findings is 
currently being undertaken by other members of the Fairbanks group. 
 
5.4.3. Conclusion 
A method for the one-pot direct aqueous synthesis of a glycosyl thioacetate from un-
protected GlcNAc has been discovered. Simple de-esterification under basic conditions 
will yield the desired glycosyl thiol, which can then be further advanced by attachment 
to peptides and proteins using existing methods.88 This reaction may provide many 
opportunities in chemical biology, and since the direct conversion of naturally 
occurring sugars and to glycosyl thiols and their subsequent attachment to peptides and 
proteins would avoid the tedious syntheses that are generally required to generate 
biologically-relevant glycoconjugates. 
 
5.5. One-Pot Synthesis of Glycosyl Acetates in water 
5.5.1. Introduction 
The regioselective introduction of protecting groups is of central importance in 
carbohydrate chemistry. Acyl groups, especially acetyl and benzoyl, are widely used 
electron-withdrawing protecting groups. In particular, ester protection of the 2-OH of 




participation. There have been multiple efforts at regioselective acylation of sugars, 
however these methodologies have mostly focused on the selective acylation of sugar 
2,3- or 4,6-diols.89–93 Indeed most of the known derivatives of glucose in which the 
anomeric centre is selectively acylated have been obtained via acylation of 2,3,4,6-
tetra-O-benzyl-D-glucopyranose, which occurs usually with low stereoselectivity. 
Alternatively, ethyl 2,3,4,6-O-benzyl-1-thio-β-D-galactopyranoside was reacted with 
N-iodosuccinimide and AcOH in DCM to furnished the 1-O-acetate in excellent yield, 
but as a 1:1 mixture of anomers that could not be separated.94 Coupling anomeric 
mixtures of O-glycosyl trichloroacetimidates with carboxylic acids in non-polar 
solvents has also produced 1-O-acyl sugars in high yield, and complete inversion of 
stereochemistry.95 In this latter case, the β-anomer could be separated by crystallization. 
Hydrogenolytic debenzylation then gave the de-protected galactoside.  
 
Plusquellec et al. demonstrated an elegant method for regioselective anomeric acylation 
where acyl chlorides were reacted with mercaptothiazoline (Entry 1), 
mercaptobenzothiazole (Entry 2), p-nitrophenol (Entry 3), and 8-hydroxyquinoline 























Figure 50 – Generation of reactive species for regioselective anomeric acylation by 
Plusquellec et al.96 
 
This was then reacted with an unprotected sugar to give the acylated glycoside in 
moderate yields. However, some reactions needed to be performed at elevated 
temperatures (up to 70 ºC) and for long periods (up to 72 h). Moreover, the reactions 
were performed in an organic solvent (pyridine).  
The regioselective acylation of the anomeric hydroxyl group is therefore still quite a 
challenge for chemists.97 To date, there have been no published methods for accessing 
1-O-acetyl glycosides in water. Here, I present a method for the facile access of 1-O-






5.5.2. Synthesis of Glycosyl Acetates in Water using DMC 
As mentioned in Section 5.5.2, an attempt to synthesise glycosyl thiols led to the 
discovery of an unexpected reaction (Scheme 69). Herein stirring N-acetyl-D-
glucosamine 5.4 with thioacetic acid and triethylamine, followed by the addition of 
DMC, led to selective acetylation of the anomeric centre. This reaction outcome was 
due to the preferential attack of the thiolate on DMC to generate a thioester intermediate 
5.51. The thioester was then attacked by the anomeric hydroxyl group, resulting in a 
transfer of the acetyl functionality onto the sugar and ejecting a thiourea as the by-
product.  
 
It was found that this method could be applied to various reducing sugars to generate 
products in which the anomeric centre had been regioselectively acetylated. Table 23 















Sugar Product Yield α/β 
GlcNAc  
5.52 
86 % 3:2 
GalNAc  
5.55 














Table 23: Direct aqueous synthesis of glycosyl acetates. Reaction conditions: sugar, water, 
TEA, AcSH, 0 °C, then DMC, 30 mins. 
 
5.5.3. Conclusion 
A method for the direct synthesis of otherwise unprotected glycosyl acetates from the 
corresponding reducing sugars in water has been achieved. Unprotected glycosyl 
acetates are interesting in that they have significant potential for use as activated 
donors for glycosidase and glycosynthases enzymes. Their use as glycosyl donors for 
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Chapter 6: Experimental Section 
General Chemical Experimental 
Reactions conducted at 0 C were cooled by means of an ice bath. Solvent was removed 
under reduced pressure using a BuchiTM rotary evaporator. Reagents were used as 
supplied without further purification unless otherwise stated. 
Thin Layer Chromatography (t.l.c.) was carried out on Merck Silica Gel 60F254 
aluminium-backed plates. Visualisation of the plates was achieved using a UV lamp 
(νmax = 254 or 365 nm), and/or ammonium molybdate (5% in 2 M H2SO4), and/or 
aniline-diphenylamine-85 % phosphoric acid (4 mL:4 g:20 mL) in acetone (96 mL), 
and/or a solution of CuBr (spatula tip amount), ethanol (40 mL), and propargyl alcohol 
(40 mL). Flash column chromatography was carried out using Sorbisil C60 40/60 silica. 
Melting points were recorded on an Electrothermal® melting point apparatus. Proton 
and carbon nuclear magnetic resonance (1H, 13C) spectra were recorded on Bruker 
AV400 (400 MHz), and Bruker AV500 (500 MHz) spectrometers. All chemical shifts 
are quoted on the δ-scale in ppm using residual solvent as an internal standard. 1H and 
13C spectra were assigned using COSY, DEPT, HSQC, HMBC and TOCSY. High 
resolution mass spectra were recorded a Bruker FT-ICR mass spectrometer using 
electrospray ionisation (ESI) or chemical ionisation (CI) techniques as stated. M/z 
values are reported in Daltons. Optical rotations were measured on a Perkin-Elmer 241 
polarimeter with a water-jacketed 1 cm3 cell with a path length of 1 dm, and are quoted 





Experimental for Chapter 2 
Chemical reagents and equipment suppliers 
All chemicals and reagents other than those listed below were supplied by Sigma-
Aldrich Chemical Co. 
 
Multiple sequence alignments 
Multiple sequence alignments were generated using ClustalW.1 
 
Water 
All water used in these experiments was from a Millipore Milli-W system. Water used 
for PCRs was autoclaved prior to use. 
 
pH measurements 
The pH of solutions was measured using an UltraBASIC UB-10 Benchtop pH meter 
(Denver Instrument). Solutions were made more acidic by addition of 1 M or 10 M 
HCl, and basic by addition of either 1 M or 10 M NaOH. 
 
Plasmids 
engEF (pET-23d, ampicillinr, C-(His)6 tagged) provided by Dr. Makoto Ito, Kyushu 
University, Japan. 
engBL (340~1694, pET-28b, kanamycinr, N-(His)6 tagged), provided by Prof. Shinya 








All plasmid-containing strains of E. coli were stored frozen at -80 °C as glycerol stocks. 
Glycerol stocks were created by mixing 0.4 mL of 50 % (v/v) glycerol with 0.8 mL of 
an overnight culture in a 1.6 mL micro-centrifuge tube. 
 
Antibiotics 
The genes for engBL had previously been cloned into the pET-28b vector which carries 
resistance to kanamycin. Kanamycin was added to all growth media to a final 
concentration of 0.05 mg/mL. Stock solutions of kanamycin at 50 mg/mL were created, 
filter sterilized and stored at -80 °C, and freeze-thawed a maximum of two times. 
 
The genes for engEF had previously been cloned into the pET-23d vector which carries 
resistance to ampicillin. Ampicillin was added to all growth media to a final 
concentration of 0.1 mg/mL. Stock solutions of ampicillin at 100 mg/mL were created, 
filter sterilized and stored at -80 °C, and freeze-thawed a maximum of two times. 
 
Site-directed mutagenesis 
Mutagenesis was performed using a Quikchange II Site Directed Mutagenesis Kit 
(Agilent) with Phusion® High-Fidelity DNA Polymerase (Thermo Fisher Scientific). 
PCRs were performed in a DNA Engine® Peltier Thermal Cycler (Bio-rad). Typically 
each PCR was 50 μL and used 50-100 ng of plasmid template and 125 ng of each 
primer. Primers for mutagenesis were synthesised by Invitrogen and resuspended in 
sterilized Milli-Q water to a concentration of 100 μM. Template DNA (which is 
methylated) was digested by treatment with the restriction enzyme DpnI according to 




The forward and reverse primers designed for mutagenesis of engEF were: 
 
D725A  Forward 5’ gat tat att tat gtt gct gtt tgg ggc aat caa gcc 3’ 
        Reverse  5’ ggc ttg att gcc cca aac agc aac ata aat ata atc 3’ 
 
D725G  Forward 5’ gat tat att tat gtt ggg gtt tgg ggc aat caa gcc 3’ 
  Reverse 5’ ggc ttg att gcc cca aac ccc aac ata aat ata atc 3’ 
 
D725S  Forward 5’ gat tat att tat gtt agc gtt tgg ggc aat caa gcc 3’ 
  Reverse 5’ ggc ttg att gcc cca aac gct aac ata aat ata atc 3’ 
 
The forward and reverse primers designed for mutagenesis of engBL were: 
 
D789A  Forward 5’ gac ttc atc tac ctc gct gtg tgg ggc aac ctg 3’ 
        Reverse  5’ cag gtt gcc cca cac agc gag gta gat gaa gtc 3’ 
 
D789G  Forward 5’ gac ttc atc tac ctc ggg gtg tgg ggc aac ctg 3’ 
  Reverse 5’ cag gtt gcc cca cac ccc gag gta gat gaa gtc 3’ 
 
D789S  Forward 5’ gac ttc atc tac ctc agc gtg tgg ggc aac ctg 3’ 








Plasmid extraction and purification 
Plasmids were extracted using a High Pure Plasmid Isolation Kit (Roche). Small 
cultures (5 mL) of plasmid-containing cells were grown overnight with the appropriate 
antibiotic. The cultures were harvested the following morning and plasmids extracted 
and purified as per the kit instructions.  
The concentration of purified plasmid was measure by absorption at 260 nm using an 
appropriately blanked Nanodrop ND-1000 spectrophotometer. 
 
DNA sequencing 
All DNA sequencing was performed at Canterbury Sequencing and Genotyping using 
an Applied Biosystems 3130xl Genetic Analyzer with BigDye Terminator v3.1 
(Applied Biosystems) sequencing chemistry. Typically 200 ng to 250 ng of purified 
double-stranded plasmid and 3.2 μM of primer were supplied for each sample. The 
















Chemically competent cells (10 μL aliquots) were thawed on ice before addition of 2 
μL of either PCR product or purified plasmid. The mixture was left on ice for 30 mins 
then placed in a 42 °C water bath for 30 s to 45 s before being placed on ice again for 
2 mins. Cells were then outgrown for 1 h at 37 °C while shaking after addition of 150 
μL super optimal broth (SOC) medium. 
A portion (50 μL to 200 μL) of the transformed cells was spread directly onto an LB-
agar plate containing the appropriate antibiotic and left to grow on the inverted medium 
overnight at 37 °C. 
SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgSO4, 20 mM glucose. Filter sterilized in aliquots. 
 
Cell lines 
The cell lines used for plasmid propagation were either E. coli TOP10 (Invitrogen) or 
DH5α. For protein expression, either E. coli BL21 (DE3) or BL21 (DE3) Star 
(Invitrogen) cell lines were used. 
 
Culture media 
LB-agar was prepared by dissolving either LB-agar (Miller’s) (37 g/L) or LB (Lennox) 
(20 g/L) and agar (15 g/L) base in Milli-Q water and sterilized by autoclaving. The LB-
agar solution was then heated in a microwave oven until boiling, and left to cool in a 
60 °C. The LB-agar solution was then further cool to ≤50 °C before antibiotic was 




LB media for plasmid extraction, pre-cultures and protein expression cultures were 
prepared by dissolving 20 g/L LB (Lennox L) base in Milli-Q water and sterilizing by 
autoclaving. Antibiotic was added immediately prior to use. 
 
Protein expression cultures 
Cultures for protein expression were grown in 2 L to 3 L beveled conical flasks in a 
shaking incubator at 200 rpm. Expression cultures were inoculated with an overnight 
culture and grown at 37 °C until induction of protein expression.  
Transcription of the engEF genes were under the control of a lac operon therefore 
protein expression was induced by addition of IPTG to a final concentration of 0.5 mM, 
when cultures were at a mid-logarithmic phase (OD600 of 0.4 to 0.6 AU). After 
induction, cultures were kept shaking at 23 °C and harvested the following morning. 
 
Cell harvesting 
Typically, large cultures were harvested in 1L bottles at 14 000 g for 15 min at 4 °C. 
The supernatant liquid was removed and the cell pellet either immediately lysed, or 
stored at -80 °C. Small volume cultures (≤ 5 mL) were progressively harvested in 1.6 
mL micro-centrifuge tubes at 16 000 g for 1 min. 
 
Cell lysis 
Cells were lysed by sonication. Sonication was performed with an Ultrasonic Processor 
UP200S (Hielscher). Cell pellets were resuspended in chilled suspension buffer 
(approximately 25 mL) on ice, and sonicated in a beaker surrounded by packed ice. 




between each interval (5-7 times). The solution was clarified by centrifugation (4 °C, 
12,000 rpm, 35 mins). The supernatant was poured off and filtered using a 0.2 μm filter. 
 
Protein purification 
All proteins were purified by a two-step procedure composed of, in step order, 
immobilized metal ion affinity (IMAC), cation exchange chromatography (CEC), and 
size-exclusion (SEC) chromatography. The chromatography was performed on an 
ÄKTA FPLC system.  
Before use, all buffers were filtered (0.2 µm) under vacuum and degassed. Samples 
were all likewise filtered before being loaded onto the appropriate columns. The eluates 
were fractionated in 2 mL fractions collected in 96-well plates. Elution from the 
columns was monitored principally at 280 nm. Fractions containing protein were then 
pooled and prepared for the next chromatographic step. 
 
Buffers used at various stages of protein purification 




10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 
20 mM imidazole 
Buffer B 
10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 
200 mM imidazole 
Ion exchange 
chromatography 
Buffer A 10 mM Tris/HCl, pH 7.5, 20 mM NaCl 
Buffer B 10 mM Tris/HCl, pH 7.5, 1 M NaCl 
Size exclusion 
chromatography 





Immobilized metal ion affinity chromatography (IMAC) 
IMAC was performed using a HisTrap™ FF crude column (5 mL) at 4 °C. The elution 
from the column was performed using gradients of increasing imidazole (up to 500 
mM) at a flow rate of 1 mL/min. The clarified lysate was filtered through a 0.22 µm 
syringe filter and applied to a HisTrap™ column pre-equilibrated in Buffer A [10 
column volumes (CV)] using a Gilson peristaltic pump. The column was washed with 
10 CV of buffer A to remove any unbound protein. Pure protein was eluted with a 
gradient set to 100% buffer B. All flow rates were maintained at 1 mL/min. 
 
Cation exchange chromatography (CEC) 
CEC was performed using a Hi-Trap QHB (1 mL) at 4 °C in Buffer A. The elution from 
the column was performed using gradients of Buffer B (up to 1 M) at a flow rate of 1 
mL/min. 
 
Size exclusion chromatography (SEC) 
Fractions containing protein from IMAC were pooled and loaded onto a Superdex™ 
200 10/300 GL column (GE Healthcare). SEC was performed at 4 °C in Buffer A. The 
elution flow rate was 0.6 mL/min. The eluted protein fractions were collected as 0.5 
mL fractions and relevant fractions were pooled. 
 
Polyacrylamide gel electrophoresis 
SDS-PAGE was performed using a Bolt 4-12% Bis-Tris Plus Gel 1.0 mm x 15-well 
pre-cast gels (Novex®) in NuPAGE® MOPS SDS Running Buffer (Invitrogen). 




(Invitrogen), at 200 V for 35 mins. Samples were mixed with NuPAGE® LDS Sample 
Buffer (4x), and boiled, before being loaded onto the gel.  
 
Visualization 
All SDS-PAGE gels were stained by SimplyBlue™ Safe Stain (Invitrogen). Gels were 
first washed and also destained in water, and all steps were performed with heating until 
almost boiling in a microwave oven. Molecular weight standards were run as the sample 
in one lane of each gel. 
 
Enzyme storage 
Purified protein was divided into aliquots in thin-walled PCR tube in 100 µL aliquots, 
flash-frozen in liquid nitrogen, and stored at -80 °C. All protein samples were rapidly 
thawed immediately before use and kept on ice.  
 
Protein concentration determination 
The concentration was measured by absorption at 280 nm by an appropriately blanked 
Nanodrop ND-1000 spectrophotometer, using 2 µL samples of purified protein 
solution. The concentration was calculated from the absorption using molar extinction 
coefficient values of 252910 M-1 cm-1 and 221510 M-1 cm-1 for engBL and engEF, 
respectively. The coefficient values, calculated from protein sequences using the 
ProtParam tool on the ExPASy Proteomics Server, were the same for both WT and 








The determination of CD spectra were performed on a Jasco J-815 spectropolarimeter 
in a 2 mm curvette with a 2 second response time. For each experiment, five spectra 
were summed and averaged to maximize signal-to-noise. Spectra were analysed by 













2-Acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-D-glucopyranoside 3.3 (3.1 g, 7.96 
mmol) was dissolved in dry DMF (50 mL). Hydrazine acetate (1.1 g, 11.9 mmol) was 
added and the reaction stirred at rt under an N2 atmosphere. After 17 h, t.l.c. (ethyl 
acetate) indicated complete consumption of starting material (Rf 0.4) and formation of 
a major product (Rf 0.2). The reaction mixture was concentrated in vacuo and the 
residue dissolved in and extracted with ethyl acetate (5 x 100 mL), washed with brine 
(100 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (ethyl acetate) to give 2-acetamido-3,4,6-tri-O-acetyl-
2-deoxy-D-glucopyranoside 3.4 (2.0 g, 72 %) as a pale oil; δH (400 MHz, CDCl3)
2 (only 
α anomer quoted) 1.96, 2.02, 2.03, 2.09 (12H, 4 x s, 4 x CH3CO2), 4.11-4.21 (3H, m, 
H-5, H-6, H-6’), 4.29 (1H, m, H-2), 5.10-5.32 (3H, m, H-1, H-3, H-4), 5.90 (1H, d, 
J2,NH 9 Hz, NH); HMRS (ESI) Calcd. For C14H21NO9 (MNa














2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranoside 3.4 (290 mg, 0.835 mmol) 
and 1,1,1-trichloroacetonitrile (0.9 mL, 8.35 mmol) were stirred in dry DCM (10 mL) 
and cooled to 0 °C. DBU (25 μL, 0.288 mmol) was added. After 3 h, t.l.c. (ethyl acetate) 
indicated complete consumption of starting material (Rf 0.2) and the formation of a 
major product (Rf 0.7). The reaction mixture was concentrated, and the residue purified 
by flash column chromatography (ethyl acetate) to give 2-acetamido-3,4,6-tri-O-acetyl-
2-deoxy-α-D-glucopyranosyl trichloroacetimidate 3.5 (380 mg, 93 %) as a yellow oil; 
δH (400 MHz, CDCl3)
2 1.85, 1.97, 1.99 (12H, 3 x s, 4 x CH3CO2), 4.01-4.05 (2H, m, 
H-5, H-6), 4.15 (1H, m, H-6’), 4.45 (1H, m, H-2), 5.12-5.26 (2H, m, H-3, H-4), 5.77 
(1H, d, J2,NH 9.0 Hz, NHCO2) 6.28 (1H, d, J1,2 2.3 Hz, H-1), 8.77 (1H, s, NH); HRMS 
(ESI) Calcd. For C16H21Cl3N2O9 (MNa
+) 513.0210. Found 513.0210. 
 




2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranosyl trichloroacetimidate 3.5 




(70% solution in pyridine, 100 μL) was added. After 5 mins, t.l.c. (ethyl acetate) 
indicated complete consumption of starting material (Rf 0.7) and the formation of a 
major product (Rf 0.6). The reaction mixture was diluted with DCM (100 mL), washed 
with potassium hydrogen carbonate (100 mL of a saturated solution), dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (ethyl acetate/petrol, 1:1) and recrystallized (ethyl acetate/petrol) to 
give 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl fluoride 3.6 (90 mg, 
37 %) as a white crystalline solid, m.p. 130 °C (ethyl acetate/petrol); [α]D
20 +16 (c, 1.0 
in CHCl3); νmax (KBr disc) 3258 (br, NH) cm
-1, 1744 (s, C=O) cm-1; δH (400 MHz, 
CDCl3) 1.99, 2.05, 2.06, 2.10 (12H, 4 x s, 4 x CH3CO2), 3.89 (1H, m, H-5), 4.12 (1H, 
m, H-2), 4.25 (2H, m, H-6, H-6’), 5.14 (1H, m, H-4), 5.23 (1H, m, H-3), 5.42 (1H, dd, 
J1,2 6.3 Hz, JF,1 51.7 Hz, H-1) 5.79 (1H, d, J2,NH 7.5 Hz, NH); δC (100.5 MHz, CDCl3) 
20.6, 20.6, 20.7, 23.1 (2 x s, 4 x C(O)CH3), 53.8 (d, C-5), 62.0 (d, C-6), 67.7 (s, C-4), 
70.7 (d, C-3), 72.1 (d, C-5), 106.0 (d, C-1), 169.2, 170.6, 170.6, 170.6 (4 x s, 4 x C=O); 
δF (376.23 MHz, CDCl3, CF3COOH standard) -147.6 (dd, JF,1 51.8 Hz, JF,2 25.9 Hz, C-
F); HRMS (ESI) Calcd. For C14H20FNO8 (MNa
+) 372.1071. Found 372.1064. 
 




N-Acetyl-D-galactosamine 3.10 (5 g, 22.6 mmol) and triethylamine (15.6 mL, 113.0 
mmol) were stirred in H2O/MeCN (4:1, 100 mL) and cooled to 0 °C. 2-Azido-1,3-




After 3 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting 
material (Rf 0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction 
mixture was acidified to pH 2 by dropwise addition of aqueous 1.2 M HCl and then 
neutralized by addition of sat. NaHCO3 solution (100 mL). The reaction mixture was 
concentrated, and the residue dissolved in ethanol (20 mL), filtered through Celite®, 
and concentrated in vacuo. The residue was then redissolved in water (50 mL), washed 
with DCM (2 x 50 mL), filtered through a column of Amberlite® IR120 (H+, previously 
treated with 1 M NaOH solution), and concentrated in vacuo. Purification by flash 
column chromatography (CHCl3:MeOH, 7:1 → CHCl3:MeOH, 2:1) gave 2-acetamido-
2-deoxy-β-D-galactopyranosyl azide 3.13 (4.3 g, 77 %) as a white solid; m.p. 195-200 
°C; [α]D
20 -16 (c, 1.0 in MeOH); νmax (neat) 1643 (s, amide), 2094 (s, azide), 3331.3 
(bs, OH) cm-1; δH (400 MHz, D2O)
  1.94 (3H, s, CH3), 3.63-3.78 (4H, m, H-3, H-5, H-
6, H-6’), 3.80 (1H, at, J 10.2 Hz, H-2), 3.86 (1H, ad, J 3.1 Hz, H-4), 4.55 (1H, d, J1,2 
9.4 Hz, H-1); δC (100 MHz, D2O) 22.1 (d, NHCOCH3), 51.7 (d, C-2), 60.9 (t, C-6), 
67.6 (d, C-4), 70.7 (d, C-3), 77.2 (d, C-5), 89.0 (d, C-1), 175.0 (s, NHCOCH3); HRMS 
(ESI) Calcd. For C8H14N4O5 (MNa






Sodium acetate (82.0 g, 1000 mmol) was added to acetic anhydride (630 mL) and 
refluxed at 120 °C for 1 h. D-Galactose 3.14 (60 g, 330 mmol) was then added portion-




(petrol:ethyl acetate, 1:1) indicated complete consumption of starting material (Rf 0.1) 
and formation of a single product (Rf 0.7). The reaction mixture was allowed to cool to 
rt, and then poured into ice-cold water (10 L). The resulting precipitate was filtered, 
and washed with water. Filtration and purification of the crude residue by 
recrystallization (ethanol) to afford 1,2,3,4,6-penta-O-acetyl-β-D-galactopyranoside 
3.2 (48 g, 37 %) as a white crystalline solid, m.p. 125 °C [lit. m.p. 137-139 °C];4 [α]D
20 
+29.1 (c, 1.0 in CHCl3) [lit. [α]D
23.5 +27.1 (c, 1.03 in CHCl3)];
5 δH (500 MHz, CDCl3)
6 
1.99, 2.04, 2.11, 2.16 (15H, 4 x s, 5 x CH3CO2), 4.07 (1H, m, H-5), 4.13-4.16 (2H, m, 
H-6, H-6’), 5.06 (1H, dd, J3,4 3.5 Hz, H-3), 5.32 (1H, dd, J2,3 10.5 Hz, H-2), 5.42 (1H, 
m, H-4), 5.69 (1H, d, J1,2 8.3 Hz, H-1); HRMS (ESI) Calcd. For C16H22O11 (MNa
+) 
413.1054. Found 413.1054. 
 




1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranoside 3.15 (50 g, 128 mmol) was dissolved 
in DCM (450 mL) and cooled to 0 °C. Hydrogen bromide solution (33 % in AcOH 
solution, 140 mL) was added slowly and the reaction was stirred at rt. After 3 h, t.l.c. 
(petrol:ethyl acetate, 2:1) indicated the complete consumption of starting material (Rf 
0.3) and formation of a single product (Rf 0.5). The reaction mixture was transferred to 
ice-water (500 mL) and the organic layer was extracted with DCM (100 mL), washed 




(MgSO4), filtered, and concentrated in vacuo to yield 2,3,4,6-tetra-O-acetyl-α-D-
galactopyranosyl bromide 3.16 (52.3 g, 100 %) as a yellow oil; δH (500 MHz, CDCl3)
8 
1.90, 1.95, 2.01, 2.05 (12H, 4 x s, CH3CO2), 3.99-4.11 (2H, m, J5,6’ 6.5 Hz, J6,6’ 11.4 
Hz, H-6, H-6’), 4.40 (1H, at, H-5), 4.94 (1H, dd, J1,2 3.9 Hz, J2,3 10.6 Hz, H-2), 5.29 
(1H, dd, J3,4 3.1 Hz, J4,5 10.6 Hz, H-4), 5.41 (1H, ad, H-3), 6.61 (1H, d, H-1). This 






Activated zinc dust (50.7 g, 769 mmol) and N-methylimidazole (10.2 mL, 128 mmol) 
was stirred in ethyl acetate (200 mL) and the mixture was refluxed. Galactosyl bromide 
3.16 (52.3 g, 128 mmol) dissolved in ethyl acetate (200 mL) was added drop-wise to 
the stirring solution. After 2 h, the reaction mixture was filtered through Celite® washed 
with ethyl acetate (100 mL). The filtrate was washed with hydrochloric acid (100 mL 
of a 1.2 M solution), sodium hydrogen carbonate (2 x 200 mL of a saturated solution), 
dried (MgSO4), and concentrated in vacuo. The residue was purified by flash column 
chromatography (petrol:ethyl acetate, 2:1) to yield 3,4,6-tri-O-acetyl-D-galactal 3.17 
(27.6 g, 79 %) as a pale yellow oil, [α]D
20 -9 (c, 1.0 in EtOAc) [lit. [α]D
25 -9 (c, 1.0 in 
EtOAc)];9 δH (500 MHz, CDCl3)
8 2.01, 2.07, 2.12 (9H, 3 x s, 3 x CH3CO2), 4.20-4.31 
(3H, m, H-5, H-6, H-6’), 4.71 (1H, dd, J1,2 6.2 Hz, J2,3 1.5 Hz, H-2), 5.41 (1H, m, H-
4), 5.53 (1H, m, H-3), 6.44 (1H, dd, H-1); HRMS (ESI) Calcd. For C12H16O7 (MNa
+) 









Tri-O-acetyl-D-galactal 3.17 (8.3 g, 30.5 mmol) was dissolved in dry DCM (50 mL) 
and stirred at rt under an N2 atmosphere. A solution containing 
bis(acetoxy)iodobenzene (13.8 g, 42.7 mmol) and diphenyl diselenide (5.7 g, 18.3 
mmol) dissolved in dry DCM (50 mL) was added, and the reaction mixture cooled to 0 
°C. Sodium azide (4.8 g, 73.2 mmol) was then added slowly and the reaction mixture 
was allowed to warm to rt. After 17 h, t.l.c. (petrol:ethyl acetate, 3:1) indicated the 
complete consumption of starting material (Rf 0.2) and formation of two major products 
(Rf 0.3, 0.35). The reaction mixture was diluted with DCM (300 mL), washed with 
water (4 x 250 mL), sodium hydrogen carbonate (2 x 100 mL of a saturated solution), 
brine (2 x 100 mL), dried (MgSO4), and concentrated in vacuo. The residue was 
purified by flash column chromatography (petrol:ethyl acetate, 4:1) and recrystallized 
(petrol/ethyl acetate) to yield phenyl 2-azido-2-deoxy-3,4,6-tri-O-acetyl-1-seleno-α-D-
galactopyranoside 3.18 (5.7 g, 40 %) as a white crystalline solid, m.p. 100 °C  [lit. m.p. 
104-105 °C];11 [α]D
20 +156 (c, 1.0 in EtOAc) [lit. [α]D + 156 (c, 1.03 in EtOAc)];
11 δH 
(500 MHz, CDCl3)
11 1.99, 2.08, 2.17 (9H, 3 x s, 3 x CH3CO2), 4.02-4.10 (2H, m, J5,6 
5.7 Hz, J6,6’ 11.4 Hz, H-6, H-6’), 4.27 (1H, dd, J1,2 5.5 Hz, J2,3 11 Hz, H-2), 4.69 (1H, 




7.63 (5H, m, Ar-H); HRMS (ESI) Calcd. For C18H21N3O7Se (MNa
+) 494.0437. Found 
494.0440. 
 




3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranosyl trichloroacetimidate 3.21 
(1.8 g, 3.79 mmol), p-nitrophenol (634 mg, 4.56 mmol) and pre-dried 4Å molecular 
sieves (5 g) in dry DCM (40 mL) were stirred at -20 °C under an N2 atmosphere. 
TMSOTf (0.69 mL, 3.79 mmol) was added dropwise. After 3.5 h, t.l.c. (petrol:ethyl 
acetate, 2:1) indicated complete consumption of starting material (Rf 0.4) and formation 
of a major product (Rf 0.3). The reaction mixture was diluted with DCM (100 mL) and 
the organic phase was washed with sodium hydrogen carbonate (100 mL of a saturated 
solution), brine (100 mL), dried (MgSO4), and concentrated in vacuo. The crude 
product was purified by flash column chromatography (petrol:ethyl acetate, 4:1) to give 
p-nitrophenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranoside 3.19 (1.3 g, 
76 %) as a white solid, m.p. 110-113 °C; δH (400 MHz, CDCl3)
12 1.95, 2.11, 2.19 (9 H, 
3 x s, 3 x CH3CO2), 3.91 (1H, dd, J1,2 2.7 Hz, J2,3 10.9 Hz, H-2), 4.00-4.13 (2H, m, H-
6, H-6’), 4.26 (1H, m, H-5), 5.03 (1H, at, J 10.2 Hz, H-4), 5.55 (1H, m, H-3), 5.74 (1H, 
m, H-1), 7.14-7.23 (2H, m, Ar-H), 8.23-8.26 (2H, m, Ar-H); HRMS (ESI) Calcd. For 
C18H20N4O10 (MNa










Phenyl 2-azido-2-deoxy-3,4,6-tri-O-acetyl-1-seleno-α-D-galactopyranoside 3.18 (5 g, 
10.0 mmol) in THF-H2O (50 mL, 1:1) was treated at rt with N-iodosuccinimide (7.2 g, 
31.8 mmol). After 5 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated complete consumption 
of starting material (Rf 0.5) and the formation of a major product (Rf 0.2). The mixture 
was diluted with ethyl acetate (100 mL) and washed with brine (100 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography (petrol:ethyl acetate, 3:1) to give 3,4,6-tri-O-acetyl-2-azido-
2-deoxy-D-galactopyranoside 3.20 (3.5 g, 99 %) as a pale yellow oil; δH (500 MHz, 
CDCl3)
13 2.04-2.16 (9H, 3 x s, 3 x CH3CO2), 3.52 (1H, d, J1,OH 2.4 Hz, OH), 3.66 (1H, 
dd, J1,2 8.1 Hz, J2,3 10.8 Hz, H-2β), 3.74 (1H, dd, J1,2 3.1 Hz, J2,3 11.0 Hz, H-2α), 3.90 
(1H, m, H-5β), 4.06-4.14 (4H, m, H-6α, H-6’α, H-6β, H-6’β), 4.45 (1H, at, H-5α), 4.70 
(1H, dd, J1,OH 5.1 Hz, J1,2 7.5 Hz, H-1β), 4.81 (1H, dd, J2,3 11.0 Hz, J3,4 3.3 Hz, H-3β), 
5.33-5.39 (2H, m, H-4α, H-4β), 5.40 (1H, m, H-3α), 5.46 (1H, d, H-1α); HRMS (ESI) 
Calcd. For C12H17N3O8 (MNa













3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-galactopyranoside 3.20 (1.34 g, 4.05 mmol) and 
1,1,1-trichloroacetonitrile (4.1 mL, 40.5 mmol) were dissolved in dry DCM (40 mL) 
and the mixture was stirred at 0 °C. DBU (0.12 mL, 0.81 mmol) was added. After 3 h, 
t.l.c. (petrol:ethyl acetate, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of a major product (Rf 0.4). The reaction mixture was 
concentrated, and purified by flash column chromatography (petrol:ethyl acetate, 3:1) 
to give 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranosyl trichloroacetimidate 
3.21 (1.88 g, 98 %) as a yellow oil; [α]D
20 +102.6 (c, 1.0 in CHCl3) [lit. [α]D
25 +104 (c, 
1.0 in CHCl3);
15 δH (400 MHz, CDCl3)
15 2.01, 2.08, 2.17 (9H, 3 x s, 3 x CH3CO2), 4.01-
4.18 (3H, m, H-2, H-6, H-6’), 4.42 (1H, m, H-5), 5.38 (1H, dd, J2,3 11.0 Hz, J3,4 3.2 Hz, 
H-3), 5.54 (1H, m, H-4), 6.51 (1H, d, J1,2 3.5 Hz, H-1), 8.79 (1H, s, NH); HRMS (ESI) 
Calcd. For C14H17O8N4Cl3 (MNa










p-Nitrophenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranoside 3.19 (1.2 g, 
2.65 mmol) was dissolved in dry methanol (40 mL). Sodium metal (920 mg, 39.2 
mmol) was then added portionwise. After 2 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated 
complete consumption of starting material (Rf 0.3) and the formation of a single product 
(Rf 0). The reaction mixture was neutralized using Amberlite
® IR120 (H+), filtered and 
concentrated in vacuo. The residue was dissolved in acetonitrile (20 mL) and DMF (8 
mL). Anisaldehyde dimethyl acetal (1.4 mL, 7.95 mmol) and p-toluene sulfonic acid 
(250 mg, 1.33 mmol) were added, and the reaction was stirred at rt under an N2 
atmosphere. After 24 h, t.l.c. (toluene:ethyl acetate, 2:1) indicated complete 
consumption of starting material (Rf 0) and the formation of a major product (Rf 0.5). 
The reaction mixture was diluted with DCM (100 mL) and the organic phase was 
separated and washed with sodium hydrogen carbonate (200 mL), brine (200 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography (toluene:ethyl acetate, 5:1) to give p-nitrophenyl 2-azido-2-
deoxy-4,6-O-p-methoxybenzylidene-α-D-galactopyranoside 3.22 (440 mg, 37 %) as a 
white solid, m.p. 150 °C; [α]D
20 +66.7 (c, 1.7 in CHCl3) [lit. [α]D
20 +68 (c. 1.7 in 
CHCl3)];
16 δH (400 MHz, CHCl3)
16 2.55 (1H, bs, OH), 3.79-3.84 (5H, m, C6H4OCH3, 
H-2, H-5), 4.04-4.08 (1H, m, H-6’), 4.26 (1H, m, H-6), 4.38 (2H, m, H-3, H-4), 5.58 




7.20-7.23 (2H, m, OC6H4NO2), 7.42-7.45 (2H, m, OC6H4NO2), 8.22-8.25 (2H, m, 
OC6H4NO2); HRMS (ESI) Calcd. For C20H20N4O8 (MNa






D-Galactose 3.14 (5 g, 27.8 mmol) was stirred in pyridine (150 mL) at 0 °C under an 
N2 atmosphere. Benzoyl chloride (21 mL, 172 mmol) was added dropwise and the 
reaction was allowed to warm to rt. After 18 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated 
complete consumption of starting material (Rf 0) and the formation of a single product 
(Rf 0.5). The reaction mixture was diluted with ethyl acetate (500 mL), washed with 
hydrochloric acid (8 x 250 mL of a 1.2 M solution), sodium hydrogen carbonate (4 x 
200 mL of a saturated solution), brine (2 x 200 mL), dried (MgSO4), and concentrated 
in vacuo. Recrystallisation (petrol:ethyl acetate) gave 1,2,3,4,6-penta-O-benzoyl-D-
galactopyranoside 3.23 (15.3 g, 79 %) as a white solid, m.p. 130 °C [lit. m.p. 129 -131 
°C];17 δH (500 MHz, CDCl3)
17 (major α anomer quoted) 4.42 (1H, dd, J5,6 7.1 Hz, J6,6’ 
11.2 Hz, H-6) 4.63 (1H, dd, J5,6’ 6.4 Hz, H-6’), 4.83 (1H, at, H-5), 6.02 (1H, dd, J1,2 3.7 
Hz, J2,3 10.8 Hz, H-2), 6.12 (1H, at, J 10.5 Hz) H-3), 6.19 (1H, m, H-4), 6.95 (1H, d, 













1,2,3,4,6-Penta-O-benzoyl-D-galactopyranoside 3.23 (5 g, 7.14 mmol) was dissolved 
in dry DMF (50 mL). Hydrazine acetate (990 mg, 10.7 mmol) was added and the 
reaction was stirred at rt. After 5.5 h, t.l.c. (petrol:ethyl acetate, 2:1) indicated complete 
consumption of starting material (Rf 0.5) and the formation of a major product (Rf 0.3). 
The reaction mixture was diluted with ethyl acetate (200 mL) and the organic phase 
was washed with water (4 x 100 mL), sodium hydrogen carbonate (2 x 100 mL of a 
saturated solution), dried (MgSO4), and concentrated in vacuo. The residue was purified 
by flash column chromatography (petrol:ethyl acetate, 3:1) to give 2,3,4,6-tetra-O-
benzoyl-D-galactopyranoside 3.24 (4.05 g, 95 %) as a white solid, m.p. 75 °C; δH (400 
MHz, CDCl3)
17 (only α anomer quoted) 4.37-4.42 (1H, m, H-6’), 4.59-4.64 (1H, m, H-
6), 4.87 (1H, m, H-5), 5.71 (1H, at, J 3.5 Hz, H-2), 5.85 (1H, d, J1,2 3.5 Hz, H-1), 6.07 
(2H, m, H-3, H-4), 7.22-8.10 (20H, m, Ar-H); HRMS (ESI) Calcd. For C34H28O10 















2,3,4,6-Tetra-O-benzoyl-D-galactopyranoside 3.24 (1 g, 1.68 mmol) and 1,1,1-
trichloroacetonitrile (1.7 mL, 16.8 mmol) were stirred in dry DCM (20 mL) and cooled 
to 0 °C. DBU (50 μL, 0.34 mmol) was added. After 5 h, t.l.c. (petrol:ethyl acetate, 2:1) 
indicated complete consumption of starting material (Rf 0.3) and the formation of a 
major product (Rf 0.6). The reaction mixture was concentrated, and the residue purified 
by flash column chromatography (petrol:ethyl acetate, 5:1) to give 2,3,4,6-tetra-O-
benzoyl-α-D-galactopyranosyl trichloroacetimidate 3.25 (1.0 g, 81 %) as a white solid; 
[α]D
20 +99 (c, 6.0 in CHCl3) [lit. [α]D +105 (c, 6.05 in CHCl3)];
17 δH (400 MHz, 
CDCl3)
17 4.44 (1H, dd, J5,6 5.9 Hz, J6,6’ 11.3 Hz, H-6’), 4.61 (1H, dd, J5,6 7.0 Hz, H-6), 
4.86 (1H, at, J 6.3 Hz, H-5), 5.96 (1H, dd, J1,2 3.9 Hz, J2,3 10.9 Hz, H-2), 6.07 (1H, dd, 
J3,4 3.1 Hz, H-3), 6.15 (1H, m, H-5), 6.92 (1H, d, H-1), 7.24-8.10 (20H, m, Ar-H), 8.63 
(1H, s, NH); HRMS (ESI) Calcd. For C36H28Cl3NO10 (MNa















A mixture of p-nitrophenyl 2-azido-2-deoxy-4,6-O-p-methoxybenzylidene-α-D-
galactopyranoside 3.22 (300 mg, 0.68 mmol), 2,3,4,6-tetra-O-benzoyl-α-D-
galactopyranosyl trichloroacetimidate 3.25 (600 mg, 0.81 mmol) and 4Å MS in dry 
DCM (20 mL) was stirred for 30 min under an N2 atmosphere and then cooled to -20 
°C. TMSOTf (6.1 μL, 0.034 mmol) was then added and the reaction mixture was stirred 
at -20 °C. After 4 h, t.l.c. (toluene:ethyl acetate, 7:1) indicated complete consumption 
of acceptor 3.22 (Rf 0.2) and the formation of a major product (Rf 0.4). The mixture 
was diluted with DCM (100 mL) and filtered through a pad of Celite® The filtrate was 
washed with hydrochloric acid (50 mL of a 1.2 M solution), sodium hydrogen carbonate 
(50 mL of a saturated solution), water (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification by flash column chromatography (toluene:ethyl 
acetate, 20:1) afforded p-nitrophenyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl-
(1→3)-2-azido-2-deoxy-4,6-O-p-methoxybenzylidene-α-D-galactopyranoside 3.26 
(310 mg, 45 %) as a white solid, m.p. 90 °C; [α]D
20 +150 (c. 1.7 in CHCl3) [lit. [α]D
20 
+156 (c, 1.63 in CHCl3)]
16 δH (400 MHz, CDCl3)
16 3.50 (1H, m, H-5), 3.69-3.79 (1H, 
m, H-6’b), 3.82 (3H, s, C6H4OCH3), 4.02-4.11 (2H, m, H-6a, H-2a), 4.34 (1H, dd, J2a,3a 
10.6 Hz, J3a,4a 3.2 Hz, H-3a), 4.40-4.45 (2H, m, H-5b, H-6’b), 4.80 (1H, dd, J6b,6b’ 12.5 
Hz, J5b,6b 8.6 Hz, H-6b), 5.25 (1H, d, J1b,2b 7.8 Hz, H-1b), 5.48 (1H, s, CHC6H4OCH3), 




(1H, dd, J1b,2b 7.8 Hz, J2,3 10.2 Hz, H-2b), 6.02 (1H, m, H-4b), 6.87-6.90 (2H, m, 
C6H4OCH3), 7.13-7.19 (2H, m, OC6H4NO2), 7.33-7.39 (4H, m, C6H5), 7.40-7.49 (6H, 
m, C6H5, C6H4OCH3), 7.50-7.53 (1H, m, C6H5), 7.60-7.65 (1H, m, C6H5), 7.79-7.82 
(2H, m, C6H5), 7.97-7.99 (2H, m, C6H5), 8.00-8.03 (2H, m, C6H5), 8.08-8.11 (2H, m, 
C6C5), 8.19-8.21 (2H, m, OC6H4NO2); HRMS (ESI) Calcd. For C54H47N4O17 (MH
+) 






Acetic acid (80 % aq. solution, 20 mL) was added to a solution of p-nitrophenyl 2,3,4,6-
tetra-O-benzoyl-β-D-galactopyranosyl-(1→3)-2-azido-2-deoxy-4,6-O-p-
methoxybenzylidene-α-D-galactopyranoside 3.26 (200 mg, 0.196 mmol) in DCM (4 
mL) and stirred at rt overnight. After 19 h, t.l.c. (toluene:ethyl acetate, 2:1) indicated 
complete consumption of starting material (Rf 0.8) and the formation of a major product 
(Rf 0.3). The mixture was diluted with DCM (50 mL) and carefully washed with sodium 
hydrogen carbonate (2 x 100 mL of saturated solution), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (toluene:ethyl acetate, 2:1) to afford p-nitrophenyl 2,3,4,6-tetra-O-
benzoyl-β-D-galactopyranosyl-(1→3)-2-azido-2-deoxy-α-D-galactopyranoside 3.27 
(150 mg, 85 %) as a white solid, m.p. 100 °C; [α]D
20 +175 (c, 0.1 in CHCl3) [lit. [α]D
20 
+167 (c, 0.15 in CHCl3)];
16 δH (400 MHz, CHCl3)
16 2.16 (1H, bs, OH), 3.00 (1H, bs, 




3.87 (1H, dd, J2a,3a 10.4 Hz, J3a,4a 2.5 Hz, H-2a), 4.27 (1H, ad, H-3a), 4.36 (1H, m, H-
4a), 4.48-4.51 (1H, m, H-5b) 4.54 (1H, dd, J6b,6b’ 11.7 Hz, J5b,6b’ 3.9 Hz, H-6’b), 4.68 
(1H, dd, J6b,6b’ 11.3 Hz, J5b,6b’ 7.4 Hz, H-6b), 5.15 (1H, d, J1b,2b 7.8 Hz, H-1b), 5.64-
5.73 (2H, m, H-3b, H-1a), 5.94 (1H, at, H-2b), 6.05 (1H, m, H-4b), 7.08-7.11 (2H, m, 
OC6H4NO2), 7.21-7.25 (2H, m, C6H5), 7.32-7.44 (5H, m, C6H5), 7.46-7.55 (4H, m, 
C6H5), 7.59-7.64 (1H, m, C6H5), 7.77-7.80 (2H, m, C6H5), 7.99-8.01 (4H, m, C6H5), 
8.09-8.15 (4H, m, OC6H4NO2, C6H5); HRMS (ESI) Calcd. For C46H40N4O16 (MNa
+) 






α-D-galactopyranoside 3.27  (130 mg, 0.17 mmol) was dissolved in dry pyridine (5 
mL). Thioacetic acid (1.5 mL, 20.9 mmol) was added and the reaction was stirred at rt. 
After 36 h, t.l.c. (ethyl acetate/toluene, 1:1) indicated complete consumption of starting 
material (Rf 0.7) and the formation of a major product (Rf 0.1). The reaction mixture 
was diluted with DCM (50 mL) and the organic phase was washed with hydrochloric 
acid (100 mL of a 1.2 M solution), sodium hydrogen carbonate (100 mL of a saturation 
solution), brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (ethyl acetate/toluene, 1:1) to 
give a white powder which was used directly for the next step. The residue was 
dissolved in dry methanol (10 mL) and methanolic sodium methoxide (10 mL of a 0.1 




(ethyl acetate/toluene, 1:1) indicated complete consumption of starting material (Rf 0.1) 
and formation of a single product (Rf 0). The reaction mixture was neutralized with 
Amberlite® IR120 (H+), filtered, and concentrated in vacuo. The residue was purified 
by RP HPLC (column: Phenomenex Luna 5U C18 100 Å (250 x 10 mm x 10 µm); 
eluent: linear gradient of MeCN using a gradient method, 10-100% MeCN; flow rate: 
3.5 mLmin-1; column oven: 40 °C; detection: UV 210 nm) and concentrated in vacuo 
to give p-nitrophenyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-
galactopyranoside 3.13 (6.4 mg, 9 %) as a white solid; HPLC: tR = 7.86 min; m.p. 200 
°C [lit. 212 – 214 °C];18 [α]D
20 +11.3 (c, 0.5 in H2O) [lit. [α]D
23 +10.2 (c, 0.5 in H2O)];
18 
δH (400 MHz, CDCl3)
19 1.92 (3H, s, CH3CO2), 3.47 (1H, at, J 7.8 Hz, H-2b), 3.55-3.85 
(8H, m, H-5a, H-6a, H-6a’, H-3b, H-4b, H-5b, H-6b, H-6b’), 3.91 (1H, m, H-4a), 4.20 
(1H, m, H-3a), 4.44-4.51 (2H, m, H-1b, H-2a), 5.74 (1H, d, J1a,2a 3.6 Hz, H-1a), 7.19 
(2H, d, J 9.4 Hz, OC6H4NO2), 8.17 (2H, d, J 9 Hz, OC6H4NO2); HRMS (ESI) Calcd. 
For C20H28N2O13 (MNa















NaOH (2.4 g, 60.3 mmol) was added to a stirred solution of D-glucosamine 
hydrochloride 3.29 (10 g, 46.4 mmol) in methanol (20 mL) and water (40 mL). Phthalic 
anhydride (13.8 g, 92.8 mmol) was dissolved in acetone (80 mL) and added while 
maintaining the temperature below 15 °C. Sodium hydrogen carbonate (10.1 g, 121 
mmol) was added, and the solution was subsequently stirred at rt. After 25 h, t.l.c. (ethyl 
acetate:acetic acid:methanol:water, 12:3:3:2) indicated the complete consumption of 
starting material (Rf 0.1) and the formation of a major product (Rf 0.3). The mixture 
was then brought to pH 1 with concentrated hydrochloric acid, concentrated in vacuo, 
and left at 2 °C in the refrigerator overnight. The resulting precipitate was filtered off, 
washed with cold water and dried under vacuum. The crude product was dissolved in 
pyridine (140 mL) and stirred at 0 °C. Acetic anhydride (105 mL, 1.1 mol) was then 
added and the mixture was stirred at rt overnight. At this point, t.l.c. (petrol:ethyl 
acetate, 1:1) indicated complete consumption of starting material (Rf 0) and the 
formation of a major compound (Rf 0.5). The reaction mixture was quenched by slowly 
adding it to ice-water (2 L). The organic phase was separated and washed with 
hydrochloric acid (6 x 1 L of a 1.2 M solution), sodium hydrogen carbonate (3 x 1 L of 
a saturated solution), brine (1 L), dried (MgSO4), filtered, and concentrated in vacuo. 
The crude product was purified by flash column chromatography (petrol:ethyl acetate, 
2:1) to give 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-D-glucopyranoside 3.30 
(16.6 g, 75 %) as a mixture of anomers (α/β, 2:1); δH (400 MHz, CDCl3)




2.02, 2.08 (12H, 4 x s, 4 x CH3CO2), 3.97-4.02 (1H, m, H-5β), 4.04-4.09 (1H, m, H-
6’α), 4.10-4.13 (1H, m, H-6β), 4.26-4.30 (1H, m, H-5α), 4.31-4.36 (2H, m, H-6α, H-
6’β), 4.43 (1H, dd, J1,2 9.0 Hz, J2,3 10.6 Hz, H-2β), 4.68 (1H, dd, J1,2 3.2 Hz, J2,3 11.4Hz, 
H-2α), 5.10-5.30 (2H, m, H-4α, H-4β), 5.85 (1H, dd, J3,4 10.2 Hz, H-3β), 6.24 (1H, as, 
H-1α), 6.47 (H, as H-1β), 6.53 (1H, dd, J3,4  9.0 Hz, H-3α), 7.74-7.85 (4H, m, Phth); 
HRMS (ESI) Calcd. For C22H23NO11 (MNa





1,3,4,6-Tetra-O-acetyl-2-deoxy-2-phthalimido-D-glucopyranoside 3.30 (10 g, 21.0 
mmol) was dissolved in dry DMF (100 mL). Hydrazine acetate (2.9 g, 31.4 mmol) was 
added and the reaction was stirred at rt. After 23 h, t.l.c. (petrol:ethyl acetate, 1:1) 
indicated complete consumption of starting material (Rf 0.5) and the formation of a 
major product (Rf 0.2). The reaction mixture was diluted with DCM (200 mL) and the 
organic phase was washed with brine (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(petrol:ethyl acetate, 1:1) to give 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-D-
glucopyranoside 3.31 (6.3 g, 69 %) as a white solid, m.p. 170 °C [lit. m.p. 166-167 °C 
];21 δH (400 MHz, CDCl3)
22 (only α anomer quoted) 1.87, 2.04, 2.12 (9H, 3 x s, 3 x 
CH3CO2), 3.24 (1H, bd, J1,OH 6.7 Hz, 1-OH), 3.93 (1H, m, H-5), 4.18-4.29 (3H, m, H-
2, H-6, H-6’), 5.17 (1H, at, J 9.4 Hz, H-4), 5.63 (1H, m, H-1), 5.85 (1H, at, J 9.8 Hz, 
H-3), 7.74 (2H, m, Phth), 7.85 (2H, m, Phth); HRMS (ESI) Calcd. For C34H28O10 










3,4,6-Tri-O-acetyl-2-deoxy-2-phthalimido-α-D-glucopyranoside 3.31 (300 mg, 0.69 
mmol) and 1,1,1-trichloroacetonitrile (0.7 mL, 6.90 mmol) were stirred in dry DCM 
(10 mL) and cooled to 0 °C. DBU (20 μL, 0.14 mmol) was added. After 6 h, t.l.c. 
(petrol:ethyl acetate, 1:1) indicated complete consumption of starting material (Rf 0.2) 
and the formation of a major product (Rf 0.4). The reaction mixture was concentrated, 
and the residue purified by flash column chromatography (petrol:ethyl acetate, 1:1) to 
give 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
trichloroacetimidate 3.32 (370 mg, 93 %) as a yellow oil; δH (400 MHz, CDCl3)
15 1.87, 
2.03, 2.10 (9H, 3 x s, 3 x CH3CO), 4.06 (1H, m, H-5), 4.18 (1H, m, H-6), 4.37 (1H, m, 
H-6’), 4.61 (1H, at, J 9.8 Hz, H-2), 5.26 (1H, at, J 9.3 Hz, H-4), 5.90 (1H, at, J 9.8 Hz, 
H-3), 6.61 (1H, d, J1,2 9 Hz, H-1), 7.72 (2H, m, Phth), 7.81 (2H, m, Phth), 8.65 (1H, s, 
NH); HRMS (ESI) Calcd. For C22H21Cl3N2O10 (MNa














A mixture of p-nitrophenyl 2-azido-2-deoxy-4,6-O-p-methoxybenzylidene-α-D-
galactopyranoside 3.22 (100 mg, 0.225 mmol), 3,4,6-tri-O-acetyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl trichloroacetimidate 2.32 (300 mg, 0.527 mmol), and 
4Å MS in dry DCM (40 mL) was stirred for 30 min under an N2 atmosphere and then 
cooled to -20 °C. TMSOTf (4.1 μL, 0.023 mmol) was then added and the reaction 
mixture was stirred at -20 °C. After 7 h, t.l.c. (toluene:ethyl acetate, 2:1) indicated 
complete consumption of acceptor 3.22 (Rf 0.5) and the formation of a major product 
(Rf 0.4). Water (10 mL) was added. After 30 mins, the mixture was diluted with DCM 
(50 mL) and filtered through a pad of Celite®. The filtrate was washed with sodium 
hydrogen carbonate (50 mL of a saturated solution), brine (50 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification by flash column chromatography 
(toluene:ethyl acetate, 4:1) afforded p-nitrophenyl 3,4,6-tri-O-acetyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl-(1→3)-2-azido-2-deoxy-4,6-O-p-
methoxybenzylidene-α-D-galactopyranoside 3.33 (140 mg, 72 %) as a white solid, m.p. 
95-96 °C; [α]D
20 +97 (c, 1.0 in CHCl3) [lit. [α]D
20 +135 (c, 0.57 in CHCl3)]
16 δH (400 
MHz, CDCl3)
16 1.86, 2.04, (9H, 2 x s, 3 x CH3CO2), 3.67 (1H, m, H-5a), 3.80 (3H, s, 




6b’), 4.42-4.53 (3H, m, H-4a, H-2b, H-6b), 5.22 (1H, at, J 9.4 Hz, H-4b), 5.53 (1H, s, 
CHC6H4OCH3), 5.67 (1H, m, H-1a), 5.76-5.84 (2H, m, H-3b, H-1b), 6.87 (2H, m, 
C6H4OCH3), 7.14 (2H, m, OC6H4OCH3) 7.40 (2H, m, C6H4OCH3) 7.70 (2H, m, Phth), 
7.82 (2H, m, Phth), 8.16 (2H, m, OC6H4NO2); HRMS (ESI) Calcd. For C40H39N5O17 






Acetic acid (80 % aq. solution, 10 mL) was added to a solution of p-nitrophenyl 3,4,6-
tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2-azido-2-deoxy-4,6-
O-p-methoxybenzylidene-α-D-galactopyranoside 3.33 (120 mg, 0.139 mmol) in DCM 
(10 mL) and stirred at rt. After 44 h, t.l.c. (toluene:ethyl acetate, 2:1) indicated complete 
consumption of starting material (Rf 0.4) and the formation of a major product (Rf 0.1). 
The mixture was diluted with DCM (50 mL) and carefully washed with sodium 
hydrogen carbonate (2 x 100 mL of saturated solution), brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. The crude product was purified by flash column 
chromatography (toluene:ethyl acetate, 1:1→0:1) to afford p-nitrophenyl 3,4,6-tri-O-
acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2-azido-2-deoxy-α-D-
galactopyranoside 3.34 (70 mg, 68 %) as a white solid, m.p. 170 °C; [α]D
20 +169 (c, 1.0 
in CHCl3) [lit. [α]D
20 +213 (c, 0.63 in CHCl3)];
16 δH (400 MHz, CHCl3)
16 1.89, 2.07, 
2.13 (9H, 3 x s, 3 x CH3CO2), 3.76 (2H, m, H-6a, H-6a’), 3.85 (2H, m, H-2a, H-5a), 




m, H-2b), 5.17 (1H, at, J 10.6 Hz, H-4b), 5.60 (1H, d, J1,2 3.4 Hz, H-1a), 5.75 (1H, d, 
J1,2 8.2 Hz, H-1b), 5.81 (1H, at, J 10.1 Hz, H-3b), 7.13 (2H, m, OC6H4NO2), 7.75 (2H, 
m, Phth), 7.87 (2H, m, Phth), 8.18 (2H, m, OC6H4NO2); HRMS (ESI) Calcd. For 
C32H33N5O16 (MNa







2-azido-2-deoxy-α-D-galactopyranoside 3.34 (70 mg, 0.094 mmol) in dry methanol (10 
mL) was added methanolic sodium methoxide (10 mL of a 0.1 M solution) and stirred 
overnight under N2 atmosphere, at which point t.l.c. (toluene/ethyl acetate, 1:1) 
indicated complete consumption of starting material (Rf 0.4) and formation of a single 
product (Rf 0). The reaction mixture was neutralized with Amberlite
® IR120 (H+), 
filtered, and concentrated in vacuo to afford a white solid which was used directly for 
the next step. The crude residue was dissolved in ethanol (10 mL) and stirred at 70 °C. 
Hydrazine hydrate (70 μL, 1.41 mmol) was added. After 18 h, the reaction mixture was 
cooled to rt, concentrated in vacuo, and azeotroped with toluene to afford a yellow 
material which was used directly for the next step. The crude material was dissolved in 
pyridine (3 mL). Acetic anhydride (3 mL) and DMAP (2 mg, 0.02 mmol) were added 
and the reaction mixture was stirred overnight, at which point t.l.c. (ethyl acetate) 
indicated complete consumption of starting material (Rf 0) and formation of a major 




(50 mL), washed with hydrochloric acid (20 mL of a 1.2 M solution), sodium hydrogen 
carbonate (2 x 50 mL of a saturated solution), brine (50 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. Purification by flash column chromatography (toluene:ethyl 
acetate, 1:1) afforded p-nitrophenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl-(1→3)-4,6-di-O-acetyl-2-azido-2-deoxy-α-D-galactopyranoside 3.35 
(56 mg, 80 %) as a white solid, m.p. 180 - 185 °C; [α]D
20 +82 (c. 1.0 in CHCl3) [lit. 
[α]D
20 +150 (c, 0.25 in CHCl3)]
16 δH (400 MHz, CDCl3)
16 1.91, 1.96, 2.04, 2.10, 2.16 
(18H, 5 x s, 6 x CH3CO2), 3.72 (1H, m, H-5b), 3.84 (1H, m, H-2b), 3.95 (2H, m, H-2a, 
H-6a), 4.14 (3H, m, H-5a, H-6b, H-6a’), 4.30 (2H, m, H-3a, H-6b’), 4.99 (1H, d, J1b,2b 
8.6 Hz, H-1b), 5.11 (1H, at, J 10.2 Hz, H-4b), 5.32 (1H, at, J 10.5 Hz, H-3b) 5.50 – 
5.67 (2H, m, H-4a, NH), 5.66 (1H, d, J1a,2a 3.6 Hz, H-1a), 7.20 (2H, m, OC6H4NO2), 








4,6-di-O-acetyl-2-azido-2-deoxy-α-D-galactopyranoside 3.35 (160 mg, 0.216 mmol) 
was dissolved in dry pyridine (2 mL). Thioacetic acid (1.5 mL, 20.9 mmol) was added 
and the reaction was stirred at rt. After 49 h, t.l.c. (ethyl acetate/toluene, 1:1) indicated 
complete consumption of starting material (Rf 0.6) and the formation of a major product 
(Rf 0.1). The reaction mixture was diluted with DCM (50 mL) and the organic phase 




carbonate (100 mL of a saturation solution), brine (100 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(ethyl acetate→ethyl acetate/MeOH (9:1)) to give a white powder which was used 
directly for the next step. The residue was dissolved in dry methanol (10 mL) and 
methanolic sodium methoxide (10 mL of a 0.1 M solution) was added and the reaction 
mixture stirred for 1 h, at which point t.l.c. (ethyl acetate/toluene, 1:1) indicated 
complete consumption of starting material (Rf 0.1) and formation of a single product 
(Rf 0). The reaction mixture was neutralized with Amberlite
® IR120 (H+), filtered, and 
concentrated in vacuo. The residue was purified by RP HPLC (column: Phenomenex 
Luna 5U C18 100 Å (250 x 10 mm x 10 µm); eluent: linear gradient of MeCN using a 
gradient method, 10-100% MeCN; flow rate: 3.5 mLmin-1; column oven: 40 °C; 
detection: UV 210 nm) and concentrated in vacuo to give p-nitrophenyl 2-acetamido-
2-deoxy-β-D-glucopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-galactopyranoside 
3.14 (10 mg, 11 %) as a white solid; HPLC: tR = 9.63 min; m.p. 215-220 °C; [α]D
20 
+237 (c, 0.6 in H2O); δH (400 MHz, CDCl3)
16 1.92 (3H, s, CH3CO2), 2.11 (3H, s, 
CH3CO2), 3.35-3.39 (2H, m, H-4b, H-5b), 3.47 (1H, at, J 7.8 Hz, H-3b), 3.54-3.69 (4H, 
m, H-2b, H-6a, H-6a’, H-6b), 3.78-3.82 (1H, m, H-6b’), 3.87 (1H, m, H-5a), 4.12 (1H, 
dd, J2,3 10.9 Hz, J3,4 2.7 Hz, H-3a), 4.39 (1H, dd, J1,2 3.9 Hz, H-2a), 4.55 (1H, d, J1,2 
8.3 Hz, H-1b), 5.66 (1H, d, H-1a), 7.15 (2H, d, J 9.3 Hz, OC6H4NO2), 8.15 (2H, d, J 
9.3 Hz, OC6H4NO2); HRMS (ESI) Calcd. For C22H31N3O13 (MNa














galactopyranoside (10 mg, 37.99 µmol) was dissolved in sodium acetate buffer (100 
µL of a 25 mM, pH 6.0 solution). EngEF (2 µL of a 1.5 mg/mL solution) was added 
and the reaction mixture was incubated at 37 ºC. The reaction mixture was analysed by 
HPLC and UV until the complete disappearance of starting material after 1 h. The 
product was isolated by RP-HPLC (column: Phenomenex Luna 5U C18 100 Å (250 x 
10 mm x 10 µm); eluent A: water, eluent B: MeCN; 0-9 min: 100% A, 9-12 min 100% 
B, 12-15 min: 100 % A, 15-20 min: 10% A; flow rate: 2.0 mLmin-1; column oven: 15 
°C; detection: CAD) to give β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-D-
galactopyranose 3.37 (15 mg, 99 %) as a white solid; tR = 7.22 min (α anomer), 8.08 
min (β anomer); νmax (neat) 3298 (s, OH), 1625 (s, C=O) cm
-1; δH (400 MHz, D2O) 1.89 
(6H, s, 2 x CO2CH3), 3.36-3.41 (2H, m, H-2bα, H-2bβ), 3.46-3.54 (10H, m, H-6aα, H-
6’aα, H-6aβ, H-6’aβ, H-6bα, H-6b’β,H-6bβ, H-6’β), 3.57 (6H, m, H-3bα, H-3bβ, H-5aα, H-
5aβ, H-5bα, H-5bβ), 3.72 (1H, dd, J2,3 11 Hz, J3,4 3.6 Hz, H-3aα), 3.78 (1H, m, H-4bβ), 
3.85 (1H, m, H-3aβ), 3.89 (1H, dd, J1,2 3.9 Hz, J2,3 10.9 Hz, H-2aα), 4.00 (1H, at, J 6.3 
Hz, H-4bα), 4.04 (1H, d, J 3.1 Hz, H-4aβ), 4.11 (1H, d, J 3.1 Hz, H-4aα), 4.16 (1H, dd, 
J1,2 3.9 Hz, H-2aα), 4.30 (1H, d, J1,2 7.9 Hz, H-1bα), 4.36 (1H, d, J1,2 7.9 Hz, H-1bβ), 
4.56 (1H, d, J1,2 9.0 Hz, H-1aβ), 5.07 (1H, d, J1,2 3.6 Hz, H-1aα); δC (100 MHz, D2O) 
21.9, 22.2 (q, 2 x CH3), 48.9 (d,  C-2aα), 52.4 (d C-2aβ), 60.9, 60.9, 61.1, 62.7 (4 x t, 4 




50.6 (d, C-2bα), 72.4 (d, C-3bβ), 72.5 (d, C-2bβ), 74.8 (d, C-5bα), 74.9 (d, C-5bβ), 77.0 
(d, C-4bα), 80.0 (d, C-4bβ), 91.1 (d, C-1aα), 95.1 (d, C-1aβ), 104.6 (d, C-1bα), 104.8 (d, 
C-1bβ), 174.6, 174.9 (2 x s, 2 x C=O); HRMS (ESI) Calcd. For C14H25NO11 (MNa
+) 







 (5 mg, 13.0 µmol), triethylamine (16.3 μL, 117 µmol), and thioacetic acid (4.7 μL, 
65.2 µmol) were stirred in D2O (52.2 μL) and cooled to 0 °C. 2-Chloro-1,3-
dimethylimidazolinium chloride (6.64 µg, 39.1 µmol) dissolved in MeCN (10 µL) was 
added in 2 µL portions. After 30 mins, the reaction mixture was diluted with water (400 
µL), washed with DCM (2 x 400 µL), filtered through a column of Amberlite® IR120 
(H+) previously activated by 1M NaOH solution, and then lyophilized. The product was 
purified by semi-preparative RP (column: Phenomenex Luna 5U C18 100 Å (250 x 10 
mm x 10 µm); eluent A: water, eluent B: MeCN; 0-30 min: 100% A, 30-40 min 100% 
B, 40-60 min: 100 % A, 60-70 min: 100% A; flow rate: 1.0 mLmin-1; column oven: 15 
°C; detection: CAD) to afford 1-O-acetyl-β-D-galactopyranosyl-(1→3)-2-acetamido-2-
deoxy-D-galactopyranose (4.8 mg, 87 %) as a white foam (α/β, 1:1.1), tR (α anomer) = 
42.89 mins; tR (β anomer) = 46.35 mins; νmax (neat) 3304 (s, OH), 2929 (s, CH), 1738 
(s, C=O), 1593 (s, N-H) cm-1; δH (400 MHz, D2O) (α anomer) 1.86 (3H, s, NHCOCH3), 




H-6a’, H-6b, H-6b’), 3.78 (1H, m, H-4b), 3.97 (1H, m, H-4a), 4.17 (1H, m, H-3a), 4.33-
4.36 (2H, m, H-1b, H-2a), 5.96 (1H, d, J1a,2a 3.5 Hz, H-1a); (β anomer) 1.87 (3H, s, 
NHCOCH3), 2.00 (3H, s, COCH3), 3.37-3.49 (2H, m, H-2b, H-6a), 3.50-3.54 (2H, m, 
H-3b, H-6b), 3.61-3.71 (4H, m, H-5a, H-5b, H-6a’, H-6b’), 3.78 (1H, m, H-4b), 3.87 
(1H, dd, J2,3 11.0 Hz, J3,4 3.0 Hz, H-3a), 4.03-4.10 (2H, m, H-2a, H-4a), 4.33 (1H, d, 
J1b,2b 7.4 Hz, H-1b), 5.50 (1H, d, J1a,2a 9.0 Hz, H-1a); HRMS (ESI) Calcd. For 
C16H27NO12 (MNa






Experimental for Chapter 4 
Standard kinetic assay  
The standard assay for GH101 endo-α-N-acetylgalactosaminidase activity monitored 
the release of p-nitrophenol by gain of absorbance at 235 nm. All kinetic measurements 
were made using a Varian Cary 100 UV-visible spectrophotometer, stoppered 1 cm 
pathlength quartz cuvettes and a total assay volume of 1 mL. Standard assays were 
carried out at 37 °C and all assay solutions were equilibrated to temperature and 
baseline absorbance before initialisation. The enzymatic reaction was initiated by the 
addition of 2 μL of purified enzyme at a stock concentration of 2-3 mg/mL. Standard 
reaction mixtures contained 25 mM NaOAc buffered at pH 7.5, and a variable 
concentration of Galβ1,3GalNAc-α-pNP. Metal-ion solutions were created using Milli-
Q water. Initial rates of reaction were measured as a least-squares fit of the initial rate 
data using Cary WinUV Kinetics Application (version 3.00, Varian). The values of the 
kinetic parameters were determined by fitting data to the Michaelis-Menten equation 
using the software GraFit 5 (Erithacus Software Limited).  
 
Kinetic assay for glycosyl acetates 
Glycosyl acetates lack a chromophore which was problematic for determining the 
kinetic parameters for hydrolysis. The kinetic parameters could not be determined using 
UV spectroscopy. Therefore, the hydrolysis reaction was monitored using a charged 
aerosol detector, whereby initial rates of hydrolysis could be inferred by integrating the 
peak areas, calculating hydrolysis yield, and dividing by the time of the reaction to 
obtain a rate. The kinetic parameters were then obtained by fitting these experimental 






General endo-α-N-acetylgalactosaminidase-catalysed reaction procedure 
Activated glycoside (1 equiv) and acceptor (10 equiv) were dissolved in 25 mM NaOAc 
buffer (pH 6.0) and warmed to 37 ˚C. Enzyme was added and the reaction mixture was 
incubated for 16 h before quenching with 1 M NaOH. The reaction mixture was then 
analysed by RP-HPLC (column: Phenomenex Luna 5U C18 100 Å (250 x 10 mm x 10 
µm); eluent A: water, eluent B: MeCN; 0-30 min: 100% A, 30-40 min 100% B, 40-60 
min: 100 % A, 60-70 min: 100% A; flow rate: 1.0 mLmin-1; column oven: 15 °C; 
detection: CAD/UV 210 nm). 




N-Acetyl-D-galactosamine (20 mg, 0.09 mmol), triethylamine (125 μL, 0.9 mmol), and 
thioacetic acid (32 μL, 0.452 mmol) were stirred in D2O (500 μL) and cooled to 0 °C. 
2-Chloro-1,3-dimethylimidazolinium chloride (46 mg, 0.27 mmol) was added. After 30 
mins, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material 
(Rf 0.2) and the formation of a major product (Rf 0.5). The reaction mixture was diluted 
with water (10 mL), washed with DCM (5 x 20 mL), lyophilised to 1 mL, filtered 
through a column of Amberlite® IR120 (H+) previously activated by 1M NaOH 
solution, and then lyophilized. The product was purified by semi-preparative RP HPLC 




run at 1 mL/min for 40 mins; column oven: 40 °C; detection: CAD) to afford gave 
acetyl 2-acetamido-2-deoxy-D-galactopyranoside 4.1 & 4.2 (18 mg, 86 %) as a white 
foam (α/β, 1:1.1), tR = 11.65 mins; νmax (neat) 3273 (s, OH), 1742 (s, C=O), 1642 (s, N-
H) cm-1; δH (400 MHz, D2O) 1.91 (6H, s, α-NHCOCH3, β-NHCOCH3), 2.04 (3H, s, β-
COCH3), 2.08 (3H, s, α-COCH3), 3.63-3.68 (7H, H-4β, H-5α, H-5β, H-6α, H-6’α, H-
6β, H-6’β), 3.89-3.97 (4H, m, H-2α, H-3α, H-3β, H-4α), 4.20 (1H, m, H-2α), 5.49 (1H, 
d, J1,2 8.6 Hz, H-1β), 6.01 (1H, s, H-1α); δC (100 MHz, D2O) 20.2, 20.2, 21.7, 22.0 (4 
x q, 4 x CH3CO2), 48.7 (d, C-2α), 51.3 (d, C-2β), 60.7, 61.0 (2 x t, C-6α. C-6β), 67.2, 
67.5 (2 x d, C-3α, C-3β), 68.2, 70.4 (2 x d, C-4α, C-4β), 73.2, 76.1 (2 x d, C-5α, C-5β), 
91.2 (d, C-1α), 93.3 (d, C-1β), 172.4, 172.8, 174.8, 175.0 (4 x s, 4 x COCH3); HRMS 
(ESI) Calcd. For C10H17NO7 (MNa
+) 286.0903. Found 286.0904. 
 




N-Acetyl-D-galactosamine (5 g, 22.6 mmol) and triethylamine (15.6 mL, 113.0 mmol) 
were stirred in H2O/MeCN (4:1, 100 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate (19.3 g, 67.8 mmol) was added. After 3 
h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction mixture was 









addition of sat. NaHCO3 solution (100 mL). The reaction mixture was concentrated, 
and the residue dissolved in ethanol (20 mL), filtered through Celite®, and concentrated 
in vacuo. The residue was then redissolved in water (50 mL), washed with DCM (2 x 
50 mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 
1M NaOH solution), and concentrated in vacuo. Purification by flash column 
chromatography (CHCl3:MeOH, 7:1 → CHCl3:MeOH, 2:1) gave 2-acetamido-2-
deoxy-β-D-galactopyranosyl azide 4.3 (4.3 g, 77 %) as a white solid; m.p. 195-200 °C; 
[α]D
20 -16 (c, 1.0 in MeOH); νmax (neat) 1643 (s, amide), 2094 (s, azide), 3331.3 (bs, 
OH) cm-1; δH (400 MHz, D2O)
  1.94 (3H, s, CH3), 3.63-3.78 (4H, m, H-3, H-5, H-6, H-
6’), 3.80 (1H, at, J 10.2 Hz, H-2), 3.86 (1H, ad, J 3.1 Hz, H-4), 4.55 (1H, d, J1,2 9.4 Hz, 
H-1); δC (100 MHz, D2O) 22.1 (d, NHCOCH3), 51.7 (d, C-2), 60.9 (t, C-6), 67.6 (d, C-
4), 70.7 (d, C-3), 77.2 (d, C-5), 89.0 (d, C-1), 175.0 (s, NHCOCH3) HRMS (ESI) Calcd. 
For C8H14N4O5 (MNa








α-D-galactopyranoside (130 mg, 0.17 mmol) was dissolved in dry pyridine (5 mL). 




36 h, t.l.c. (ethyl acetate/toluene, 1:1) indicated complete consumption of starting 
material (Rf 0.7) and the formation of a major product (Rf 0.1). The reaction mixture 
was diluted with DCM (50 mL) and the organic phase was washed with hydrochloric 
acid (100 mL of a 1.2 M solution), sodium hydrogen carbonate (100 mL of a saturation 
solution), brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (ethyl acetate/toluene, 1:1) to 
give a white powder which was used directly for the next step. The residue was 
dissolved in dry methanol (10 mL) and methanolic sodium methoxide (10 mL of a 0.1 
M solution) was added and the reaction mixture stirred overnight, at which point t.l.c. 
(ethyl acetate/toluene, 1:1) indicated complete consumption of starting material (Rf 0.1) 
and formation of a single product (Rf 0). The reaction mixture was neutralized with 
Amberlite® IR120 (H+), filtered, and concentrated in vacuo. The residue was purified 
by RP HPLC (column: Phenomenex Luna 5U C18 100 Å (250 x 10 mm x 10 µm); 
eluent: linear gradient of MeCN using a gradient method, 10-100% MeCN; flow rate: 
3.5 mLmin-1; column oven: 40 °C; detection: UV 210 nm) and concentrated in vacuo 
to give p-nitrophenyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-
galactopyranoside 4.4 (6.4 mg, 9 %) as a white solid; HPLC: tR = 7.86 min; m.p. 200 
°C [lit. 212 – 214 °C]; [α]D
20 +11.3 (c, 0.5 in H2O) [lit. [α]D
23 +10.2 (c, 0.5 in H2O)]; 
δH (400 MHz, CDCl3) 1.92 (3H, s, CH3CO2), 3.47 (1H, at, J 7.8 Hz, H-2b), 3.55-3.85 
(8H, m, H-5a, H-6a, H-6a’, H-3b, H-4b, H-5b, H-6b, H-6b’), 3.91 (1H, m, H-4a), 4.20 
(1H, m, H-3a), 4.44-4.51 (2H, m, H-1b, H-2a), 5.74 (1H, d, J1a,2a 3.6 Hz, H-1a), 7.19 
(2H, d, J 9.4 Hz, OC6H4NO2), 8.17 (2H, d, J 9 Hz, OC6H4NO2); HRMS (ESI) Calcd. 
For C20H28N2O13 (MNa










β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-D-galactopyranose (5 mg, 13.0 
µmol), triethylamine (16.3 μL, 117 µmol), and thioacetic acid (4.7 μL, 65.2 µmol) were 
stirred in D2O (52.2 μL) and cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium 
chloride (6.64 µg, 39.1 µmol) dissolved in MeCN (10 µL) was added in 2 µL portions. 
After 30 mins, the reaction mixture was diluted with water (400 µL), washed with DCM 
(2 x 400 µL), filtered through a column of Amberlite® IR120 (H+) previously activated 
by 1M NaOH solution, and then lyophilized. The product was purified by semi-
preparative RP (column: Phenomenex Luna 5U C18 100 Å (250 x 10 mm x 10 µm); 
eluent A: water, eluent B: MeCN; 0-30 min: 100% A, 30-40 min 100% B, 40-60 min: 
100 % A, 60-70 min: 100% A; flow rate: 1.0 mLmin-1; column oven: 15 °C; detection: 
CAD) to afford gave 1-O-acetyl-β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-
D-galactopyranose (4.8 mg, 87 %) as a white foam (α/β, 1:1.1), tR (α anomer 4.7) = 
42.89 mins; tR (β anomer 4.8) = 46.35 mins; νmax (neat) 3304 (s, OH), 2929 (s, CH), 
1738 (s, C=O), 1593 (s, N-H) cm-1; δH (400 MHz, D2O) (α anomer) 1.86 (3H, s, 
NHCOCH3), 2.06 (3H, m, COCH3), 3.42 (1H, m, H-2b), 3.49-3.65 (7H, m, H-3b, H-
5a, H-5b, H-6a, H-6a’, H-6b, H-6b’), 3.78 (1H, m, H-4b), 3.97 (1H, m, H-4a), 4.17 (1H, 
m, H-3a), 4.33-4.36 (2H, m, H-1b, H-2a), 5.96 (1H, d, J1a,2a 3.5 Hz, H-1a); (β anomer) 




3.54 (2H, m, H-3b, H-6b), 3.61-3.71 (4H, m, H-5a, H-5b, H-6a’, H-6b’), 3.78 (1H, m, 
H-4b), 3.87 (1H, dd, J2,3 11.0 Hz, J3,4 3.0 Hz, H-3a), 4.03-4.10 (2H, m, H-2a, H-4a), 
4.33 (1H, d, J1b,2b 7.4 Hz, H-1b), 5.50 (1H, d, J1a,2a 9.0 Hz, H-1a); HRMS (ESI) Calcd. 
For C16H27NO12 (MNa












Experimental for Chapter 5 




1,3-Dimethylimidazolidinone (18.9 mL, 175 mmol) was dissolved in toluene (200 mL) 
and stirred under an N2 atmosphere. Oxalyl chloride (19.8 mL, 219 mmol) was added 
dropwise and the reaction was stirred at 50 °C. After 3 h, the flask was allowed to cool 
to rt and stirred overnight. After 18 h, the precipitate was filtered, washed with cold 
toluene and recrystallized (acetonitrile/diethyl ether). The white solid was filtered and 
dried under vacuum to yield 2-chloro-1,3-dimethylimidazolidinium chloride 5.1 (18.1 
g, 61 %) as a white powdery solid, m.p. 83-85 °C [lit. m.p. 95-100 °C];24 δH (400 MHz, 
CD3CN)
25 3.17 (6H, s, 2 x CH3), 4.02 (4H, s, 2 x CH2); δC (100 MHz, CD3CN)
25 34.4, 
50.0; HRMS (ESI) Calcd. For C5H10ClN2 (M
+) 133.0527. Found 133.0529. 
 




2-Chloro-1,3-dimethylimidazolidinium chloride 5.1 (4 g, 23.7 mmol) was dissolved in 




mmol) was added and the reaction stirred at rt. After 30 mins, the solution was filtered 
through Celite® and washed with acetonitrile (30 mL). The filtrate was concentrated in 
vacuo and the resultant solid was dissolved in a minimal amount of acetonitrile. Et2O 
was added until a precipitate formed, which was collected by suction filtration to afford 
2-chloro-1,3-dimethylimidazolinium hexafluorophosphate 5.2 (6.60 g, 99 %) as a white 
solid, m.p. 210 °C [lit. 230-231 °C];26 δH (400 MHz, CD3CN)
26 3.14 (6H, s, 2 x CH3), 
3.95 (4H, s, 2 x CH2); δC (100 MHz, CD3CN)
26 34.2, 49.8; δF (376.23 MHz, CD3CN) -
72.08 (d, J = 705.7 Hz, PF6); δP (161.86 MHz, CD3CN) -143.36 (sep, J = 706.6 Hz, 
PF6); HRMS (ESI) Calcd. For C5H10ClN2 (M
+) 133.0527. Found 133.0529. 
 




2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate 5.2 (6.60 g, 23.8 mmol) 
was dissolved in anhydrous acetonitrile (60 mL) and stirred at 60 °C under an N2 
atmosphere. KF (4.14 g, 71.2 mmol), which had been dried with a heat gun under 
vacuum, was added to the reaction mixture. After 4 h, the mixture was cooled to rt and 
filtered through Celite® washed with acetonitrile. The filtrate was concentrated in vacuo 
and the resulting solid dissolved in a minimal amount of acetonitrile. Et2O was added 
until a precipitate formed, which was collected by suction filtration to afford 2-fluoro-
1,3-dimethylimidazolinium hexafluorophosphate 5.3 (3.76 g, 60 %) as a white solid, 
m.p. 150-155 °C [lit. 168-169 °C];27 δH (400 MHz, CD3CN)




CH2), 3.02 (s, 6H, CH3); δC (100 MHz, CD3CN)
27 29.9 (s, CH3), 46.7 (s, CH2); δP 
(161.86 MHz, CD3CN) -143.4 (sep, J = 705.7 Hz, PF6); δF (376.23 MHz, CD3CN) -
73.0 (d, J = 705.7 Hz, PF6), -90.5 (s, C-F); HRMS (ESI) Calcd. For C5H10FN2 (M
+) 
117.0823. Found 117.0825. 
 




N-Acetyl-D-glucosamine 5.4 (1 g, 4.52 mmol) was suspended in acetyl chloride (100 
mL). After 22 h, t.l.c. (petrol:ethyl acetate, 1:2) indicated complete consumption of 
starting material (Rf 0) and the formation of two major products (Rf 0.2, 0.4). The 
reaction mixture was diluted with DCM (100 mL) and the organic phase was washed 
with ice-water (100 mL), sodium hydrogen carbonate (2 x 100 mL of a saturated 
solution), brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (ethyl acetate) to give 2-
acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride 5.7 (410 mg, 25 %) 
as a yellow oil, [α]D
20 +118  (c, 1.0 in CHCl3); δH (400 MHz, CDCl3)
28 1.98, 2.06, 2.10 
(12H, 3 x s, 4 x CH3CO), 4.15 (1H, m, H-6), 4.30, (2H, m, H-5, H-6’), 4.53 (1H, m, H-
2), 5.21 (1H, at, J 10.5 Hz, H-4), 5.31 (1H, at, J 9.8 Hz, H-3), 5.75 (1H, d, J2,NH 7 Hz, 













N-Acetyl-D-glucosamine 5.4 (500 mg, 2.26 mmol) and triethylamine (1.6 mL, 11.3 
mmol) were stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (1.9 g, 6.78 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction mixture was 
acidified to pH 2 by dropwise addition of aqueous 1.2 M HCl and then neutralized by 
addition of sat. NaHCO3 solution (10 mL). The reaction mixture was concentrated, and 
the residue dissolved in ethanol (20 mL), filtered through Celite®, and concentrated in 
vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 20 
mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 M 
NaOH solution), and concentrated in vacuo. Purification by flash column 
chromatography (CHCl3:MeOH, 5:1) gave 2-acetamido-2-deoxy-β-D-glucopyranosyl 
azide 5.9 (480 mg, 86 %) as a white solid; m.p. 125 - 130 °C; [α]D
20 -34 (c, 1.0 in 
MeOH); δH (400 MHz, D2O)
29  1.88 (3H, s, CH3), 3.32 (1H, m, H-4), 3.35-3.42 (2H, 
m, H-3, H-5), 3.53 (1H, at, J 9.5 Hz, H-2), 3.60 (1H, dd, J5,6 5.4 Hz, J6,6’ 12.2 Hz, H-
6), 3.75 (1H, m, H-6’), 4.58 (1H, d, J1,2 9.3 Hz, H-1); HRMS (ESI) Calcd. For 
C8H14N4O5 (MNa











2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate 5.2 (11.6 g, 41.64 mmol) 
was dissolved in anhydrous acetonitrile (120 mL) and stirred at 0 °C under an N2 
atmosphere. NaN3 (3.8 g, 58.5 mmol) was added to the reaction mixture. After 3 h, the 
mixture was filtered through Celite® washed with acetonitrile. The filtrate was 
concentrated in vacuo and the resulting solid dissolved in a minimal amount of 
acetonitrile. Et2O was added until a precipitate formed, which was collected by suction 
filtration to afford 2-azido-1,3-dimethylimidazolinium hexafluorophosphate 5.10 (11.8 
g, quant.) as a white solid, m.p. 200-205 °C [lit. 205-207 °C];26 δH (400 MHz, CD3CN)
26 
3.08 (s, 6H, CH3), 3.80 (s, 4H, CH2); δP (161.86 MHz, CD3CN); δF (376.23 MHz, 
CD3CN); HRMS (ESI) Calcd. For C5H10N5 (M






N-Acetyl-D-glucosamine 5.4 (500 mg, 2.26 mmol) and triethylamine (1.6 mL, 11.3 














dimethylimidazolinium hexafluorophosphate 5.10 (1.9 g, 6.78 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction mixture was 
acidified to pH 2 by dropwise addition of aqueous 1.2 M HCl and then neutralized by 
addition of sat. aqueous NaHCO3 (10 mL). Propargyl alcohol (0.3 mL, 4.52 mmol), 
CuSO4.5H2O (8.5 mg, 0.03 mmol), and L-ascorbic acid (80 mg, 0.45 mmol) were added 
and the reaction mixture was stirred at 50 °C for 14 h, after which time, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) and 
formation of a single product (Rf 0.2). The reaction mixture was concentrated, and the 
residue was dissolved in ethanol (20 mL), filtered through Celite®, and concentrated in 
vacuo. The residue was then redissolved in water, washed with DCM (2 x 20 mL), 
filtered through a column of Amberlite® IR120 (H+, previously treated by 1 M NaOH 
solution), and concentrated in vacuo. Purification by flash column chromatography 
(CHCl3:MeOH, 3:1) gave 1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-4-
hydroxymethyl-1,2,3-triazole 5.12 (580 mg, 85 %) as a white solid; m.p. 80-85 °C 
(CHCl3/MeOH); [α]D
20 -99 (c, 1.0 in MeOH); νmax (neat) 3268 (s, OH), 1650 (s, C=O), 
1548 (s, NH) cm-1; δH (400 MHz, D2O)
 1.67 (3H, s, NHCOCH3), 3.52-3.70 (4H, m, H-
3, H-4, H-5, H-6), 3.78 (1H, m, J 12.5 Hz, H-6’), 4.11 (1H, t, J 10 Hz, H-2), 4.56 (2H, 
s, CH2), 5.69 (1H, d, J1,2 9.8 Hz, H-1), 8.03 (1H, s, C=CH); δC (100 MHz, D2O) 21.5 
(q, C(O)CH3), 54.4 (t, CCH2OH), 55.3 (d, C-2), 60.3 (t, C-6), 69.2 (d, C-4), 73.4 (d, C-
3), 78.8 (d, C-5), 86.3 (d, C-1), 122.6 (s, CH=C), 147.0 (s, CH=C), 174.1 (s, 
NHCOCH3); HRMS (ESI) Calcd. For C11H18N4O6 (MNa












N-Acetyl-D-galactosamine 5.13 (500 mg, 2.26 mmol) and triethylamine (1.6 mL, 11.3 
mmol) were stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (1.9 g, 6.78 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction mixture was 
acidified to pH 2 by dropwise addition of 1.2 M HCl solution and then neutralized by 
addition of sat. NaHCO3 solution (10 mL). Propargyl alcohol (0.3 mL, 4.52 mmol), 
CuSO4.5H2O (8.5 mg, 0.03 mmol), and L-ascorbic acid (80 mg, 0.45 mmol) were added 
and the reaction mixture was stirred at 50 °C overnight, at which time, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) and 
formation of a single product (Rf 0.2). The reaction mixture was concentrated, and the 
residue was dissolved in ethanol (20 mL), filtered through Celite®, and concentrated in 
vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 20 
mL), filtered through a column of Amberlite® IR120 (H+) previously activated by 1 M 
NaOH solution, and concentrated in vacuo. Purification by flash column 
chromatography (CHCl3:MeOH, 3:1) gave 1-(2'-acetamido-2'-deoxy-β-D-
galactopyranosyl)-4-hydroxymethyl-1,2,3-triazole 5.14 (510 mg, 75 %) as a white 
solid; m.p. 95-100 °C; [α]D
20 +26 (c, 1.0 in MeOH); νmax (neat) 3284 (s, OH), 1648 (s, 
C=O), 1547 (s, NH) cm-1; δH (500 MHz, D2O)











H-6, H-6’), 3.83 (2H, m, H-3, H-5), 3.95 (1H, d, J 1.2 Hz, H-4), 4.28 (1H, t, J 10.6 Hz, 
H-2), 4.57 (2H, s, CH2), 5.62 (1H, d, J1,2 9.5 Hz, H-1), 8.07 (1H, s, C=CH); δC (125 
MHz, D2O) 21.6 (q, NHCOCH3), 51.9 (d, C-2), 54.4 (t, CH2), 60.8 (t, C-6), 67.6 (d, C-
4), 70.5 (d, C-5), 78.2 (d, C-3), 86.8 (d, C-1), 122.5 (d, CH=C), 147.0 (s, CH=C), 174.3 
(s, NHCOCH3); HRMS (ESI) Calcd. For C11H18N4O6 (MNa







D-Glucose 5.15 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
3 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). Propargyl alcohol (0.32 mL, 5.55 
mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 0.56 mmol) 
were added and the reaction mixture was stirred at 50 °C for 14 h, after which time, 
t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) 
and formation of a single product (Rf 0.2). The reaction mixture was concentrated, and 
the residue was dissolved in ethanol (20 mL), filtered through Celite®, and concentrated 
in vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 
20 mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 












chromatography (CHCl3:MeOH, 3:1) gave 1-(β-D-glucopyranosyl)-4-hydroxymethyl-
1,2,3-triazole 5.16 (530 mg, 73 %) as a white solid; m.p. 65-70 °C; [α]D
20 -4 (c, 1.0 in 
MeOH); νmax (neat) 3274 (s, OH) cm
-1; δH (500 MHz, D2O)
 3.48 (1H, at, J 9.3 Hz, H-
4), 3.55-3.66 (3H, m, H-3, H-5, H-6), 3.77 (1H, m, H-6’), 3.87 (1H, t, J 9.3 Hz, H-2), 
4.62 (2H, s, CH2), 5.61 (1H, d, J1,2 9.1 Hz, H-1), 8.07 (1H, s, C=CH); δC (125 MHz, 
D2O) 54.5 (t, CH2), 60.3 (t, C-6), 68.8 (d, C-4), 72.1 (d, C-2), 75.8 (d, C-3), 78.8 (d, C-
5), 87.3 (d, C-1), 123.2 (d, CH=C), 147.0 (s, CH=C); HRMS (ESI) Calcd. For 
C9H15N3O6 (MNa






D-Mannose 5.17 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
3 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). Propargyl alcohol (0.32 mL, 5.55 
mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 0.56 mmol) 
were added and the reaction mixture was stirred at 50 °C overnight, at which time, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) and 
formation of a single product (Rf 0.2). The reaction mixture was concentrated, and the 




vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 20 
mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 M 
NaOH solution), and concentrated in vacuo. Purification by flash column 
chromatography (CHCl3:MeOH, 3:1) gave 1-(α-D-mannopyranosyl)-4-
hydroxymethyl-1,2,3-triazole 5.18 (530 mg, 73 %) as a white solid; m.p. 45-50 °C; 
[α]D
20 +43 (c, 1.0 in MeOH); νmax (neat) 3276 (s, OH) cm
-1; δH (500 MHz, D2O)
 3.18 
(1H, m, H-5), 3.56 (1H, m, H-4), 3.53 (1H, m, H-6), 3.58 (1H, m, H-6’), 4.01 (1H, dd, 
J2,3 3.4 Hz, J3,4 9.0 Hz, H-3), 4.61 (2H, s, CH2), 4.65 (1H, m, H-2), 5.99 (1H, d, J1,2 0.7 
Hz, H-1), 8.01 (1H, s, C=CH); δC (125 MHz, D2O) 54.4 (t, CH2), 60.4 (t, C-6), 66.4 (d, 
C-4), 68.2 (d, C-2), 70.4 (d, C-3), 76.0 (d, C-5), 86.5 (d, C-1), 123.6 (d, CH=C), 147.1 
(s, CH=C); HRMS (ESI) Calcd. For C9H15N3O6 (MNa







Isomaltose 5.19 (250 mg, 0.73 mmol) and triethylamine (0.5 mL, 3.7 mmol) were 
stirred in D2O/MeCN (4:1, 5 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (630 mg, 2.2 mmol) was added. 
After 3 h, propargyl alcohol (85 μL, 1.5 mmol), CuSO4.5H2O (3 mg, 0.011 mmol), and 
L-ascorbic acid (30 mg, 0.15 mmol) were added and the reaction mixture was stirred at 




was dissolved in methanol (20 mL), filtered through Celite®, and concentrated in vacuo. 
The residue was then redissolved in water, washed with DCM (2 x 20 mL), filtered 
through a column of Amberlite® IR120 (H+, previously treated with 1 M NaOH 
solution), and concentrated in vacuo. Purification by flash column chromatography 
(CHCl3:MeOH, 3:1 → H2O:iPrOH:EtOAc, 1:6:3) gave 1-(6-O-α-D-glucopyranosyl-β-
D-glucopyranosyl)-4-hydroxymethyl-1,2,3-triazole 5.20 (267 mg, 86 %) as a white 
solid; m.p. 95-100 °C; [α]D
20 +61 (c, 1.0 in MeOH); νmax (neat) 3295 (s, OH), 1016 (s, 
O-C-O) cm-1; δH (500 MHz, D2O) 3.24 (1H, at, J 9.3 Hz, H-4b), 3.37 (1H, dd, J1b,2b 3.6 
Hz, J2b,3b 10.0 Hz, H-2b), 3.49 (3H, m, H-3b, H-6a, H-6’a), 3.54 (1H, m, H-5b), 3.56 
(2H, m, H-3a, H-4a), 3.72 (1H, m, H-6b), 3.81 (1H, m, H-6’b), 3.92 (1H, at, J 9.0 Hz, 
H-2a) , 4.61 (2H, s, CH2), 4.76 (1H, d, H-1b), 5.62 (1H, d, J1a,2a 9.3 Hz, H-1a), 8.08 
(1H, s, C=CH); δC (125 MHz, D2O) 54.4 (t, CH2), 60.0 (t, C-6a), 65.9 (t, C-6b), 68.9 
(d, C-4a), 69.1 (d, C-4b), 71.2 (d, C-2b), 71.6 (d, C-3b), 71.9 (d, C-2a), 72.9 (d, C-5b), 
76.0 (d, C-3a), 77.4 (d, C-5a), 87.2 (d, C-1a), 98.0 (d, C-1b), 123.4 (d, CH=C), 146.9 
(s, CH=C); HRMS (ESI) Calcd. For C15H24DN3O11 (MNa











Isomaltotriose 5.21 (125 mg, 0.25 mmol) and triethylamine (0.17 mL, 1.24 mmol) 
were stirred in D2O/MeCN (4:1, 2 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (210 mg, 0.74 mmol) was added. 
After 3 h, propargyl alcohol (27 μL, 0.50 mmol), CuSO4.5H2O (1 mg, 0.0037 mmol), 
and L-ascorbic acid (9 mg, 0.050 mmol) were added and the reaction mixture was 
stirred at 50 °C for 14 h, after which time, the reaction mixture was concentrated. The 
residue was dissolved in methanol (20 mL), filtered through Celite®, and concentrated 
in vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 
20 mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 
M NaOH solution), and concentrated in vacuo. The reaction mixture was purified by 
gel filtration on a column (8.7 x 1.7 cm) of Sephadex G-25 (pre-equilibrated and 
eluted with 0.01% ammonia) to give 1-[α-D-glucosyl-[1→6]-α-D-glucosyl-[1→6]-β-
D-glucopyranosyl)-4-hydroxymethyl-1,2,3-triazole 5.22 (128 mg, 88 %) as a white 
solid; m.p. 45-50  °C; [α]D
20 +34 (c, 0.45 in H2O); νmax (neat) 3273 (s, OH), 1008 (s, 
O-C-O) cm-1; δH (400 MHz, D2O) 3.27-3.43 (6H, m, H-2b, H-4b, H-6b, H-2c, H-3c, 
H-4c), 3.53-3.57 (4H, m, H-4a, H-3b, H-5b, H-5c), 3.60-3.77 (4H, m, H-3a, H-6a, H-
6’a, H-6’b), 3.80-3.83 (3H, m, H-5a, H-6c, H-6’c), 3.95 (1H, at, J 9.0 Hz, H-2a), 4.66 
(2H, s, CH2), 4.73 (1H, d, J1b,2b 3.5 Hz, H-1b), 4.80 (1H, d, J1c,2c 3.9 Hz, H-1c), 5.65 
(1H, d, J1a,2a 9.0 Hz, H-1a); 8.12 (1H, s, C=CH); δC (100 MHz, D2O) 54.6 (t, CH2), 
60.3 (t, C-6a), 64.9 (t, C-6b), 66.3 (t, C-6c), 69.1 (d, C-4c), 69.1 (d, C-4a) 69.4 (d, C-
4b), 70.1 (d, C-2c), 71.2 (d, C-2b), 71.4 (d, C-3c), 71.7 (d, C-3b), 71.9 (d, C-2a), 73.0 
(d, C-5b), 73.2 (d, C-5c), 76.0 (d, C-3a), 77.4 (d, C-5a), 87.3 (d, C-1a), 97.6 (d, C-1c), 
98.0 (d, C-1b), 123.8 (d, CH=C), 146.0 (s, CH=C); HRMS (ESI) Calcd. For 
C21H36N3O16 (MH









D-Glucose 5.15 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). 2-Methyl-3-butyn-2-ol (0.54 mL, 
5.55 mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 0.56 
mmol) were added and the reaction mixture was stirred at 50 °C for 14 h, after which 
time, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.5) and the formation of a single product (Rf 0.3). The reaction mixture was 
concentrated, and the residue was dissolved in ethanol (20 mL), filtered through 
Celite®, and concentrated in vacuo. The residue was then redissolved in water (10 mL), 
washed with DCM (2 x 20 mL), filtered through a column of Amberlite® IR120 (H+, 
previously treated with 1 M NaOH solution), and concentrated in vacuo. Purification 
by flash column chromatography (CHCl3:MeOH, 5:1 → CHCl3:MeOH, 2:1) gave 1-
(β-D-glucopyranosyl)-4-(dimethylhydroxy)methyl-1,2,3-triazole 5.23 (650 mg, 81 %) 
as a white solid; m.p. 45-50 °C; [α]D
20 +1 (c, 1.0 in MeOH); νmax (neat) 3288 (bs, OH) 
cm-1; δH (500 MHz, D2O)
 1.47 (6H, s, 2 x CH3), 3.47 (1H, at, J 9.6 Hz, H-4), 3.57 (1H, 
m, H-3), 3.61 (1H, m, H-5), 3.63 (1H, m, H-6), 3.76 (1H, dd, J5,6 1.8 Hz, J6,6’ 12.3 Hz, 
H-6’), 3.85 (1H, at, J 9.3 Hz, H-2), 5.58 (1H, d, J1,2 9.3 Hz, H-1), 8.01 (1H, s, C=CH); 











72.1 (d, C-2), 75.8 (d, C-3), 78.7 (d, C-5), 87.3 (d, C-1), 120.8 (d, CH=C), 154.9 (s, 
CH=C); HRMS (ESI) Calcd. For C11H19N3O6 (MH






D-Glucose 5.15 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
3 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). Propiolic acid (0.34 mL, 5.55 mmol), 
CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 0.56 mmol) were 
added and the reaction mixture was stirred at 50 °C for 14 h, after which time, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) and 
formation of a single product (Rf 0). The reaction mixture was concentrated, and the 
residue was dissolved in ethanol (20 mL), filtered through Celite®, and concentrated in 
vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 20 
mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 M 
NaOH solution), and concentrated in vacuo. Purification by reverse phase 
chromatography (H2O → H2O/MeOH, 9:1) gave 1-(β-D-glucopyranosyl)-4-carboxy-
1,2,3-triazole 5.24 (740 mg, 97 %) as a yellow solid; m.p. 45-50 °C; [α]D
20 -2 (c, 1.0 in 
H2O); νmax (neat) 3284 (bs, OH) cm
-1; δH (400 MHz, D2O)
 3.62 (1H, t, J 3.9 Hz, H-4), 




4.60 (2H, s, CH2), 5.71 (1H, d, J1,2 9.1 Hz, H-1), 8.40 (1H, s, C=CH); δC (125 MHz, 
D2O) 60.5 (t, C-6), 69.0 (d, C-4), 72.3 (d, C-2), 75.9 (d, C-5), 78.9 (d, C-3), 87.5 (d, C-
1), 126.6 (d, C=CH), 145.0 (s, C=CH), 167.3 (s, C=O); HRMS (ESI) Calcd. For 
C9H12DN3O7 (MNa






N-Acetyl-D-glucosamine 5.4 (500 mg, 2.26 mmol) and triethylamine (1.6 mL, 11.3 
mmol) were stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (1.9 g, 6.78 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction mixture was 
acidified to pH 2 by dropwise addition of 1.2 M aqeuous HCl and then neutralized by 
addition of sat. aqueous NaHCO3 (10 mL). 4-Pentyn-1-ol (0.42 mL, 4.52 mmol), 
CuSO4.5H2O (8.5 mg, 0.03 mmol), and L-ascorbic acid (80 mg, 0.45 mmol) were added 
and the reaction mixture was stirred at 50 °C for 14 h, after which time, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.5) and 
formation of a single product (Rf 0.3). The reaction mixture was concentrated, and the 
residue was dissolved in ethanol (20 mL), filtered through Celite®, and concentrated in 
vacuo. The residue was then redissolved in water (10 mL), washed with DCM (2 x 20 
mL), filtered through a column of Amberlite® IR120 (H+, previously treated with 1 M 












chromatography (CHCl3:MeOH, 3:1) gave 1-(2'-acetamido-2'-deoxy-β-D-
glucopyranosyl)-4-hydroxypropyl-1,2,3-triazole 5.25 (710 mg, 95 %) as a white solid; 
m.p. 55-60 °C; [α]D
20 -5 (c, 1.0 in MeOH); νmax (neat) 3261 (s, OH), 1648 (s, C=O), 
1548 (s, N-H) cm-1; δH (500 MHz, D2O)
 1.65 (3H, s, NHCOCH3), 1.72 (2H, t, J 7.1 Hz, 
CH2), 2.61 (2H, t, J 7.3 Hz, CH2), 3.42 (2H, t, J 6.4 Hz, CH2), 3.51-3.70 (4H, m, H-3, 
H-4, H-5, H-6), 3.77 (1H, m, H-6’), 4.07 (1H, t, J 9.8 Hz, H-2), 5.63 (1H, d, J1,2 9.6 Hz, 
H-1), 7.83 (1H, s, C=CH); δC (125 MHz, D2O) 20.8 (q, NHCOCH3), 21.5 (t, CH2), 30.8 
(t, CH2), 55.3 (d, C-2), 60.3 (t, C-6), 60.5 (t, CH2), 69.2 (d, C-4), 73.4 (d, C-3), 78.8 (d, 
C-5), 86.2 (d, C-1), 121.7 (d, CH=C), 147.9 (s, CH=C), 173.9 (s, C=O); HRMS (ESI) 
Calcd. For C13H22N4O6 (MNa






N-Acetyl-D-glucosamine 5.4 (130 mg, 0.59 mmol) and triethylamine (0.4 mL, 2.94 
mmol) were stirred in D2O/MeCN (4:1, 2 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (500 mg, 1.76 mmol) was added. 
After 1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting 
material (Rf 0.2) and the formation of two major products (Rf 0.5, 0.6). The reaction 
mixture was acidified to pH 2 by dropwise addition of 1.2 M aqueous HCl and then 
neutralized by addition of sat. aqueous NaHCO3 solution (10 mL). (S)-2-(Boc-amino)-




acid (21 mg, 0.12 mmol) were added and the reaction mixture was stirred at 50 °C for 
14 h, after which time, the reaction mixture was filtered through Celite®, and 
concentrated in vacuo. The residue was then redissolved in water, washed with DCM 
(2 x 20 mL), filtered through a column of Amberlite® IR120 (H+, previously activated 
by 1 M NaOH solution), and concentrated in vacuo. Purification by reverse phase 
chromatography (H2O → H2O/MeOH, 9:1) gave 1-(2'-acetamido-2'-deoxy-β-D-
glucopyranosyl)-4-((S)-2-(Boc-amino)-4-pentanoic acid)-1,2,3-triazole 5.26 (210 mg, 
78 %) as a white solid; m.p. 200-210 °C; [α]D
20 +15 (c, 1.0 in MeOH); νmax (neat) 3275 
(s, OH), 1709 (s, C=O) cm-1; δH (400 MHz, D2O) 1.22 (9H, s, Boc), 1.67 (3H, s, 
NHCOCH3), 2.85-3.11 (2H, m, CαHCH2), 3.52-3.69 (4H, m, H-3, H-4, H-5, H-6), 3.77 
(1H, d, H-6’), 4.10 (2H, m, H-2, CαHCH2), 5.65 (1H, d, J1,2 9.3 Hz, H-1), 7.84 (1H, s, 
C=CH); δC (100 MHz, D2O) 21.6 (q, NHCOCH3), 27.6 (t, CHCH2), 28.1 (q, C(CH3)3), 
55.3 (d, C-2), 60.4 (t, C-6), 69.2 (d, C-4), 73.6 (d, C-3), 78.8 (d, C-5), 81.1 (s, C(CH3)3), 
86.1 (d, C-1), 122.8 (d, CH=C), 144.2, 157.2, 174.0 (3 x s, 3 x C=O); HRMS (ESI) 
Calcd. For C18H29N5O9 (MNa






Diacetone galactose 5.28 (1.5 g, 7.56 mmol) and KOH (740 mg, 13.3 mmol) were 









mL, 13.3 mmol) was added dropwise and the reaction mixture was stirred 16 h, after 
which time, t.l.c (petrol/ethyl acetate, 3:1) indicated the complete consumption of 
starting material (Rf 0.1) and the formation of a major product (Rf 0.4). The reaction 
mixture was concentrated in vacuo. The residue was dissolved in DCM (20 mL), 
washed with brine (30 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
Purification by flash column chromatography (petrol/ethyl acetate, 4:1) gave 1,2:3,4-
di-O-isopropylidine-6-O-prop-2-yn-1-yl-α-D-galactopyranose 5.29 (1.3 g, 76 %) as a 
white solid; m.p. 50-55 °C; [α]D
20 -83 (c, 1.0, CHCl3); δH (400 MHz, CDCl3)
30 1.33, 
1.34, 1.45, 1.54 (12H, 4 x s, 4 x CH3), 2.42 (1H, t, J 2.4 Hz, H2CCCH, 3.67 (1H, dd, 
J5,6 7 Hz, J6,6’ 10.1 Hz, H-6), 3.77 (1H, dd, J5,6’ 5.4 Hz, H-6’), 4.01 (1H m, H-5), 4.22 
(2H, dd, J 2.4 Hz, 8.2 Hz, H2CCCH), 4.26 (1H, dd, J3,4 8.2 Hz, J4,5 2.3 Hz, H-4), 4.31 
(1H. dd, J1,2 5.1 Hz, J2,3 2.4 Hz, H-2), 4.60 (1H, dd, J2,3 2.4 Hz, J3,4 7.9 Hz, H-3), 5.54 
(1H, d, H-1); HRMS (ESI) Calcd. For C15H22O6 (MNa






1,2:3,4-Di-O-isopropylidine-6-O-prop-2-yn-1-yl-α-D-galactopyranose 5.29 (4.8 g, 
16.1 mmol) was stirred in water (100 mL). Dowex® 50WX8 (H+) (6 g) was added and 
the reaction mixture was heated at 80 °C and stirred overnight. The reaction mixture 
was then filtered, and lyophilized to give 6-O-prop-2-yn-yl-D-galactopyranose 5.30 








3.38 (1H, m, H-2β), 3.50-3.86 (11H, m, H-2α, H-3α, H-3β, H-4α, H-4β, H-5α, H-5β, 
H-6α, H-6β, H-6’α, H-6’β), 4.14 (4H, m, 2 x CH2CCH), 4.45 (1H, d, J1,2 7.8 Hz, H-
1β), 5.12 (1H, d, J1,2 3.5 Hz, H-1α); HRMS (ESI) Calcd. For C9H14O6 (MNa
+) 
241.0688. Found 241.0680. 
 




Penta-O-acetyl-β-D-glucopyranose (16 g, 41.00 mmol) and propargyl alcohol (4.8 mL, 
82.00 mmol) were stirred in dry DCM (400 mL) under an N2 atmosphere and the 
solution was cooled to 0 °C. Boron trifluoride diethyl etherate (6.1 mL, 49.2 mmol) was 
added, and the mixture was allowed to warm to room temperature. After 24 h, the 
reaction mixture was diluted with DCM (200 mL), washed with sodium hydrogen 
carbonate (2 x 500 mL of a saturated aqueous solution), brine (500 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was recrystallized (ethanol) to afford 
2’-propynyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 5.32 (12.5 g, 79 %) as a white 
crystalline solid; m.p. 100-105 °C [lit. 116-117 °C];31 [α]D
20 -49 (c, 1.0 in CHCl3) [lit. 
[α]D
23 –43.4 (c, 0.9 in CHCl3)];
31 δH (400 MHz, CDCl3)
31 2.00, 2.03, 2.06, 2.09 (12H, 
4 x s, 4 x CH3CO2), 2.47 (1H, t, J 2.3 Hz, CCH), 3.73 (1H, ddd, J4,5 7.0 Hz, J5,6 2.3 Hz, 
J5,6’ 4.7 Hz, H-5), 4.15 (1H, dd, J6,6’ 12.1 Hz, H-6), 4.27 (1H, dd, H-6’), 4.37 (2H, d, J 










(1H, t, J 9.3 Hz, H-3); HRMS (ESI) Calcd. For C17H22O10 (MNa







2’-Propynyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 5.32 (10 g, 25.9 mmol) was 
stirred in dry methanol (200 mL). Sodium metal (440 mg) was added portionwise. After 
1 h, t.l.c. (petrol:ethyl acetate, 1:1) indicated complete consumption of starting material 
(Rf 0.7) and the formation of a single product (Rf 0). The reaction mixture was 
neutralized with Dowex® 50WX8 (H+), filtered, and concentrated in vacuo to give 2’-
propynyl-β-D-glucopyranoside 5.33 (5.4 g, 96 %) as a yellow solid; m.p. 85-90 °C; 
[α]D
20 -97 (c, 1.0 in CH3OH) [lit. [α]D
23 –91.9 (c, 0.66 in CH3OH)];
32 δH (400 MHz, 
D2O)
32 2.79 (1H, t, J 2.3 Hz, CH2CH), 3.17 (1H, t, J 9.0 Hz, H-2), 3.26 (1H, m, H-4), 
3.32-3.41 (2H, m, H-3, H-5), 3.60 (1H, dd, J5,6 5.9 Hz, J6,6’ 12.5 Hz, H-6), 3.80 (1H, 
dd, J5,6’ 2.0 Hz, J6,6’ 12.5 Hz, H-6’), 4.34 (2H, t, J 2.3 Hz, CH2CH), 4.51 (1H, d, J1,2 8.2 
Hz, H-1); HRMS (ESI) Calcd. For C9H14O6 (MNa
















Sodium acetate (13.2 g, 161 mmol) was added to acetic anhydride (160 mL) and 
refluxed at 120 °C for 1 h. D-Lactose 5.34 (100 g, 292 mmol) was then added portion-
wise while the reaction mixture was vigorously stirred. After the final portion was 
added, the solution became clear and was allowed to stir for an additional 1 h. The 
reaction mixture was allowed to cool to rt, and then poured into ice-cold water (5 L). 
The product was then extracted with DCM (3 x 1 L), washed with sodium hydrogen 
carbonate (6 x 500 mL of a saturated solution), brine (2 x 500 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Recrystallization (ethanol) afforded 
1,2,3,6,2’,3’,4’,6’-Octa-O-acetyl-β-D-lactoside 5.35 (135 g, 68 %) as a white solid; 
m.p. 125-130 °C [lit. m.p. 140-143 °C];33 [α]D
20 -2 (c, 1.0 in CHCl3) [lit. [α]D
27 -4.0 (c, 
3.60 in CHCl3)];
33 δH (400 MHz, CDCl3)
33 1.96, 2.03, 2.04, 2.05, 2.07, 2.09, 2.12, 2.15 
(24H, 8 x s, 8 x CH3CO2), 3.76 (1H, m, H-5a), 3.86 (2H, m, H-4a, H-5b) 4.04-4.16 (3H, 
m, H-6a, H-6b, H-6b’), 4.43-4.49 (2H, m, H-1b, H-6a’), 4.94 (1H, dd, J2b,3b 10.2 Hz, 
J3b,4b 3.2 Hz, H-3b), 5.01-5.13 (2H, m, H-2a, H-2b), 5.24 (1H, at, J 9 Hz, H-3a), 5.34 
(1H, d, J 3.5 Hz, H-4b), 5.66 (1H, d, J1a,2a 8.3 Hz, H-1a); HRMS (ESI) Calcd. For 
C28H38O19 (MNa

















1,2,3,6,2’,3’,4’,6’-Octa-O-acetyl-β-D-lactoside 5.35 (24 g, 35.4 mmol) and propargyl 
alcohol (4.2 mL, 70.7 mmol) were stirred in dry DCM (300 mL) under an N2 
atmosphere and the solution was cooled to 0 °C. Boron trifluoride diethyl etherate (5.3 
mL, 42.4 mmol) was added and the mixture was allowed to warm to room temperature. 
After 16 h, the reaction mixture was diluted with DCM (300 mL), washed with 
saturated aqueous NaHCO3 (2 x 500 mL), brine (500 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification by flash column chromatography (petrol:ethyl 
acetate 3:2) afforded 1-(2’-propargyloxy)-2,3,5,6,2,3,4,6-hepta-O-acetyl-β-D-lactoside 
5.36 (10.6 g, 44 %) as a white crystalline solid; m.p. 155-160 °C [lit. 153-155 °C];35 
[α]D
20 -25 (c, 1.0 in CHCl3) [lit. [α]D
20 –23.8 (c, 1.0 in CHCl3)];
35 δH (400 MHz, 
CDCl3)
35 1.96, 2.04, 2.05, 2.06, 2.12, 2.15 (21H, 6 x s, 7 x CH3CO2), 2.44 (1H, t, J 2.3 
Hz, CH2CH), 3.63 (1H, m, H-5a), 3.78-3.88 (2H, m H-4a, H-5b), 4.07-4.14 (3H, m, H-
6a, H-6b, H-6b’), 4.32 (2H, d, J 2.4 Hz, CH2CH), 4.46-4.51 (2H, m, H-1b, H-6a’), 4.73 
(1H, d, J1a,2a 7.8 Hz, H-1a), 4.88-4.97 (2H, m, H-2a, H-3b), 5.10 (1H, dd, J2b,3b 10.2 Hz, 
H-2a), 5.22 (1H, at, J 9.0 Hz, H-3a) 5.33 (1H, d, J 3.5 Hz, H-4b); HRMS (ESI) Calcd. 
For C29H38O18 (MNa

















1-(2’-Propargyloxy)-2,3,5,6,2,3,4,6-hepta-O-acetyl-β-D-lactoside 5.36 (10 g, 16.7 
mmol) was stirred in dry methanol (300 mL), and sodium metal (660 mg) was added 
portionwise. After 15 h, t.l.c. (ethyl acetate) indicated complete consumption of starting 
material (Rf 0.7) and the formation of a single product (Rf 0). The reaction mixture was 
neutralized with Amberlite® IR120 (H+), filtered, and concentrated in vacuo to give 2’-
propargyloxy-β-D-lactoside 5.37 (5.7 g, quant.) as a white powder, m.p. 100-105 °C; 
[α]D
20 -39 (c, 1.0 in MeOH) δH (400 MHz, D2O)
34 2.81 (1H, m, CH2CCH), 3.23 (1H, 
at, J 7.8 Hz, H-2a), 3.43 (1H, t, J 9.0 Hz, H-2b), 3.51-3.58 (4H, m, H-3a, H-3b, H-5a, 
H-5b), 3.60-3.72 (4H, m, H-4a, H-6a, H-6a’, H-6b), 3.81-3.89 (2H, m, H-4b, H-6b’), 
4.34 (1H, d, J1b,2b 8.6 Hz, H-1b), 4.36 (2H, bs, CH2CCH), 4.56 (1H, d, J1a,2a 7.9 Hz, H-
1a); HRMS (ESI) Calcd. For C15H24O11 (MNa























D-Glucose 5.15 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). Propargyl ether (86 μL, 0.834 mmol), 
CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 0.56 mmol) were 
added and the reaction mixture was stirred at 50 °C for 14 h, after which time, t.l.c. 
(H2O/iPrOH/EtOAc, 1:6:3) indicated complete consumption of starting material (Rf 
0.8) and the formation of a single product (Rf 0.2). The reaction mixture was 
concentrated, and the residue was dissolved in ethanol (20 mL), filtered through 
Celite®, and concentrated in vacuo. The residue was then redissolved in water (10 mL), 
washed with DCM (2 x 20 mL), filtered through a column of Amberlite® IR120 (H+, 
previously treated with 1 M NaOH solution, and concentrated in vacuo. Purification by 
flash column chromatography (CHCl3:MeOH, 3:1 → H2O:iPrOH:EtOAc, 1:6:3) gave 
bis(1-(β-D-glucopyranosyl)-1,2,3-triazol-4-methyl)ether 5.38 (350 mg, 84 %) as a 
white solid; m.p. 125-130 °C; [α]D
20 -4 (c, 1.0 in MeOH); νmax (neat) 3271 (bs, OH), 
1030 (s, C-O-C) cm-1; δH (500 MHz, D2O)
 3.53 (2H, at J 9.4 Hz, 2 x H-4), 3.56 (2H, 
m, 2 x H-3), 3.58 (2H, m, 2 x H-5), 3.62 (2H, m, 2 x H-6), 3.78 (2H, m, 2 x H-6’) 3.89 




(2H, s, 2 x C=CH); δC (125 MHz, D2O) 60.3 (t, 2 x C-6), 62.2 (t, 2 x CH2), 68.8 (d, 2 x 
C-4) 72.1 (d, 2 x C-2), 75.7 (d, 2 x C-3), 78.8 (d, 2 x C-5), 87.3 (d, 2 x C-1), 124.4 (d, 
2 x C=CH), 143.7 (s, 2 x C=CH); HRMS (ESI) Calcd. For C18H27D2N6O11 (MH
+) 







D-Glucose 5.15 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). 6-O-Prop-2-yn-1-yl-D-
galactopyranose 5.30 (1.2 g, 5.56 mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-
ascorbic acid (100 mg, 0.56 mmol) were added and the reaction mixture was stirred at 
50 °C for 14 h, after which time, t.l.c. (CHCl3/MeOH, 2:1) indicated complete 
consumption of starting material (Rf 0.5) and the formation of a single product (Rf 0.1). 
The reaction mixture was then concentrated, and the residue was dissolved in methanol 
(20 mL), filtered through Celite®, and concentrated in vacuo. The residue was then 
redissolved in water (10 mL), washed with DCM (2 x 20 mL), filtered through a column 




concentrated in vacuo. Purification by flash column chromatography (CHCl3:MeOH, 
3:1 → H2O:iPrOH:EtOAc, 1:6:3) gave methyl 6-O-[1’(β-D-glucopyranosyl)-[1’,2’,3’]-
triazoly-4’-yl]-α/β-D-galactopyranose 5.39 (910 mg, 80 %) as a white solid; m.p. 40-
45 °C; νmax (neat) 3258 (s, OH), 1018 (s, C-O-C) cm
-1; δH (500 MHz, D2O) 3.29 (1H, 
at, J 7.9 Hz, H-2βGal), 3.45-3.79 (14H, m, H-4Glc, H-5Glc, H-6Glc, H-6’Glc, H2Galα, H-3Galα, 
H-3Galβ, H-4 Galβ, H-5 Galα, H-5 Galβ, H-6 Galα, H-6 Galβ, H-6’ Galα, H-6’ Galβ), 3.85 (1H, at, J 
9.3 Hz, H-2Glc), 4.06 (1H, at, J 6.6 Hz, H-4Galα), 4.40 (1H, J1,2 7.8 Hz, H-1Galβ), 4.60 
(2H, s, CH2), 5.08 (1H, d, J1,2 3.4 Hz, H-1Galα), 5.61 (1H, d, J1,2 9.3 Hz, H-1Glc), 8.13 
(1H, s, C=CH); δC (125 MHz, D2O) 60.3 (t, C-6Glc), 63.2 (t, CH2), 68.1 (d, C-2Galα), 
68.6 (d, C-4Glc), 68.8, 68.9 (2 x d, C-4 Galαβ), 69.3 (t, C-2, C-6 Galαβ), 69.4 (t, C-6 Galαβ), 
69.6 (d, C-2Galα), 71.6 (d, C-2 Galβ), 72.1 (d, C-2Glc), 72.6, 73.2 (d, C-5Galα, C-5Galβ), 75.8 
(d, C-3Glc), 78.8 (d, C-5Glc),  87.3 (d, C-1Glc), 92.2 (d, C-1Galα), 96.3 (d, C-1Galβ), 124.4 









D-Glucose 5.4 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-




1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). Prop-2-yn-1-yl β-D-glucopyranoside 
5.33 (1.2 g, 5.56 mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 
mg, 0.56 mmol) were added and the reaction mixture was stirred at 50 °C for 14 h, after 
which time, t.l.c. (H2O/iPrOH/EtOAc, 1:6:3) indicated complete consumption of 
starting material (Rf 0.8) and formation of a single product (Rf 0.2). The reaction 
mixture was concentrated, and the residue was dissolved in ethanol (20 mL), filtered 
through Celite®, and concentrated in vacuo. The residue was then redissolved in water, 
washed with DCM (2 x 20 mL), filtered through a column of Amberlite® IR120 (H+, 
previously treated with 1 M NaOH solution), and concentrated in vacuo. Purification 
by flash column chromatography (CHCl3:MeOH, 3:1 → H2O:iPrOH:EtOAc, 1:6:3) 
gave methyl (1’-(β-D-glucopyranosyl)-[1’,2’,3’]-triazoly-4’-yl)-β-D-glucopyranoside 
5.40 (950 mg, 84 %) as a white solid; m.p. 65-70 °C; [α]D
20 -21 (c, 1.0 in MeOH); νmax 
(neat) 3273 (s, OH), 1030 (s, O-C-O) cm-1; δH (500 MHz, D2O)
 3.12 (1H, at, J 8.6 Hz, 
H-2b), 3.22 (1H, at, J 9.5 Hz, H-3b), 3.29-3.33 (2H, m, H-4a, H-4b), 3.44-3.64 (5H, m, 
H-3a, H-5a, H-5b, H-6a, H-6b), 3.75 (2H, m, H-6a’, H-6b’), 3.84 (1H, at, J 12.7 Hz, H-
2a), 4.40 (1H, d, J1b,2b 7.9 Hz, H-1b), 4.80 (2H, m, CH2), 5.61 (1H, d, J1a,2a 9.0 Hz, H-
1a), 8.14 (1H, s, C=CH); δC (125 MHz, D2O) 60.3 (t, C-6a), 60.8 (t, C-6b), 61.8 (t, 
CH2), 68.6 (d, C-4a), 69.4 (d, C-4b), 72.1 (d, C-2a), 72.9 (d, C-2b), 75.6 (d, C-5a), 75.8 
(d, C-5b), 75.8 (d, C-3a), 78.8 (d, C-3b), 87.3 (d, C-1a), 101.4 (d, C-1b) 124.6 (d, 













D-Glucose 5.4 (500 mg, 2.78 mmol) and triethylamine (1.9 mL, 13.9 mmol) were 
stirred in D2O/MeCN (4:1, 10 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (2.4 g, 8.33 mmol) was added. After 
1 h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.5). 2’-Propargyloxy-β-lactoside 5.37 
(840 mg, 2.21 mmol), CuSO4.5H2O (10 mg, 0.04 mmol), and L-ascorbic acid (100 mg, 
0.56 mmol) were added and the reaction mixture was stirred at 50 °C for 14 h, after 
which time, t.l.c. (CHCl3:MeOH, 2:1) indicated complete consumption of starting 
material (Rf 0.5) and formation of a single product (Rf 0). The reaction mixture was 
filtered through a column of Amberlite® IR120 (H+, previously treated with 1 M NaOH 
solution, and concentrated in vacuo. The reaction mixture was purified by gel filtration 
on a column (8.7 x 1.7 cm) of Sephadex G-25 (pre-equilibrated and eluted with 0.01% 
ammonia) to give methyl (1’(β-D-glucopyranosyl)-[1’,2’,3’]-triazoly-4’-yl)-β-D-
lactopyranoside 5.41 (990 mg, 75 %) as a white solid; m.p. 100-105 °C; [α]D
20 -4 (c, 
1.0 in H2O); νmax (neat) 3270 (s, OH), 1031 (s, O-C-O) cm
-1; δH (500 MHz, D2O)
 3.18 
(1H, at, J 8.3 Hz, H-2c), 3.38 (1H, at, J 7.8 Hz, H-2b), 3.48-3.50 (5H, m, H-3b, H-3c, 
H-4b, H-4c, H-5a, H-5b), 3.57 (2H, m, H-3a, H-5c), 3.61-3.66 (4H, m, H-6a, H-6b, H-
6’b, H-6c), 3.77 (1H, m, H-6’a), 3.81 (1H, m, H-6’c), 3.86 (1H, at, J 9.2 Hz, H-2a), 




CH2), 5.61 (1H, d, J1a,2a 9.0 Hz, H-1a), 8.16 (1H, s, C=CH); δC (125 MHz, D2O) 59.9 
(t, C-6c), 60.3 (t, C-6a), 60.9 (t, C-6b), 61.9 (t, CH2), 68.4 (d, C-4c), 68.8 (d, C-4b), 
70.9 (d, C-2c), 72.2 (d, C-2a), 72.4 (d, C-4a), 72.6 (d, C-2b), 74.2 (d, C-5a), 74.7 (d, C-
5b), 75.3 (d, C-5c), 75.8 (d, C-3a), 78.1 (d, C-3b), 78.8 (d, C-3c), 87.3 (d, C-1a), 101.3 
(d, C-1b), 102.8 (d, C-1c), 124.5 (d, CH=C), 143.9 (s, CH=C); HRMS (ESI) Calcd. For 
C21H35N3O16 (MNa









Isomaltotriose 5.21 (100 mg, 0.20 mmol) and triethylamine (0.14 mL, 0.99 mmol) were 
stirred in D2O/MeCN (4:1, 2 mL) and cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 5.10 (170 mg, 0.60 mmol) was added. 
After 1 h, 2’-propargyloxy-β-lactoside 5.37 (150 mg, 0.40 mmol), CuSO4.5H2O (1 mg, 
3 μmol), and L-ascorbic acid (7 mg, 0.04 mmol) were added and the reaction mixture 
was stirred at 50 °C overnight. The reaction mixture was then filtered through a column 
of Amberlite® IR120 (H+, previously treated with 1 M NaOH solution, and concentrated 
in vacuo. The reaction mixture was purified by gel filtration on a column (8.7 x 1.7 cm) 
of Sephadex G-25 (pre-equilibrated and eluted with 0.01% ammonia) to give methyl 
(1’-(α-D-glucosyl-[1→6]-α-D-glucosyl-[1→6]-β-D-glucopyranosyl)-[1’,2’,3’]-
triazoly-4’-yl)-β-D-lactopyranoside 5.42 (145 mg, 81 %) as a white solid, m.p. 180-185 
°C; [α]D
20 +52 (c, 1.0 in H2O); νmax (neat) 3313 (bs, OH), 1019 (s, O-C-O) cm
-1; δH (400 
MHz, D2O) 3.19 (1H, at, J 8.6 Hz, H-2b’), 3.25-4.43 (4H, m, H-2b, H-4b, H-2a’, H-
3a’), 3.46-3.69 (18H, m, H-3a, H-4a, H-6a, H-6’a, H-3b, H-5b, H-6’, H-6’b, H-2c, H-
3c, H-4c, H-5c, H-4a’, H-5a’, H-6a’, H-6’a’, H-3b’, H-5’b), 3.76-3.82 (5H, m, H-5a, 




H-1b’), 4.46 (1H, d, J1a’2a’ 8.1 Hz, H-1a’), 4.71 (1H, d, J1c,2c 3.7 Hz, H-1c), 4.77-4.90 
(3H, m, H-1b, CH2), 5.64 (1H, d, J1a,2a 9.0 Hz, H-1a), 8.21 (1H, s, C=CH); δC (100 
MHz, D2O) 60.0 (t, C-6b’), 60.4 (t, C-6a), 61.0 (t, C-6a’), 62.0 (t, CH2), 65.0 (d, C-6b) 
66.3 (t, C-6c), 68.5 (d, C-4b’), 69.1 (d, C-4c), 69.2 (d, C-4a’), 69.4 (d, C-4b), 70.1 (d, 
C-2c), 70.9 (d, C-2b’), 71.2 (d, C-2b), 71.4 (d, C-3c), 71.7 (d, C-3b), 72.0 (d, C-2a), 
72.5 (d, C-4a), 72.7 (d, C-2a’), 73.1 (d, C-5b), 73.2 (d, C-5c), 74.3 (d, C-3a’), 74.8 (d, 
C-5a’), 75.3 (d, C-5b’), 76.1 (d, C-3a), 77.5 (d, C-5a), 78.2 (d, C-3b’), 87.3 (d, C-1a), 
97.7 (d, C-1c), 98.1 (d, C-1b), 101.4 (d, C-1a), 102.9 (d, C-1b’), 124.8 (d, CH=C) 143.9 
(s, CH=C); HRMS (ESI) Calcd. For C33H55N3O26 (MNa
+) 932.2971. Found 932.2967. 
 




N-Acetyl-D-galactosamine 5.13 (0.52 mg, 2.33 μmol) and triethylamine (1.6 μL, 11.6 
μmol) were dissolved in D2O (7.46 μL). 2-Azido-1,3-dimethylimidazolinium 
hexafluorophosphate 5.10 (2 mg, 6.99 μmol) dissolved in MeCN (1.86 μL) was added 
and the reaction mixture was incubated at rt for 6 h, at which time, 1.2 M HCl (10 μL) 
was added until the solution was acidic (pH 2), followed by sat. NaHCO3 (9.5 μL). 
Then, peptide 5.43 (1 mg, 1.16 μmol) dissolved in water (10 μL), CuSO4.5H2O (250 
μg, 1 μmol), and L-ascorbic acid (180 μg, 1 μmol) were added and the reaction mixture 
was stirred at 50 °C for 14 h, after which time, the crude product was isolated by 




A (0.05% TFA in H2O) and B (0.1% TFA in MeCN); gradient: sample was run at 1 
mL/min with a gradient of 5-65% B over 40 mins; column oven: 40 °C; detection: UV 
235 nm) to afford compound 5.45 (0.6 mg, 47 %) as a white solid; HRMS (ESI) Calcd. 
For C47H72N14O17 (MH
+) 1105.5278. Found 1105.5253. 
 




N-Acetyl-D-galactosamine 5.13 (0.47 mg, 2.13 μmol) and triethylamine (1.48 μL, 10.7 
μmol) were dissolved in D2O (6.8 μL). 2-Azido-1,3-dimethylimidazolinium 
hexafluorophosphate 5.10 (1.8 mg, 6.4 μmol) dissolved in MeCN (1.7 μL) was added 
and the reaction mixture was incubated at rt for 6 h, at which time, 1.2 M HCl (7 μL) 
was added until the solution was acidic (pH 2), followed by sat. NaHCO3 (13.4 μL). 
Then, peptide 5.44 (1 mg, 0.53 μmol) dissolved in water (10 μL), CuSO4.5H2O (250 
μg, 1 μmol), and L-ascorbic acid (180 μg, 1 μmol) were added and the reaction mixture 
was stirred at 50 °C for 14 h, after which time, the crude product was isolated by 
analytical RP HPLC (column: Jupiter 5U C18 (300 Å) column (Phenomenex); eluent: 
A (0.05% TFA in H2O) and B (0.1% TFA in MeCN); gradient: sample was run at 1 
mL/min with a gradient of 5-65% B over 40 mins; column oven: 40 °C; detection: UV 
235 nm) to afford compound 5.46 (600 μg, 46%) as a white solid; HRMS (ESI) Calcd. 
For C98H151N33O36 (MH





Click Neoglycopeptide 5.48 
 
 
Tetrasaccharide 5.47 (1.6 mg, 2.33 μmol) and triethylamine (1.6 μL, 11.6 μmol) were 
dissolved in D2O (7.46 μL). 2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 
5.10 (2 mg, 6.99 μmol) dissolved in MeCN (1.86 μL) was added and the reaction 
mixture was incubated at rt for 6 h, at which time, 1.2 M HCl (10 μL) was added until 
the solution was acidic (pH 2), followed by sat. NaHCO3 (9.5 μL). Then, peptide 5.43 
(1 mg, 1.16 μmol) dissolved in water (10 μL), CuSO4.5H2O (250 μg, 1 μmol), and L-
ascorbic acid (180 μg, 1 μmol) were added and the reaction mixture was stirred at 50 
°C for 14 h, after which time, the crude product was isolated by analytical RP HPLC 
(column: Jupiter 5U C18 (300 Å) column (Phenomenex); eluent: A (0.05% TFA in 
H2O) and B (0.1% TFA in MeCN); gradient: sample was run at 1 mL/min with a 
gradient of 5-65% B over 40 mins; column oven: 40 °C; detection: UV 235 nm) to 
afford compound 5.48 (0.5 mg, 27 %) as a white solid; HRMS (ESI) Calcd. For 
C65H101DN14O32 (MH









Click Neoglycopeptide 5.50 
 
 
Sialoglycan 5.49 (4.7 mg, 2.33 μmol) and triethylamine (1.6 μL, 11.6 μmol) were 
dissolved in D2O (7.46 μL). 2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 
5.10 (2 mg, 6.99 μmol) dissolved in MeCN (1.86 μL) was added and the reaction 
mixture was incubated at rt for 6 h, at which time, 1.2 M HCl (10 μL) was added until 
the solution was acidic (pH 2), followed by sat. NaHCO3 (9.5 μL). Then, peptide 5.43 
(1 mg, 1.16 μmol) dissolved in water (10 μL), CuSO4.5H2O (250 μg, 1 μmol), and L-
ascorbic acid (180 μg, 1 μmol) were added and the reaction mixture was stirred at 50 
°C for 14 h, after which time, the crude product was isolated by analytical RP HPLC 
(column: Jupiter 5U C18 (300 Å) column (Phenomenex); eluent: A (0.05% TFA in 
H2O) and B (0.1% TFA in MeCN); gradient: sample was run at 1 mL/min with a 
gradient of 5-65% B over 40 mins; column oven: 40 °C; detection: UV 235 nm) to 
afford compound 5.50 (0.6 mg, 42 %) as a white solid; HRMS (ESI) Calcd. For 
C115H180DN18O68 (MH










N-Acetyl-D-glucosamine 5.4 (500 mg, 2.26 mmol), thioacetic acid (0.8 mL, 11.3 
mmol), and triethylamine (3.1 mL, 22.6 mmol) were stirred in H2O (10 mL) and cooled 
to 0 °C. 2-Chloro-1,3-dimethylimidazolinium chloride 5.1 (1.2 g, 6.78 mmol) was 
added. After 30 mins, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of 
starting material (Rf 0.2) and the formation of a major product (Rf 0.5). The reaction 
mixture was then diluted with water (20 mL), washed with DCM (5 x 20 mL), 
concentrated to 1 mL, filtered through a column of Amberlite® IR120 (H+) previously 
activated by 1 M NaOH solution, and concentrated in vacuo. Purification by flash 
column chromatography (CHCl3:MeOH, 5:1) gave 1-acetyl-2-acetamido-2-deoxy-D-
glucopyranoside 5.52 (510 mg, 86 %) as a white solid (α/β, 3:2); δH (400 MHz, D2O) 
1.83 (3H, s, α-NHCOCH3), 1.89 (3H, s, β-NHCOCH3), 3.36-3.55 (4H, m, H-4α, H-3β, 
H-4β, H-5β), 3.61-3.80 (6H, m, H-3α, H-5α, H-2β, H-6α, H-6’α, H-6β, H-6’β), 3.93 
(1H, dd, J1α,2α 3.6 Hz, J2α,3α 10.6 Hz, H-2α), 5.51 (1H, d, J1β,2β 8.7 Hz, H-1), 5.95 (1H, 
d, H-1α); δC (100 MHz, D2O) 19.9, 20.1 (2 x q, 2 x NHCOCH3), 21.6 (q, β-CO2CH3), 
21.9 (q, α-CO2CH3), 52.4 (d, C-2α), 54.4 (d, C-2β), 60.1, 60.2 (2 x t, 2 x C-6), 69.2 (d, 
C-4β), 69.3 (d, C-4α), 70.4 (d, C-3α), 73.2 (d, C-3β), 73.9 (d, C-5α), 76.6 (d, C-5β), 
90.9 (d, C-1α), 92.8 (d, C-1β), 172.1, 172.7, 174.6, 174.8 (4 x s, 4 x C=O); HRMS (ESI) 
Calcd. For C10H17NO7 (MNa










N-Acetyl-D-glucosamine 5.4 (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 
mmol) were stirred in D2O (10 mL) and cooled to 0 °C. 2-Chloro-1,3-
dimethylimidazolinium chloride 5.1 (1.2 g, 6.78 mmol) was added. After 30 mins, t.l.c. 
(CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 0.2) and 
the formation of a major product (Rf 0.6). Thioacetic acid (2.4 mL, 33.9 mmol) was 
added dropwise and the reaction mixture was allowed to stir for an additional 30 mins 
at 0 °C. The reaction mixture was then diluted with water (10 mL) and washed with 
DCM (5 x 20 mL). The aqueous phase was concentrated to 1 mL, filtered through a 
column of Amberlite® IR120 (H+, previously activated by 1 M NaOH solution), and 
concentrated in vacuo. Purification by flash column chromatography (CHCl3:MeOH, 
5:1) gave 1-thioacetyl-2-acetamido-2-deoxy-β-D-glucopyranoside 5.54 (570 mg, 90 %) 
as a white solid, m.p. 195-200 °C; [α]D
20 +24 (c, 1.0 in MeOH); δH (400 MHz, D2O) 
1.89 (3H, s, NHCOCH3), 2.31 (3H, s, SCOCH3), 3.40 (1H, at, J 9.0 Hz, H-4), 3.46 (1H, 
m, H-5), 3.52 (1H, at, J 9.0 Hz, H-3), 3.62 (1H, dd, J5,6 5.0 Hz, J6,6’ 12.3 Hz, H-6), 3.75-
3.82 (2H, m, H-2, H-6’), 5.10 (1H, d, J1,2 10.6 Hz, H-1); δC (100 MHz, D2O) 22.0 (q, 
NHCOCH3), 30.2 (q, SCOCH3), 53.4 (d, C-2), 60.5 (t, C-6), 69.4 (d, C-4), 74.9 (d, C-
3), 80.4 (d, C-5), 80.9 (d, C-1), 174.5 (s, NHCOCH3), 197.6 (s, SCOCH3); HRMS (ESI) 
Calcd. For C10H18NO6S (MH










N-Acetyl-D-galactosamine 5.13 (20 mg, 0.09 mmol), triethylamine (125 μL, 0.9 mmol), 
and thioacetic acid (32 μL, 0.452 mmol) were stirred in D2O (500 μL) and cooled to 0 
°C. 2-Chloro-1,3-dimethylimidazolinium chloride 5.1 (46 mg, 0.27 mmol) was added. 
After 30 mins, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting 
material (Rf 0.2) and the formation of a major product (Rf 0.5). The reaction mixture 
was diluted with water (10 mL), washed with DCM (5 x 20 mL), lyophilised to 1 mL, 
filtered through a column of Amberlite® IR120 (H+) previously activated by 1 M NaOH 
solution, and then lyophilized. The product was purified by semi-preparative RP HPLC 
(column: Luna 5U C18 (100 Å) column (Phenomenex); eluent: H2O only. Sample was 
run at 1 mL/min for 40 mins; column oven: 40 °C; detection: CAD) to afford gave 
acetyl 2-acetamido-2-deoxy-D-galactopyranoside 5.55 (18 mg, 86 %) as a white foam 
(α/β, 1:1.1), tR = 11.65 mins; νmax (neat) 3273 (s, OH), 1742 (s, C=O), 1642 (s, N-H) 
cm-1; δH (400 MHz, D2O) 1.91 (6H, s, α-NHCOCH3, β-NHCOCH3), 2.04 (3H, s, β-
COCH3), 2.08 (3H, s, α-COCH3), 3.63-3.68 (7H, H-4β, H-5α, H-5β, H-6α, H-6’α, H-
6β, H-6’β), 3.89-3.97 (4H, m, H-2α, H-3α, H-3β, H-4α), 4.20 (1H, m, H-2α), 5.49 (1H, 
d, J1,2 8.6 Hz, H-1β), 6.01 (1H, s, H-1α); δC (100 MHz, D2O) 20.2, 20.2, 21.7, 22.0 (4 
x q, 4 x CH3CO2), 48.7 (d, C-2α), 51.3 (d, C-2β), 60.7, 61.0 (2 x t, C-6α. C-6β), 67.2, 
67.5 (2 x d, C-3α, C-3β), 68.2, 70.4 (2 x d, C-4α, C-4β), 73.2, 76.1 (2 x d, C-5α, C-5β), 
91.2 (d, C-1α), 93.3 (d, C-1β), 172.4, 172.8, 174.8, 175.0 (4 x s, 4 x COCH3); HRMS 
(ESI) Calcd. For C10H17NO7 (MNa









D-Mannose 5.17 (500 mg, 2.78 mmol), triethylamine (3.8 mL, 27.7 mmol), and 
thioacetic acid (1 mL, 13.8 mmol) were stirred in D2O (10 mL) and cooled to 0 °C. 2-
Chloro-1,3-dimethylimidazolinium chloride 5.1 (1.4 g, 8.33 mmol) was added. After 2 
h, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting material (Rf 
0.3) and the formation of a major product (Rf 0.6). The reaction mixture was then 
diluted with water (90 mL), washed with DCM (3 x 100 mL), lyophilised to 1 mL, 
filtered through a column of Amberlite® IR120 (H+) previously activated by 1 M NaOH 
solution, and then lyophilized. The product was purified by flash column 
chromatography (10:1 CHCl3:MeOH → 5:1 CHCl3:MeOH) to afford acetyl α-D-
galactopyranoside 5.56 (450 mg, 73 %) as a white foam; [α]D
20 +72 (c, 1.0 in MeOH); 
νmax (neat) (s, OH), (s, C=O), (s, N-H) cm
-1; δH (400 MHz, D2O) 2.04 (3H, s, α-COCH3), 
3.59-3.65 (3H, m, H-4, H-5, H-6), 3.71-3.73 (1H, m, H-6’), 3.77 (1H, m, H-3), 3.87 
(1H, m, H-2), 5.86 (1H, d, J1,2 1.8 Hz, H-1); δC (100 MHz, D2O) 20.2 (q, CO2CH3), 
60.6 (t, C-6), 66.1 (d, C-5), 68.9 (d, C-2), 69.0 (d, C-3), 70.1 (d, C-3), 74.7 (d, C-4), 












D-Galactose 5.57 (20 mg, 0.111 mmol), triethylamine (154 μL, 1.11 mmol), and 
thioacetic acid (40 μL, 0.555 mmol) were stirred in D2O (500 μL) and cooled to 0 °C. 
2-Chloro-1,3-dimethylimidazolinium chloride 5.1 (57 mg, 0.333 mmol) was added. 
After 30 mins, t.l.c. (CHCl3/MeOH, 2:1) indicated complete consumption of starting 
material (Rf 0.3) and the formation of a major product (Rf 0.6). The reaction mixture 
was then diluted with water (10 mL), washed with DCM (5 x 20 mL), lyophilised to 1 
mL, filtered through a column of Amberlite® IR120 (H+) previously activated by 1 M 
NaOH solution, and then lyophilized. The product was purified by semi-preparative RP 
HPLC (column: Luna 5U C18 (100 Å) column (Phenomenex); eluent: H2O only. 
Sample was run at 1 mL/min for 40 mins; column oven: 40 °C; detection: CAD) to 
afford gave acetyl β-D-galactopyranoside 5.58 (21 mg, 85 %) as a white solid, tR = 6.5 
mins; m.p. 160-165 °C; νmax (neat) 3330 (s, OH), 1730 (s, C=O) cm
-1; δH (400 MHz, 
D2O) 2.08 (3H, s, COCH3), 3.59-3.64 (4H, m, H-2, H-3, H-6, H-6’), 3.71 (1H, at, J 6.3 
Hz, H-5), 4.64 (1H, s, H-4), 5.39 (1H, d, J1,2 7.1 Hz, H-1); δC (100 MHz, D2O) 20.3 (q, 
CH3), 60.7 (t, C-6), 68.3 (d, C-4), 69.5 (d, C-2), 72.3 (d, C-3), 76.0 (d, C-5), 94.3 (d, C-
1), 172.7 (s, C=O); HRMS (ESI) Calcd. For C8H14NO7 (MNa
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